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Introduction and outline of thesis 
 
 
 
“And while he lives, 
He wields the boasted prize 
Whose value all can feel, the weak, the wise, 
Displays in triumph his distinguish'd boon, 
The solid honours of the Wooden Spoon” 
 
—"The Wooden Spoon" from the Cambridge Tart (1823) 
Photo scanned from H P Stokes, Ceremonies of the University of Cambridge, 
Cambridge University Press 1927. Believed to be in the public domain: the 
photograph was originally published in the UK in 1909 and reprinted in Stokes' 
book in 1927. 
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INTRODUCTION 
 
Each year at St. John’s College of the University of Cambridge the 
students at the Mathematics faculty awarded a wooden spoon to their 
fellow student with the lowest marks in the mathematical tripos exams 
who still earned a third-class degree. It was given for the last time in 1909 
to Cuthbert Lempriere Holthouse, who can be seen in the photograph on 
the previous page. A wooden spoon is a mock or a real award, given to an 
individual or a team which has come last in a competition. 
In 1979 the Scottish physician and epidemiologist Archibald Leman 
Cochrane (Kirklands, 12 January 1909-Dorset, 18 June 1988) awarded a 
figurative wooden spoon to Obstetrics for not having used the design of 
the randomized controlled trial (RCT) to assess the effectiveness of 
interventions related to pregnancy and childbirth. A silver spoon was 
given to Phtisiology (the study of tuberculosis) for the landmark clinical 
research conducted by Sir Austin Bradford Hill on the use of streptomycin 
in patients with tuberculosis (Cochrane, 1979). A randomized controlled 
trial is an experiment in which two or more interventions are compared by 
being randomly allocated to participants as opposed to an observational 
study where the investigators simply observe the course of events and do 
not seek to intervene (Glossary of Cochrane terms). Some time before, 
‘Archie’ Cochrane had already criticized the medical profession in general 
by stating: “we have not organized a critical summary, by specialty or 
subspecialty, updated periodically, of all relevant randomized controlled 
trials” (Cochrane, 1979). Initially perinatal medicine was the first 
specialty to take up the glove of Cochrane’s provocative challenge by 
organizing the Oxford Database of Perinatal Trials (Chalmers et al, 1986). 
The first systematic review of the effectiveness of fertility treatment was 
published in 1993, hallmarking the introduction of evidence-based 
practice in the field of reproductive medicine (Vandekerckhove et al, 
1993). 
Evidence-based medicine is the conscientious, explicit, and judicious use 
of the current best evidence in making decisions about the care of 
individual patients (Sackett et al, 1996). The practice of evidence-based 
medicine (EBM) stands for the integration of individual clinical expertise 
and the patient’s unique values with the best available evidence from 
systematic research (Strauss et al, 2005). The essentials to put EBM into 
practice can be summarized in five steps: first of all, to ask the right 
answerable question; secondly, to find the best level of evidence 
available; thirdly, to appraise critically the evidence for risk of bias, 
clinical relevance and applicability; fourthly, to implement the results of 
the appraisal in every day clinical practice and fifthly to evaluate the 
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changes in practice (Farquhar et al, 2006). The highest level of evidence is 
derived from well written critically appraised systematic reviews of RCTs.  
Why should clinicians expose their clinical practice to the scrutiny of the 
RCT (Johnson et al, 2008)? The answer is simple: this study design offers 
the potential for the least biased measurement of the effectiveness of an 
intervention. Effectiveness is the extent to which an intervention, when 
used under ordinary circumstances, does what it is intended to do 
(Glossary of Cochrane terms). Trials that assess effectiveness are called 
pragmatic or management trials. A trial may have a slightly different 
purpose: it may aim to measure the extent to which an intervention 
produces a benefit for fully co-operative participants under ideal 
conditions. This design is called an explanatory trial; it aims to measure 
the efficacy of an intervention (Glossary of Cochrane terms). 
Observational studies are appropriate for detecting rare events e.g. 
surgical complications but can be misleading if used in searching for 
treatment benefits that are small to moderate as those observed in health 
care interventions. The observation of a statistically significant association 
between an intervention and its effect can be explained by the following 
mechanisms: chance, bias/confounding or causality (Elwood, 2007). Bias 
is a systematic error or deviation in results or inferences from the truth as 
opposed to imprecision, which is random sampling error (Glossary of 
Cochrane terms). Many types of bias have been described in studies of the 
effects of health care interventions; they can be classified into information 
bias, selection bias and confounding (Groenwold, 2013). The risk of bias 
can be minimized by using a randomized controlled trial as a study design 
to prevent confounding, by blinding participants and researchers to 
prevent information bias and by doing the correct analysis taking into 
account selective loss to follow-up, thereby preventing selection bias. 
Assessing the risk of bias is very important in the critical appraisal of the 
effectiveness of an intervention. Different possible scenarios have to be 
examined. Could there have been a selective error in the measurement of 
the exposure, the outcome or both? Have all confounders been carefully 
considered? How has the selection of the comparison groups been 
determined? Both the likelihood and the extent of bias have to be 
assessed; measuring the extent of bias is possible by doing several 
sensitivity analyses (Groenwold, 2013). The higher the risk of bias, the 
lesser the confidence in the estimation of the true treatment effect even 
when the confidence intervals are narrow. Systematic reviews comparing 
observational studies with RCTs of comparable interventions for 
comparable conditions in identical study populations have demonstrated 
that the former were clearly unreliable and consistently overestimated the 
treatment effect (Britton et al, 1998; Kunz et al, 2001). In surgery a non-
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evidence-based approach has been the rule by tradition (Johnson et al, 
2008). Some authorities consider that a RCT may not be the most 
appropriate design to measure the true value of a surgical intervention 
(Black, 1999). By their view factors such as training and expertise of the 
surgeon are not easy to standardize precluding the possibility to measure 
the effectiveness of a surgical intervention by a randomized controlled 
study. In other words, differences in outcomes might be caused by 
differences in skills or techniques among the participating surgeons rather 
than to a real treatment effect of the intervention under study. Several 
authors have reported data on large geographical variations in the rates of 
specific surgical interventions, e.g. prostatectomy/ hysterectomy/ 
hemorrhoidectomy (Mc Pherson et al, 1982), tonsillectomy (Mc Pherson 
et al, 1982; American Child Health Association, 1934) or coronary 
surgery (Brook et al, 1988). This illustrates that clinical practice research 
in surgery is determined by differences in the clinical judgment (or 
beliefs?) of surgeons. The appraisal of the best available evidence based 
on a rigorously scientific methodology as in basic research may be a 
stronger base for determining the efficacy and effectiveness of therapeutic 
interventions (Sackett et al, 1996; Rosenberg and Donald, 1995). 
There has been a growing recognition that pooling knowledge from high-
quality studies provides the best available evidence (Evans et al, 2006). 
Moreover concerns about spending substantial financial resources for 
ineffective treatments at the ‘cost’ of effective interventions have put 
health-care professionals under increasing pressure to work more cost-
effectively (Cochrane, 1972; Woolf et al, 1999; Agrawal et al, 2013). This 
poses a challenge for the clinician who has to struggle with the ever 
increasing volume and complexity of the published biomedical knowledge 
(Sackett et al, 1996). Reading a paper on a single study is clearly no 
longer sufficient to keep clinical knowledge up to date; most single papers 
do not represent the best available evidence on a particular subject 
(Ioannidis, 2005). The increasing biomedical knowledge and the need to 
summarize and critically appraise its findings have led to the development 
of systematic reviews, to increase the likelihood of the most reliable 
information being available to guide clinical decision making (Haynes et 
al, 2006). The Cochrane Collaboration is a global independent network of 
health practitioners, researchers, patient advocates and others, responding 
to the challenge of making the vast amounts of evidence generated 
through research useful for informing decisions about health. Since its 
formation in 1993, the central mission of this not-for-profit organization 
with almost 27,000 collaborators from over 120 countries has been to 
publish systematic reviews of the literature to aid clinicians, patients and 
Chapter 1 
 
 
14 
policy makers taking health-care decisions based on the best available 
evidence from high-quality studies (Farquhar et al, 2013). 
Given the restricted financial budget of most countries to spend money for 
public health care, the question of the effectiveness of treatments is very 
relevant for the field of subfertility: the costs for treatment with assisted 
reproductive techniques/technology (ART) are high and the success rates 
are moderate, at best only 20% live birth rate per started cycle 
(Macaldowie et al, 2012). Assisted reproductive technology (ART) 
comprises all treatments or procedures of the in vitro handling of both 
human oocytes and sperm or of embryos for the purpose of establishing a 
pregnancy. This includes among others in vitro fertilization and embryo 
transfer (IVF) (Zegers-Hochschild et al, 2009). It is estimated that 
>5,000,000 babies have been born around the globe with ART since the 
birth of Louise Brown in 1978 (ESHRE 2012). Some 1,500,000 ART 
cycles are performed annually worldwide with an estimated 350,000 
babies born. Belgium has a top ranking for consumption of ART; in 2011 
the utilization was 2,767 ART cycles per million of the population (cpm) 
based on data from the Belgian Register for Assisted Procreation 
(BELRAP) registry (Report 2011 of the College of Physicians in 
Reproductive Medicine) and the web application be.STAT of the Belgian 
Federal Government. The utilization of ART in Belgium is substantially 
higher compared with the Netherlands (1,290 cpm in 2008) (Berg 
Brigham et al, 2013). In Belgium 5% of all babies born are conceived 
after ART. The total cost of ART in Belgium for the year 2008 has been 
estimated 99,844,000 € assuming that the direct unsubsidized cost of one 
ART treatment cycle is 4,000 € (IST).The delivery rate from ART 
treatment is 22% per oocyte pick-up and 27% cumulative from a single 
started treatment cycle based on an analysis of world data for 2007 
(ESHRE-ART fact sheet). 
In this thesis we aim to study the effectiveness of reproductive surgery for 
improving the reproductive outcome in subfertile women by a critical 
appraisal of the best available evidence using the rigorously scientific 
methodology developed for writing systematic reviews. A first research 
question is whether the shift away from reproductive surgery favoring 
ART for tubal factor infertility is supported by high-quality evidence. A 
second research question concerns the effectiveness of hysteroscopy in the 
treatment of female subfertility. A third part of our research aims to 
investigate if there has been any progress in the evidence-based practice 
of reproductive surgery. In 1996 the CONSORT statement was published 
(Begg et al, 1996; Selman et al, 2008). The acronym stands for 
consolidated standards of reporting trials. Started in 1993 in Ottawa, 
Canada at a meeting of medical journal editors, clinical trialists, 
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epidemiologists and methodologists as an initiative to develop a new scale 
to assess the quality of RCT reports, the CONSORT statement refers to a 
checklist of 25 items aiming to improve the standards of reporting of 
RCTs. We aim to study the effects of the publication of the CONSORT 
statement on the quality of published RCTs on reproductive surgical 
interventions in subfertile women. 
Chapter 1 
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OUTLINE OF THIS THESIS 
 
Chapter 1 predefines the three research questions in the introduction of 
the present thesis: 
1. To examine if there is an evidence-based fundament for the shift 
from reproductive surgery to ART in women with tubal infertility 
2. To appraise the evidence on the effectiveness of hysteroscopy in 
the treatment of female subfertility 
3. To investigate if there has been any progress in the evidence-
based practice of reproductive surgery. 
 
In chapter 2 we examine the available evidence on the use of laparoscopy 
in current fertility practice by a combined narrative and systematic review 
of the literature. The alternative diagnostic procedures for the evaluation 
of tubal patency are briefly discussed. We aim to appraise the position of 
laparoscopy for the diagnosis and treatment of the general population 
attending the fertility clinic. 
 
In chapter 3 we summarize the findings of a systematic review of the 
literature on the effectiveness of hysteroscopy for improving pregnancy 
rates in subfertile women. This review aims to examine the validity of the 
statements of the Royal College of Obstetricians and Gynecologists 
(RCOG, 2004) and the European Society for Human Reproduction and 
Embryology (Crosignani et al, 2000) that hysteroscopy should not be done 
in all subfertile women but only when indicated. 
 
In chapter 4 the findings of a Cochrane systematic review on the 
effectiveness of hysteroscopy for treating subfertility associated with 
suspected major uterine cavity abnormalities are discussed. 
Ultrasonography, saline infusion/gel instillation sonography or 
hysterosalpingography are routinely performed in the initial diagnostic 
work-up of subfertility. Their use leads to the detection of uterine cavity 
abnormalities such as endometrial polyps, fibroids, septa or intra-uterine 
adhesions in 10 to 15% of women seeking treatment for subfertility. This 
Cochrane review has identified several knowledge gaps that need to be 
addressed in the near future. This chapter illustrates an often overlooked 
benefit of rigorous systematic reviews: their capacity to indicate the 
absence of evidence. 
 
In chapter 5 we discuss the effectiveness of using anti-adhesion barrier 
gels following operative hysteroscopy for treating female subfertility by a 
systematic review of the literature and a meta-analysis of the data from 
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some included studies. We aim to appraise the evidence for the use of any 
anti-adhesion barrier gel following operative hysteroscopy in subfertile 
women. 
 
In chapter 6 we present a Cochrane protocol on the broader scope of 
several different anti-adhesion strategies following operative hysteroscopy 
for treating female subfertility. The various strategies proposed by 
observational studies include the insertion of an intrauterine device (IUD) 
or a Foley catheter balloon, hormone therapy, barrier gels and human 
amnion membrane grafting. We aim to study the effectiveness of these 
four anti-adhesion strategies for treating subfertile women. 
 
In chapter 7 we aim to test the hypothesis that the publication of the 
CONSORT statement in 1996 has had a positive impact on the quality of 
the published reports of RCTs on the effectiveness of reproductive surgery 
by summarizing the findings of a systematic review. 
 
In chapter 8 we aim to write a fitting end for the story of the wooden 
spoon. 
Firstly, the findings of the studies presented in this thesis are summarized. 
Secondly, we aim to answer all three research questions of this thesis. 
Thirdly, after discussing briefly the strengths and weaknesses of RCTs in 
reproductive surgery we will conclude by ‘random reflections’ (*) on the 
future of evidence-based practice in reproductive surgery: Is EBM 
sufficient to give all the answers needed by the women under our care? 
Should we direct our attention to the emerging “patient-centered” practice 
or rather stick with “practice-based” evidence? Or is evidence-based 
practice nothing more than the incense used by yet another institution 
professing the new dogma of a too mathematical, rigorous and possibly 
too narrow view on clinical practice? 
 
 
 
 
 
 
(*) Reference to Cochrane AL. Effectiveness and Efficiency. Random Reflections 
on Health Services. London: Nuffield Provincial Hospitals Trust, 1972. 
(Reprinted in 1999 for Nuffield Trust by the Royal Society of Medicine Press, 
London). 
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ABSTRACT 
 
Background 
In everyday clinical practice, it is not always clear if and when 
laparoscopy should be done in the fertility work-up. We aimed to analyze 
the available evidence on alternative diagnostic methods for detecting 
tuboperitoneal infertility and on the position of laparoscopy in the fertility 
clinic. 
 
Methods  
We searched MEDLINE and The Cochrane Library by using a 
combination of free-text words and Medical Subject Headings (MeSH) 
terms for ‘laparoscopy’ and ‘infertility’. We included randomized 
controlled trials (RCTs) and observational studies. 
 
Results 
The laparoscopic ablation or excision of minimal/mild endometriotic 
lesions with or without adhesiolysis increases the outcome ‘ongoing 
pregnancy at 20 weeks or live birth’ in women with otherwise 
unexplained subfertility: the odds ratio (OR) was 2.0, 95% confidence 
interval (CI) was 1.2 to 3.3, P=0.01, 341 women, as demonstrated by a 
Canadian trial. According to a smaller Italian trial there was no evidence 
for such a benefit (OR 0.85, 95% CI 0.32 to 2.3, P=0.75, 96 women). 
Laparoscopic ovarian drilling in women with clomiphene-resistant 
polycystic ovaries is at least as effective as gonadotrophin treatment- OR 
was 1.0, 95% CI 0.63 to 1.6, P=0.95, 4 studies, 304 women- but 
significantly lowers the multiple pregnancy rate (OR 0.13, 95% CI 0.03 to 
0.59, P=0.008, 4 studies, 154 women). Doing a laparoscopy before a first 
treatment cycle or after several failed cycles of intrauterine insemination 
does not affect the pregnancy rates (OR 0.81, 95% CI 0.43 to 1.5, P=0.52, 
1 study, 154 women) or the incidence of pelvic pathology with therapeutic 
implications (OR 0.72, 95% CI 0.28 to 1.9, P=0.51, 1 study, 89 women). 
Based on a subgroup analysis of the data of a Cochrane review the 
laparoscopic removal of a hydrosalpinx visible on ultrasound may 
increase the delivery rate after in vitro fertilization (IVF)- the risk ratio 
(RR) was 2.4, 95% CI 1.1 to 5.3, P=0.038, 1 study, 75 women- especially 
when bilaterally detectable by ultrasound (RR 3.5, 95% CI 1.1 to 11, 
P=0.019, 1 study, 39 women). 
 
Conclusions 
In some clinical settings, limited evidence is available to recommend the 
use of laparoscopy in current fertility practice. Additional high-quality 
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randomized studies on the effectiveness of laparoscopy for treating female 
subfertility are needed. 
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INTRODUCTION 
 
The position of laparoscopy in current fertility practice is under debate. 
Until recently, laparoscopy was the final procedure of the diagnostic 
fertility work-up, as recommended by the American Fertility Society 
(AFS) in 1992 and by the World Health Organization (WHO) guidelines 
(Rowe et al, 1993). In 1997, Glatstein et al reported that 89% of all 
reproductive physicians in the USA routinely performed a laparoscopy for 
the exploration of infertility (Glatstein et al, 1997). However, some 
investigators argued that diagnostic laparoscopy detected no abnormalities 
or pathology of questionable prognostic significance, e.g. minimal or mild 
endometriosis in 40 to 70% of all cases (Forman et al, 1993). 
Already by the mid 1990s, the ‘test’ laparoscopy was reported to be less 
than an ideal predictor for infertility (Collins et al, 1995). These findings 
convinced some authors to challenge the need for this procedure in the 
routine fertility work-up of all women (Fatum et al, 2002). Worldwide, 
diagnostic laparoscopy is increasingly bypassed by IVF. Several 
explanations are possible: cutting costs, faster delivery of treatment to the 
client or aiming to protect women from complications related to surgery 
or the use of general anesthesia. 
Disadvantages of laparoscopy include the need for general anesthesia, 
operating room facilities and dedicated nursing staff, patient’s anxiety and 
the possibility of complications related to abdominal entry or the 
procedure itself. In a large Finnish follow-up study, the complication rate 
of diagnostic laparoscopy was 6 per 10,000 procedures (Härkki-Sirén et 
al, 1999). However, the main advantage of a laparoscopy is the “see and 
treat” principle, the possibility to make a diagnosis and install a therapy at 
the same time as well as the opportunity to combine the laparoscopy with 
the hysteroscopic exploration of the uterine cavity with an endometrial 
biopsy, all as part of day care surgery. 
In this review paper, we aim to define the position of laparoscopy in 
current fertility practice. We conducted a literature search of MEDLINE 
(through Pub Med) and The Cochrane Library, using a combination of 
free-text words and medical subject headings (MeSH) for the key words 
‘laparoscopy’ and ‘infertility’. We included RCTs as well as observational 
studies. 
The present review aims to study the effectiveness of laparoscopy for 
improving pregnancy rates in subfertile women; it should be considered as 
an intervention and not a diagnostic review. There is however a thin line 
between diagnostic and operative laparoscopy; therefore we will first 
address the question if alternative diagnostic procedures to evaluate 
tuboperitoneal infertility are reliable enough to replace diagnostic 
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laparoscopy. Subsequently, we will discuss the position of laparoscopy in 
the context of treatment for ovulation induction, intrauterine insemination 
(IUI) and IVF based on two questions: (i) Is it necessary to perform a 
laparoscopy before starting these fertility treatments to detect significant 
tuboperitoneal pathology with therapeutic consequences and with impact 
on the treatment’s cumulative ongoing pregnancy rate? (ii) Is it still 
indicated to perform a laparoscopy after several failed treatment cycles 
with ovulation induction or IUI/IVF to enhance the couple’s success rate?  
 
ALTERNATIVE PROCEDURES FOR EVALUATING TUBAL 
PATENCY OR THE PRESENCE OF ENDOMETRIOSIS 
 
The first topic to be discussed is the reliability of alternative diagnostic 
methods for examining the presence of tuboperitoneal infertility, based on 
taking medical history, hysterosalpingography (HSG) and serum 
Chlamydia antibody testing (CAT). 
 
Medical history and tuboperitoneal infertility 
The positive predictive value of history taking, based on symptoms 
suggestive for previous pelvic inflammatory disease (PID), a history of 
abnormal vaginal discharge and a previous diagnosis of a lower genital 
tract infection was 56, 59 and 35%, respectively, in predicting 
tuboperitoneal infertility (Hubacher et al, 2004). For endometriosis the 
predictive value of each symptom or even a combination of symptoms in 
predicting its presence, remains uncertain. Indeed, these symptoms have a 
low sensitivity and a significant proportion of women affected by 
endometriosis, are symptom-free (Kennedy et al, 2005). 
 
HSG and HyCoSy 
The HSG enables a morphological evaluation of the uterine cavity, the 
Fallopian tubes and their patency. According to a meta-analysis, HSG has 
a reasonable specificity (83%) but a low sensitivity (65%) to document 
patency of the Fallopian tubes (Swart et al, 1995). The fecundability is 
substantially reduced in cases of bilateral occlusion and/or hydrosalpinx- 
OR was 0.30 (95% CI 0.13 to 0.71) - but not for a one-sided tubal 
occlusion or hydrosalpinx (OR 0.81, 95% CI 0.47 to 1.4) (Mol et al, 
1997b). Furthermore, an HSG performed with oil-soluble media may be 
therapeutic in some subfertile women. According to a meta-analysis 
(Watson et al, 1994), a higher conception rate has been demonstrated in 
women undergoing an HSG with oil-soluble compared to water-soluble 
contrast media (OR 1.9, 95% CI 1.3 to 2.7), especially in the subgroup of 
women with unexplained subfertility (OR 2.7, 95% CI 1.9 to 3.8). 
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According to another RCT (Ogata et al, 1993), the conception rate was 
three times higher in subfertile women after having an HSG performed 
with oil-soluble media versus a control group not undergoing an HSG. 
However, in daily clinical practice an HSG is performed with water-
soluble media to prevent potentially life-threatening allergic reactions 
despite the fact that RCTs demonstrating any benefit for an increased 
fecundability after HSG with water-soluble media compared to no 
flushing are lacking. 
The technique of HSG has several possible adverse effects. Lower 
abdominal pain and discomfort are commonly experienced by women 
undergoing HSG. Many women still remember the HSG for years 
afterwards as one of the most painful outpatient exams in gynecology. An 
HSG can induce or exacerbate PID, leading to peritonitis, pelvic abscess 
and very exceptionally even to death (Chuang et al, 1971). Uterine 
perforation and post-examination hemorrhage are a possibility. Other 
complications include granuloma formation and vascular intravasation. 
Hypersensitivity reactions to iodine exist with any of the HSG media, but 
allergic reactions are rare. Finally, the ionizing radiation used for HSG 
can be detrimental to an unsuspected early pregnancy. 
A multicentre RCT comparing cumulative pregnancy rates (CPR) in a 
group where HSG was followed by diagnostic laparoscopy within one to 
two months in case tubal pathology was detected or after 6 months when 
the HSG was normal and the woman had not yet become pregnant by that 
time versus a group where diagnostic laparoscopy was performed 
immediately, showed no significant differences in CPR at 18 months 
(Perquin et al, 2006). The authors question the added value of HSG 
performed at an early stage in the fertility work- up prior to laparoscopy 
and dye, although this conclusion has been criticized by other 
investigators (Coppus et al, 2006). 
The prognostic significance of HSG and laparoscopy for fertility outcome 
was reported in a large prospective cohort study (Mol et al, 1999). 
Unilateral and bilateral tubal occlusion at HSG and laparoscopy were 
related to treatment independent pregnancy. The adjusted fecundity rate 
ratio (FRR) of a one-sided tubal occlusion at HSG was 0.80, whereas two-
sided tubal occlusion had a FRR of 0.49. A fecundity rate ratio expresses 
the probability of a spontaneous intrauterine pregnancy per time unit for 
women with a particular feature (e.g. one-sided or two-sided occlusion) 
versus women without that feature (Olsen et al, 1998). In the case of 
laparoscopy, the adjusted FRRs were 0.51 and 0.15, respectively, for one-
sided and two-sided tubal occlusion. A laparoscopy showing two-sided 
occlusion after a normal or one-sided occluded HSG was found in 5% of 
the women and the treatment-independent conception rate in this case was 
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virtually 0%. A normal laparoscopic examination after two-sided 
occluded HSG was found in 42% of all patients; in these cases fertility 
prospects were only slightly impaired with a three-year cumulative 
ongoing intrauterine pregnancy rate of 9%. On the other hand, fertility 
prospects were strongly impaired in cases where laparoscopy showed one-
sided and two-sided occlusions after a two-sided occluded HSG; the 
adjusted FRR were 0.38 and 0.19, respectively. The authors conclude that 
a diagnostic laparoscopy should be done after a two-sided occluded HSG 
because this enables to distinguish two large groups with clinically 
relevant differences in future fertility prognosis. Furthermore, a diagnostic 
laparoscopy can be reasonably delayed after a fully normal HSG for at 
least 10 months due to the very low probability of only 5% that bilateral 
tubal occlusion may be found. 
Hysterosalpingo Contrast Sonography (HyCoSy) is an attractive 
alternative to HSG since the patients are not exposed to X-rays or 
iodinated contrast media. Fallopian tubal patency is assessed using 
transvaginal ultrasonography and a galactose micro bubble contrast 
medium. There were no large differences in the diagnostic performance 
between HyCoSy and HSG when women were randomly allocated to 
undergo either procedure ; direct comparison of both procedures 
demonstrated a poor agreement beyond chance (Dijkman et al, 2000). The 
authors recommend additional studies on the capacity of HyCoSy to 
predict fertility. A case-control study has demonstrated that allocation of 
patients screened as normal with HyCoSy to treatments that rely on an 
accurate assessment of tubal patency does not change the conception rates 
(Hamilton et al, 2003). 
 
Serum CAT 
The presence of Chlamydia antibodies (by Chlamydia antibody testing or 
CAT) is indicative of a past infection with Chlamydia trachomatis, the 
most important cause of PID. The accuracy of serum Chlamydia 
antibodies in the diagnosis of tubal pathology has been critically appraised 
in a systematic review and meta-analysis by Mol and co-workers (Mol et 
al, 1997a). The discriminative capacity of Chlamydia antibody titers by 
means of enzyme-linked immuno sorbent assay (ELISA), 
microimmunofluorescence (MIF) or immunofluorescence (IF) assays in 
the diagnosis of any tubal pathology is comparable with that of HSG in 
the diagnosis of tubal occlusion or hydrosalpinx; both diagnostic tools had 
comparable receiver operating characteristics curves (ROC). A summary 
ROC curve of several diagnostic studies using ELISA or (M)IF 
demonstrated a better discrimination when compared with studies using 
immunoperoxidase assay (Mol et al, 1997a). The latter author group 
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published results of a trial aiming to study the cost-effectiveness of HSG, 
laparoscopy and CAT in >2,000 subfertile couples enrolled in the 
Canadian Infertility Treatment Evaluation Study-CITES (Mol et al, 2001). 
The diagnostic work-up to detect tubal pathology in subfertile couples 
should, according to their findings, begin with CAT in couples with 
relatively good fertility prospects and immediate HSG in couples with 
relatively poor fertility prospects. Good fertility prospects were defined by 
a threshold of having a 3-year chance of conception of >14%, whereas 
poor fertility prospects were defined by a 3-year chance of conception of 
<14%. 
The HSG and CAT screening have no role for detecting endometriosis in 
subfertile women with patent Fallopian tubes. 
In summary, both HSG and CAT are reliable procedures as a primary 
screening tool for the diagnosis of tubal infertility With these data in 
mind, the discussion if and when a diagnostic laparoscopy should be done 
in a target population of subfertile women can now be focused to the 
following clinical settings. 
 
LAPAROSCOPY AND THE TREATMENT OF MINIMAL/MILD 
ENDOMETRIOSIS 
 
Whether or not minimal or mild endometriosis should be treated in all 
cases of otherwise unexplained subfertility still remains a never ending 
discussion. The prevalence of endometriosis in the subfertile population 
(20 to 68%) is higher than that in the general population of women of 
reproductive age (2.5 to 3.3%) according to several authors (Houston et al, 
1987; Mahmood and Templeton, 1991). 
Moderate and severe stage endometriosis may lead to a disruption of the 
normal pelvic anatomy, negatively affecting the reproductive function of 
the internal genital organs. Minimal and mild stage endometriosis may 
impair fertility by a variety of hypothetical mechanisms, including toxic 
factors within the peritoneal fluid, impaired folliculogenesis and luteal 
function. The monthly fecundity rate is around 7% in r-AFS stages I–II 
endometriosis and the cumulative live birth rate with expectant 
management in endometriosis is low (Collins et al, 1995). Endometriosis 
r-AFS stages I and II are associated with a FRR of 0.52 (Mol et al, 1999). 
Although the association between minimal and mild endometriosis and 
subfertility may be co-incidental due to the role of chance, bias or 
confounding variables, many sound arguments have been presented in the 
literature that support a causal relationship between endometriosis and 
subfertility (De Hondt et al, 2006). 
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According to a meta-analysis (Jacobson et al, 2004b), the ablation or 
excision of endometriotic lesions with or without adhesiolysis is effective 
compared to diagnostic laparoscopy alone for improving fertility in 
women with minimal or mild endometriosis; OR was 1.6 (95% CI 1.1 to 
2.6, P=0.03) (Figure 1). 
 
Figure 1 Forest plot of comparison: Laparoscopic surgical treatment 
versus diagnostic laparoscopy only for minimal/mild endometriosis 
associated subfertility. Outcome: Ongoing pregnancy at 20 weeks or live 
birth. M-H: Mantel-Haenszel, fixed-effect model, CI: confidence interval. 
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This recommendation is based on a meta-analysis of two RCTs conducted 
in Italy (Parazzini et al, 1999) and in Canada (Marcoux et al, 1997) 
comparing laparoscopic ablation or excision and adhesiolysis of 
endometriotic lesions versus diagnostic laparoscopy alone. The fact that 
these two RCTs have been statistically pooled has often been criticized 
(De Hondt et al, 2006) because both studies present contradictory results, 
and by consequence should have led to different conclusions. The 
Canadian trial indicates a possible benefit favoring the treatment of 
minimal/mild endometriosis whereas the Italian study demonstrates no 
evidence for such a beneficial effect. Many possible explanations for this 
discrepancy have been put forward in the literature: the Italian study 
included a lower number of participants (n=96), had an unequal number of 
women in both comparison groups, did not include a power analysis or an 
outcome analysis on the level of monthly fecundity rate or CPR, and was 
at high risk of performance bias since a substantial number of women 
were treated with gonadotrophin releasing hormone (GnRH) agonists after 
surgery (Parazzini et al, 1999; De Hondt et al., 2006). 
In the Canadian study (Marcoux et al, 1997) including 341 infertile 
women aged 20 to 39 years with minimal or mild endometriosis, a higher 
cumulative probability of ongoing pregnancy after 36 weeks was observed 
in the surgically treated group (31%) compared with the control group 
treated by a diagnostic laparoscopy only (18%); the OR was 2.0 (95% CI 
1.2 to 3.3, P=0.01, 341 women). A first remark concerns the clinical 
The position of laparoscopy 
 
 
31 
relevance of the laparoscopic surgical treatment of minimal/mild 
endometriosis; clearly the intervention did not restore normal 
fecundability. Indeed, the monthly fecundity rate among women treated 
by laparoscopic surgery (6.1%), albeit double as high compared to the 
control group, was still lower than expected compared to normal fertile 
women (20%). A second remark is that the fertility enhancing effect of the 
laparoscopic treatment of minimal/mild endometriosis might only be 
ascribed to the laparoscopic adhesiolysis. However, the authors of the 
Canadian RCT clearly mention that in the 284 women who did not have 
adhesions, the destruction of the implants also significantly increased the 
36-week cumulative probability of ongoing pregnancy with a cumulative 
incidence ratio of 1.6 (95% CI 1.1 to 2.5) (Marcoux et al, 1997). The 
European Society for Human Reproduction and Embryology (ESHRE) 
Special Interest Group for Endometriosis have recently developed 
guidelines for the diagnosis and treatment of endometriosis. These 
guidelines recommend surgical treatment for minimal/mild endometriosis 
in subfertile women but also report that some members of the guideline 
developing group questioned the strength of the evidence (Kennedy et al, 
2005). The number needed to treat to benefit (NNTB) is 11 (95% CI 6 to 
100). One has to adjust for the prevalence of endometriosis in daily 
clinical practice: if endometriosis is diagnosed in 30% of all women 
attending a fertility clinic, then the ‘real life’ NNTB is 11/0.3=37 (95% CI 
20 to 333), which is less compelling (Practice Committee American 
Society for Reproductive Medicine-ASRM,  2006). 
Clearly, there is a need for additional RCTs on this topic. At the same 
time, it may be hard to convince ethical committees about the need for 
such studies, and even harder to recruit eligible women, in view of the 
current level of evidence indicating a likely benefit. 
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LAPAROSCOPY AND OVULATION INDUCTION TREATMENT 
 
Should a laparoscopy be done routinely in all women before starting 
ovulation induction? Can a laparoscopy, performed after several failed 
ovulation induction treatment cycles, reveal significant pathology 
amenable to surgical treatment with a positive effect on the overall 
ongoing pregnancy rate? These seemingly straightforward questions are 
difficult to answer because the limited studies available are non-controlled 
and retrospective. 
 
Laparoscopy before ovulation induction treatment 
The available evidence on the role of laparoscopy before ovulation 
induction merely focuses on the comparison between HSG and 
laparoscopy findings for the diagnosis of tubal pathology, the diagnosis 
and treatment of adhesions and the treatment of minimal and mild 
endometriosis. 
Concerning the routine use of HSG prior to laparoscopy in the fertility 
work-up, we refer to the multicentre RCT by Perquin et al (2006). For the 
CPRs at 18 months, no significant differences were found in 344 women 
randomized to an intervention group with HSG followed by diagnostic 
laparoscopy (CPR at 18 months 49%, 95% CI 42% to 57%) or a control 
group with diagnostic laparoscopy alone (CPR at 18 months 50%, 95% CI 
43% to 58%). We also refer to the discussion above on the prospective 
value of HSG and laparoscopy (Mol et al, 1999). The clinical relevance of 
treating minimal and mild endometriosis will, as also has been shown 
above, depend on the prevalence of this disease in the treated population. 
 
Laparoscopy during ovulation induction treatment 
In a retrospective observational study, Ochoa Capelo and co-workers 
performed a laparoscopy in 92 subfertile women after four failed cycles of 
ovulation induction treatment with clomiphene citrate (Ochoa Capelo et 
al, 2003). All women had at least four ovulatory cycles after treatment, 
confirmed by basal body temperature and midluteal phase serum 
progesterone, normal HSG findings and male partners with a normal 
semen analysis. The incidence of pelvic pathology in this study is 
summarized below (Table 1). Laparoscopic findings were strictly normal 
in only 36% of cases, whereas endometriosis and/or pelvic adhesions were 
observed in 50% and 33% respectively. 
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Table 1 The incidence of abnormal findings detected at laparoscopy after 
4 failed treatment cycles with ovulation induction therapy (adapted from 
Ochoa Capelo et al., 2003). 
 
Findings at laparoscopy N (*) % (*) 
Normal 
Minimal endometriosis 
Mild endometriosis 
Moderate endometriosis 
Severe endometriosis 
Endometriotic cyst 
Adhesions 
Tubal pathology 
33/92 
21/92 
  6/92 
  8/92 
  2/92 
  8/92 
30/92 
  1/92 
 36 
 23 
6.5 
8.7 
2.2 
8.7 
 33 
1.1 
(*) Several women had more than one abnormal finding at laparoscopy; 
the sum of all cases exceeds therefore 92 cases or 100%. 
 
The authors concluded that laparoscopy is a useful tool in the fertility 
work-up despite the lack of data on the pregnancy rates following 
laparoscopic surgery (Ochoa Capelo et al, 2003). Concerning the 
effectiveness of the laparoscopic treatment of minimal/mild 
endometriosis, we refer to the evidence presented above. With regard to 
laparoscopic adhesiolysis, there is only one clinical controlled study 
(CCT) by Tulandi and co-workers (1990) that reported higher CPRs of 
32% and 45% in 12 and 24 months, respectively, after operative 
laparoscopy than the 11% and 16% CPRs observed in the control group. 
To the best of our knowledge, these data have not been confirmed by a 
randomized trial. 
 
Laparoscopic ovarian drilling in PCOS patients 
About 20% of all subfertile women diagnosed with polycystic ovaries 
(PCOS) will not ovulate on the maximum daily dose of 150 mg 
clomiphene citrate (CC) as the first line of treatment (Imani et al, 1998). 
Even today, the effective treatment of CC-resistant PCOS remains 
challenging. More than 20 years ago, Gjonnaess described that the 
laparoscopic electro coagulation of the ovarian capsule in 62 CC resistant 
PCOS women resulted in an ovulation rate of 92% and a pregnancy rate 
of 69% (Gjonnaess 1994). In a recent Cochrane review (Farquhar et al, 
2005), the laparoscopic drilling of the ovarian capsule (LOD) by 
diathermy or laser in CC-resistant PCOS has been randomly compared to 
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gonadotrophin treatment. The authors retrieved 15 studies on LOD in 
PCOS women; only six trials were eligible for inclusion. The primary 
outcomes were live birth rate, ovulation rate and ongoing pregnancy rate. 
Secondary outcomes were the rate of miscarriage, multiple pregnancies, 
ovarian hyper stimulation and the total cost of the respective treatments. 
There were no differences in the live birth or ongoing pregnancy rates 
between LOD with or without ovulation induction therapy compared to 
treatment with gonadotrophins (Figure 2) but there was a substantial 
decrease in the risk for multiple pregnancies after LOD (Figure 3). 
 
Figure 2 Forest plot of comparison: LOD with or without ovulation 
induction versus gonadotrophin treatment. Outcome: Ongoing pregnancy 
per woman randomized. M-H: Mantel-Haenszel, fixed- effect model, CI: 
confidence interval. 
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Figure 3 Forest plot of comparison: LOD with or without ovulation 
induction versus gonadotrophin treatment. Outcome: Multiple pregnancy 
rates per ongoing pregnancy. M-H: Mantel-Haenszel, fixed- effect model, 
CI: confidence interval. 
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There were no statistically significant differences in miscarriage rates 
between both comparison groups (OR 0.8, 95% CI 0.36 to 1.9). 
Approximately 50% of all treated women will have a live birth and 16% 
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will have a miscarriage with either treatment. The reviewers’ conclusions 
are firstly that there are no differences in the live birth and the miscarriage 
rates in women with CC-resistant PCOS undergoing LOD versus 
gonadotrophin treatment (Farquhar et al, 2005). Secondly, the clinically 
relevant reduction in multiple pregnancy rates in women undergoing LOD 
makes this option attractive if a choice has to be made between 
gonadotrophin treatment and surgery. 
Disadvantages of the LOD procedure include the risks related to 
laparoscopic surgery, the need for general anesthesia, the possible risk of 
thermal damage to adjacent organs and ovarian adhesion formation, and 
as clearly mentioned in the Cochrane review, the lack of knowledge about 
possible adverse long-term effects of LOD on the ovarian reproductive 
function (Farquhar et al, 2005). Moreover it has been reported that the 
positive effects observed on the ovulation rates are temporary; the signs 
and symptoms of PCOS may return within months following the LOD 
(Insler and Lunenfeld, 1993). Advantages of LOD are the opportunity to 
treat concomitant pelvic pathology such as peritubal adhesions and 
endometriosis that can be associated with female infertility. Furthermore, 
during the same endoscopic procedure, tubal patency can be tested, and a 
hysteroscopy can be performed as part of the fertility work-up. 
In summary, the position of laparoscopy in the setting of ovulation 
induction is at present not clear due to the lack of high quality evidence. 
The routine use of laparoscopy to evaluate all cases of female anovulatory 
subfertility can therefore not be recommended. In specific clinical 
conditions laparoscopy is very useful to assess the tuboperitoneal status, 
to treat pelvic pathology that may limit conception (endometriosis, 
adhesions), and to perform LOD. LOD is a good option when compared 
with gonadotrophin treatment in the CC-resistant PCOS patient. 
Nevertheless gynecological surgeons should counsel women with CC 
resistant PCOS about the unknown long-term effects on the ovarian 
function. 
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LAPAROSCOPY AND IUI 
 
IUI is used in daily practice for treating cervical factor, unexplained and 
mild male subfertility. Two relevant clinical questions arise in the setting 
of IUI treatment. Firstly, does laparoscopy significantly change the 
intended treatment plan in cases where IUI is clinically indicated? 
Secondly, should laparoscopy be done before IUI or only after several 
failed IUI cycles? 
 
Laparoscopy before IUI 
After having conducted a pilot retrospective observational study 
(Tanahatoe et al, 2003) a Dutch research group published the results of a 
RCT on the role of laparoscopy in IUI (Tanahatoe et al, 2005). A group of 
154 women, eligible for IUI treatment for unexplained, cervical or mild 
male subfertility with normal HSG was randomly allocated to two 
comparison groups. In the intervention group (laparoscopy first or LSF; 
n=77) the participants were planned to undergo a laparoscopy before IUI. 
Further treatment was discontinued in 13 women, either because of 
exclusion for not giving informed consent (n=10) or because of pregnancy 
(n=3). A laparoscopy was therefore performed in the remaining 64 
women. Following laparoscopy, IUI treatment was started. Before and 
during IUI in the LSF group, 11 participants dropped out. Of the 31 
women who became pregnant in this group, 9 conceived before or 
between IUI and 22 conceived due to the IUI treatment. In the control 
group (IUI first or IUIF; n=77) women were treated with IUI during six 
treatment cycles. The first three IUI cycles were done without controlled 
ovarian hyper stimulation (COH). If pregnancy did not occur after three 
cycles of IUI in the natural cycle, the woman was offered a choice 
between continuing IUI in the natural cycle and starting IUI with COH 
with recombinant FSH for a maximum period of three additional cycles. 
Further treatment in the IUIF group was discontinued in 54 women 
because of pregnancy (n=38) or due to drop out (n=16). The remaining 23 
participants who did not conceive in the IUIF group all underwent a 
laparoscopy. The main outcomes were the pregnancy rate per woman 
randomized and the presence of pelvic pathology with therapeutic 
implications. The results are presented below in figures 4 and 5. 
The pregnancy rate per woman randomized was 40 to 50% and the 
presence of pelvic pathology with therapeutic implications was high (48 to 
56%) but both outcomes were equally distributed among both comparison 
groups. Indeed, the at random allocation of subfertile women to the 
laparoscopy first group versus the IUI first group made no difference for 
the ongoing pregnancy rates per woman randomized or the presence of 
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pelvic pathology requiring laparoscopic treatment. The respective ORs 
were 0.81 (95% CI 0.43 to 1.5, P=0.52) for the ongoing pregnancy rate 
(Figure 4) and 0.72 (95% CI 0.28 to 1.9, P=0.51) for the presence of 
pelvic pathology with therapeutic implications (Figure 5). 
 
Figure 4 Forest plot of comparison: Laparoscopy first versus IUI first in 
subfertile women treated by IUI. Outcome: Pregnancy per woman 
randomized. M-H: Mantel-Haenszel, fixed-effect model, CI: confidence 
interval.  
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Figure 5 Forest plot of comparison: Laparoscopy first versus IUI first in 
subfertile women treated by IUI. Outcome: Presence of pelvic pathology 
with therapeutic implications per woman randomized. M-H: Mantel-
Haenszel, fixed-effect model, CI: confidence interval.  
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The authors conclude that additional randomized studies are needed to 
verify the results of this single trial. They have calculated that at least 
1000 women should have been included to detect a difference of 10% in 
the cumulative ongoing pregnancy rate (Tanahatoe et al., 2005). 
Furthermore the high spontaneous pregnancy rate in both comparison 
groups (n=12 in LSF and n=16 in IUIF) is noteworthy. 
 
Laparoscopy after failed IUI 
There are to our knowledge no published studies on the added value of 
laparoscopy after several failed cycles of COH and IUI. Referring to the 
Dutch RCT (Tanahatoe et al, 2005), one may expect to detect pelvic 
pathology (endometriosis all stages, peritubal adhesions) in at least 50% 
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of cases. Laparoscopic treatment enhances the chance of spontaneous 
conception. One may, by extrapolation, expect a higher pregnancy rate 
after laparoscopic treatment after several failed IUI cycles. In conclusion, 
the position of laparoscopy for diagnosing and treating endometriosis 
and/or peritubal adhesions prior to IUI treatment or after several failed IUI 
cycles seems a matter of debate. Additional RCTs are needed on the 
position of laparoscopy in IUI. 
 
LAPAROSCOPY AND IVF 
 
Without doubt, the progress in assisted reproductive techniques/ 
technology (ART) has narrowed the indications for reproductive surgery. 
Some authors have recommended immediate treatment with ART after a 
limited and non-invasive fertility work-up in all subfertile women 
(Speroff et al, 1999). This raises two questions. Firstly, is it always 
mandatory to do a laparoscopy prior to ART? Secondly, is there any 
indication for a laparoscopy after several failed ART treatment cycles? 
 
Laparoscopy before IVF 
On the basis of the studies mentioned above (Mol et al, 2001; Mol et al, 
1999; Perquin et al, 2006) one could recommend that a laparoscopy could 
be avoided in all cases where IVF is clinically judged to be the most 
appropriate treatment. However, there is a fair degree of consensus that 
selected adnexal pathology, such as hydrosalpinx and ovarian 
endometriotic cysts, should still be treated by laparoscopic surgery prior 
to proceeding to IVF. 
With respect to hydrosalpinx, two RCTs have demonstrated increased 
success rates with IVF following salpingectomy for ultrasonically visible 
hydrosalpinges (Dechaud et al, 1998; Strandell et al, 1999). Both trials 
have been included in a recent Cochrane review (Johnson et al, 2004). The 
intention-to-treat analysis for the data of the delivery rates in the 
Scandinavian trial (Strandell et al, 1999) demonstrated no evidence for 
statistically significant differences between both comparison groups (27% 
versus 17%; risk ratio (RR) was 1.6, 95% CI 0.9 to 2.7, P=0.13, 1 study, 
n=204 women). In a subgroup analysis however, the delivery rates in 
women treated by IVF after salpingectomy for a hydrosalpinx visible by 
ultrasound were substantially increased compared to women with the 
hydrosalpinx left untreated (40% versus 17%; RR 2.4; 95% CI 1.1 to 5.3, 
P=0.038, 1 study, n=75 women). The highest increase in delivery rate was 
observed in women with bilateral hydrosalpinx on ultrasound (55% versus 
16%; RR 3.5; 95% CI 1.1 to 11, P=0.019, 1 study, n=39 women). Based 
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on the data of the meta-analysis (Johnson et al, 2004), the number needed 
to treat to benefit (NNTB) is eight (95% CI 5 to 11). 
There are several hypotheses in the literature to explain the beneficial 
effect of removing the diseased tubes: a direct toxic effect of tubal fluid 
on the embryos, a negative effect of tubal fluid on the endometrium by 
flushing out embryos, dilution of implantation factors and prevention of 
normal embryonic-endometrial apposition (Erel and Senturk, 2005). Some 
authors have argued against the indiscriminate removal of all 
hydrosalpinges prior to ART; they have recommended to consider doing a 
neosalpingostomy in selected cases identified by concomitant 
salpingoscopy (Puttemans et al, 1996). A RCT of reconstructive tubal 
surgery versus salpingectomy prior to proceeding with IVF in women 
with hydrosalpinx is needed to define the position of both treatment 
strategies in everyday clinical practice; such a management trial can, 
reasonably spoken, only be conducted in countries with a high prevalence 
of PID (Sabatini and Davis, 2005). 
There are no RCTs or meta-analyses available to answer the question 
whether surgical treatment of moderate and severe endometriosis 
enhances the rates of spontaneous conception or pregnancy after IVF 
(Kennedy et al, 2005). There were no treatment-independent pregnancies 
among couples with r-AFS stages III or IV endometriosis in an analysis of 
data from the Canadian CITES study (Mol et al, 1999). Two prospective 
cohort studies (Nezhat et al, 1989; Vercellini et al, 2006) have reported 
crude spontaneous pregnancy rates of 57% to 69% (moderate 
endometriosis) and 52% to 68% (severe endometriosis) following 
laparoscopic surgery. These numbers are substantially higher than the 
crude spontaneous pregnancy rates of 33% (moderate endometriosis) and 
0% (severe endometriosis) after expectant management reported in a third 
prospective cohort study (Olive et al, 1985). Based on these observational 
studies it is generally accepted that in case of subfertility, moderate and 
severe stage endometriosis should be treated by surgery. There seems to 
be a negative correlation between the stage of endometriosis and the 
spontaneous cumulative pregnancy rate after surgical removal of 
endometriosis based on the evidence of three observational studies 
(Adamson et al, 1993; Guzick et al, 1997; Osuga et al, 2002), but 
statistical significance was reached in one study only (Osuga et al., 2002). 
Recent ESHRE guidelines state that IVF is the appropriate treatment if 
tubal function is compromised, if there is severe male factor infertility or 
if other treatments have failed (Kennedy et al., 2005). 
The IVF pregnancy rates are lower in women with endometriosis than in 
those with tubal infertility according to a systematic review of 22 non-
randomized studies (Barnhart et al, 2002). These authors conclude that 
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there is an overall 54% reduction in pregnancy rate after IVF in women 
with endometriosis; the success rates are poorer with advancing severity 
of the disease, staged according to the r-AFS classification system. In 
contrast, according to data from large databases namely SART (the 
Society for Assisted Reproductive Technology) and HFEA (the Human 
Fertilization and Embryology Authority) endometriosis does not seem to 
adversely affect the reported pregnancy rates (Templeton et al, 1996). 
There are no RCTs available that have tested the hypothesis that surgical 
treatment of endometriosis prior to IVF results in higher pregnancy rates 
when compared to expectant management of endometriosis. 
Ovarian endometriotic cysts need extra attention in the context of ART 
since they can be disadvantageous for IVF treatment: they may interfere 
with controlled ovarian hyperstimulation (COH), create difficulties in 
aspirating the ovarian follicles during oocyte retrieval, and be held 
responsible for producing detrimental substances that are toxic to 
maturing oocytes, thus impeding embryo cleavage and implantation. 
Laparoscopic surgery for advanced stage endometriosis can be technically 
very demanding and time-consuming; moreover it carries a high risk for 
significant postoperative morbidity and long revalidation. The removal of 
ovarian endometriomas prior to COH may be associated with significant 
bleeding and destruction of normal adjacent ovarian tissue, thus 
diminishing the reproductive ovarian function. There are no RCTs 
comparing the live birth rates after IVF treatment in women who were 
surgically treated for endometriotic cysts prior to IVF versus women who 
were not. According to one retrospective case-control study (Garcia-
Velasco et al, 2004) the removal of endometriotic cysts prior to IVF did 
not improve fertility outcome. In cases of asymptomatic small 
endometriotic cysts (<3 cm), immediate proceeding to IVF may reduce 
the time to pregnancy, treatment costs and the possible detrimental effects 
of inappropriate surgery on the ovarian function. The laparoscopic 
excision of larger symptomatic endometriotic cysts (>4 cm) increases the 
chance for spontaneous pregnancy and reduces recurrence compared to 
simple drainage and coagulation (Beretta et al, 1998; Chapron et al, 2002; 
Vercellini et al, 2003b). 
 
Laparoscopic treatment of endometriosis after failed IVF 
Finally, is it worth doing laparoscopic surgery in women with 
endometriosis after several failed IVF cycles? No RCTs are available but 
a retrospective cohort study (Littman et al, 2005) deserves a closer look. 
In a series of 29 women with several failed IVF cycles and endometriosis, 
a radical treatment of all endometriotic lesions was done by one expert 
laparoscopic surgeon. After surgery, 22 pregnancies were observed, 
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including 15 spontaneous pregnancies and 7 pregnancies after repeated 
IVF treatment. The limited evidence from this retrospective observational 
study highlights the importance of treating women with severe 
endometriosis in a centre with sufficient surgical expertise (Kennedy et al, 
2005). 
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CONCLUSION 
 
The surgical treatment of minimal/mild endometriosis increases the 
spontaneous pregnancy rate in women with otherwise unexplained 
subfertility. The position of laparoscopy for diagnosing and treating 
endometriosis and/or adhesions prior to IUI treatment or after failed IUI 
treatment is a matter of debate; additional RCTs are needed to test the 
hypothesis that this surgical approach might improve the pregnancy rates 
during IUI treatment. RCTs confirming the benefit of the surgical 
treatment of moderate and severe endometriosis in subfertile women are 
lacking, but the value of surgery seems generally accepted. 
The position and timing of laparoscopy in ovulation induction treatment is 
difficult to establish due to a lack of RCTs. Laparoscopy is indicated in all 
cases of bilateral anomalies on HSG: the exclusion of bilateral anatomical 
tubal pathology by laparoscopy could avoid IVF treatment in some cases. 
LOD in the treatment of women with CC-resistant PCOS is at least as 
effective as gonadotrophin treatment, but has a significantly lower risk of 
multiple pregnancies. Prior to IVF the laparoscopic removal of 
ultrasonically visible hydrosalpinges may increase the IVF success rates; 
more research is needed to evaluate the effectiveness of alternative 
surgical strategies, such as the restoration of a hydrosalpinx with an 
otherwise healthy endosalpingeal mucosa. Small asymptomatic 
endometriotic cysts probably need no treatment prior to IVF according to 
observational evidence in contrast to the larger symptomatic 
endometriomas. 
The routine practice of doing a laparoscopy in all subfertile women is 
questionable and not supported by high-quality evidence; therefore more 
studies are needed on the add-on value and timing of laparoscopy in 
current fertility practice. 
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ABSTRACT 
 
Background 
Hysteroscopy is frequently used for treating subfertile women, but a 
systematic review of the evidence on this subject is lacking.  
 
Methods 
We summarized and appraised the evidence for the benefit yielded by this 
procedure. Our systematic search was limited to randomized controlled 
trials (RCTs). The QUOROM (Quality of Reporting of Meta-analyses) 
standards were followed. Language restrictions were not applied. 
 
Results 
We retrieved five studies. The hysteroscopic removal of endometrial 
polyps with a mean diameter of 16mm detected by ultrasound doubles the 
pregnancy rate compared to diagnostic hysteroscopy and polyp biopsy in 
women undergoing intrauterine insemination: the risk ratio (RR) was 2.2, 
95% confidence interval (CI) 1.6 to 3.1, P<0.00001.  
In subfertile women with one knot and/or one fibroid smaller than 4cm, 
there was a trend in favor of hysteroscopic myomectomy compared to 
expectant management; the differences between both comparison groups 
were not statistically significant (RR 1.9, 95% CI 0.97 to 3.7, P=0.06). 
Hysteroscopic metroplasty for septate uterus resulted in fewer pregnancies 
in subfertile women compared to those with recurrent pregnancy loss (RR 
0.7, 95% CI 0.5 to 0.9, P=0.01). There are no RCTs on the effectiveness 
of the hysteroscopic treatment of intrauterine adhesions. Hysteroscopy in 
the cycle preceding a subsequent in vitro fertilization (IVF) attempt can 
nearly double the pregnancy rate in women suffering from primary 
subfertility with at least two failed IVF attempts compared to starting a 
next IVF cycle without prior hysteroscopy (RR 1.6, 95% CI 1.3 to 1.9, 
P<0.00001). 
 
Conclusions 
Scarce evidence on the effectiveness of hysteroscopic surgery in subfertile 
women with polyps, fibroids, septate uterus or intrauterine adhesions 
indicates a potential benefit. 
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INTRODUCTION 
 
The position of hysteroscopy in current fertility practice is unclear 
(Shushan and Rojansky, 1999) despite several randomized controlled 
trials (RCTs) on its technical feasibility and high patient compliance 
(Kremer et al, 2000; Soriano et al, 2000; Unfried et al, 2001; De Angelis 
et al, 2003; Guida et al, 2003; Litta et al, 2003; Pellicano et al, 2003; 
Marsh et al, 2004; Shankar et al, 2004; Campo et al, 2005; Sharma et al, 
2005; Garbin et al, 2006; Guida et al, 2006; Sagiv et al, 2006; De Placido 
et al, 2007; Kabli and Tulandi, 2008). There seems to be fewer 
consensuses on the effectiveness of hysteroscopy for improving the 
fertility prognosis of subfertile women. 
The Royal College of Obstetricians and Gynecologists (RCOG) do not 
recommend hysteroscopy as an initial investigation in the fertility work-
up unless clinically indicated. In its evidence-based guidelines on fertility 
assessment and treatment, the statement for not recommending 
hysteroscopy as a procedure to be routinely done in all subfertile women 
has received a grade B (RCOG, 2004). It is argued that the effectiveness 
of hysteroscopy in the general subfertile population has not yet been 
proven by high-quality evidence. The European Society for Human 
Reproduction and Embryology (ESHRE) has adopted a similar viewpoint 
(Crosignani and Rubin, 2000).  
This systematic review (SR) aims to examine the effectiveness of the 
hysteroscopic removal of endometrial polyps, submucous fibroids, uterine 
septa or intrauterine adhesions in subfertile women for improving their 
chance to become pregnant. We also aimed to study the effectiveness of 
hysteroscopy in women treated by IVF or intrauterine insemination (IUI). 
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METHODS 
 
Literature search methodology 
We aimed to identify RCTs on the hysteroscopic treatment of endometrial 
polyps, submucous fibroids, septate uterus or intrauterine adhesions in 
subfertile women or prior to IVF/ICSI (intracytoplasmic sperm insertion) 
or IUI. 
Two review authors conducted independently a systematic literature 
search using Medical Subject Headings (MeSH) terms for “hysteroscopy, 
polyps, fibroids, congenital anomalies, Asherman’s syndrome, adhesions 
and assisted reproductive techniques” in MEDLINE through Pub Med 
(1966-November 2008), EMBASE (1974-November 2008), CINAHL 
(1981-November 2008), The Cochrane Library (1970-November 2008) 
and DARE (Database of Abstracts of Reviews of Effects) for relevant 
studies. We also searched clinical trial databases namely ISRCTN 
(International Standard Randomized Controlled Trial Number) register 
and Meta-register). 
We classified the retrieved studies in two main categories: studies on 
operative hysteroscopy in subfertile women with polyps, fibroids, septate 
uterus and intrauterine adhesions and studies on diagnostic or operative 
hysteroscopy in women treated by IVF/ICSI or IUI. The full-text 
manuscripts of all citations that possibly matched the predefined selection 
criteria were examined by four authors independently for final inclusion 
or exclusion; any disagreement about inclusion was resolved by consensus 
or after consultation with an independent fifth author. 
 
Study selection 
RCTs were included if they dealt with diagnostic or operative 
hysteroscopy as the study intervention and with pregnancy and/or live 
birth as one of the main outcomes. The study population included women 
with polyps, fibroids, septate uterus and intrauterine adhesions suffering 
from subfertility as the main clinical problem or treated by IVF or IUI.  
Trials on diagnostic accuracy, patient compliance and cost-effectiveness 
were excluded. Language restrictions were not applied. 
 
Data extraction 
We assessed the selected studies for methodological quality by using 
check-lists available at the Dutch Cochrane Centre website. The 
QUOROM checklist was followed (Moher et al, 1999). We contacted the 
primary study authors to obtain missing data or clarification if necessary. 
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Statistical analysis 
Statistical analysis was done using Review Manager 5. Dichotomous data 
were extracted in 2x2 tables. Results were expressed as risk ratios (RR) 
with 95% confidence intervals (CI) using a fixed-effect model (Mantel-
Haenszel). Statistical heterogeneity was assessed with the I² statistic. 
 
RESULTS 
 
The process of the literature search and selection is shown in figure 1: we 
included five RCTs. 
 
Figure 1 Flowchart for systematic review (SR) of hysteroscopy in fertility 
practice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Full manuscripts retrieved for evaluation: n=178
Potentially eligible for inclusion n=30 
Citations excluded after  
Screening titles/abstracts: n=641 
Excluded with reason: 
n=148  
 RCT: n=3 
 SR of RCTs: n=1 
 Non- controlled: n=2 
 Review articles: n=50 
 Retrospective: n=56 
 Case control: n=1 
 Case series: n=14 
 Case report: n=7 
 Clinical article: n=14 
Articles excluded 
with reason: n=25  
 RCTS: n=3 
• outcome:2 
• excluded 
fibroids:1 
 Observational: n=22 RCTs included in the present SR n=5 
Total number of citations: n= 819 
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We included three trials on the effectiveness of operative hysteroscopy in 
subfertile women with endometrial polyps, fibroids or septate uterus. A 
summary of the study characteristics of these three RCTs is presented in 
table 1.  
We included two RCTs on the effectiveness of diagnostic or operative 
hysteroscopy in women undergoing IVF: both were included in a SR with 
meta-analysis (El-Toukhy et al, 2008). See table 2. 
 
Table 1 The effectiveness of operative hysteroscopy for polyps, fibroids 
and septate uterus on outcome (pregnancy); study characteristics of the 
three included RCTs. 
 
 
Pathology Polyps Fibroids Septate uterus 
Reference Pérez-Medina 2005 Casini 2006 Colacurci 2007 
Method of randomization computer generated 
 list 
random table computer generated 
list 
Allocation concealment yes no no 
Blinding no no no 
Groups comparable unclear yes yes 
Intention-to-treat analysis no yes no 
Follow-up rate analysis > 95% > 95% < 85% 
Power calculation yes no no 
N of included women 215 94 160 
Intervention hysteroscopic 
polypectomy 
N=107 
hysteroscopy/ 
laparotomy 
N=52 
5 mm hysteroscopy  
with Versapoint 
N=80 
Control group diagnostic hysteroscopy 
N=108 
no surgery 
N=42 
8 mm resectoscopy 
N=80 
Outcome measure pregnancy rate after 4 
cycles/time to 
pregnancy 
clinical pregnancy 
rate at 12 months 
clinical pregnancy rate  
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Table 2 Effectiveness of outpatient hysteroscopy in recurrent IVF failure; 
study characteristics of the two included RCTs. 
 
 
Reference Demirol and Gurgan, 2004 Rama Raju et al, 2006 
Method of randomization computer generated list computer generated list 
Concealment yes not clear 
Blinding no yes 
Groups comparable yes yes 
Intention-to-treat analysis yes yes 
Follow-up rate analysis > 95% > 95% 
Number of included women 421 520 
Type of infertility primary primary 
Previous investigations HSG HSG 
IVF history ≥ 2 failed cycles ≥ 2 failed cycles 
Timing of hysteroscopy follicular phase follicular phase 
Distension medium saline glycine 
% abnormal findings 26% 37% 
Intervention 5 mm hysteroscopy 
n=210 
5 mm hysteroscopy 
n=265 
Control no hysteroscopy 
n=211 
no hysteroscopy 
n=255 
Outcome measure clinical pregnancy rate, 
miscarriage rate 
clinical pregnancy rate, 
miscarriage rate, live birth 
rate 
 
We excluded three RCTs: the conception rate was not studied as the main 
outcome in two studies (Muzii et al, 2007; Vercellini et al, 1993) and one 
trial on fibroids (Seracchioli et al, 2000) published in a Cochrane review 
(Griffiths et al, 2006) excluded submucous fibroids. 
 
Does operative hysteroscopy increase the pregnancy rate in subfertile 
women with a specified uterine pathology? 
 
Hysteroscopic polypectomy  
We found two RCTs on the hysteroscopic removal of endometrial polyps 
(Pérez-Medina et al, 2005; Muzii et al, 2007); only one trial studied the 
reproductive outcome after hysteroscopic polypectomy in subfertile 
women with endometrial polyps undergoing IUI (Pérez- Medina et al, 
2005). The study characteristics are presented in table 1. The study 
population consisted of subfertile women with a sonographic diagnosis of 
endometrial polyps trying to conceive for at least 24 months and planned 
for IUI. An endometrial polyp was suspected when a hyperechogenic 
image with regular contour was demonstrated on transvaginal ultrasound 
(TVUS) with the presence of a vascular stalk on color Doppler map. The 
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polyps were detected in 452 out of 2800 consecutive women scheduled 
for IUI that attended the fertility clinic of a university hospital during a 
50-month period. Of these 452 women, 215 gave informed consent for 
participation in the study. Randomization was done by a computer 
generated list using sequentially numbered opaque sealed envelopes. 
Women allocated to the intervention group (n=107) were treated by 
polypectomy with a 5.5 mm continuous flow office hysteroscope whereas 
in the control group (n=108) women underwent a diagnostic hysteroscopy 
with polyp biopsy. Participants in both comparison groups were 
subsequently treated with four cycles of IUI with ovarian stimulation with 
recombinant FSH starting three months after hysteroscopy.  
Clinical pregnancy was defined as a rising level of ß-hCG combined with 
TVUS visualization of a gestational sac. The clinical pregnancy rate after 
4 IUI cycles was 63% in the polypectomy group compared to 28% in the 
control group (RR 2.2, 95% CI 1.6 to 3.1, P<0.00001) (Figure 2). The 
number needed to treat to benefit (NNTB) is 3 (95% CI 2 to 5). 
Interestingly, 65% of all pregnancies in the polypectomy group occurred 
before the IUI was started, resulting in a spontaneous pregnancy rate of 
29% in the polypectomy group versus 3% in the control group (RR 10, 
95% CI 3 to 30, P<0.00001). Data on live birth rates were not available 
from this trial. 
There were no statistically significant differences between the groups 
according to the size of the polyps (P>0.05). There were no data on the 
number or the location of the polyps. 
 
Figure 2 Forest plot of comparison: Hysteroscopic polypectomy versus 
hysteroscopy and biopsy in subfertile women with ultrasonographically 
detected endometrial polyps undergoing intrauterine insemination. 
Outcome: Clinical pregnancy after 4 IUI cycles. M-H: Mantel-Haenszel, 
fixed- effect model, CI: confidence interval. 
 
 
Study or Subgroup
Pérez Medina 2005
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 4.51 (P < 0.00001)
Events
64
64
Total
107
107
Events
29
29
Total
108
108
Weight
100.0%
100.0%
M-H, Fixed, 95% CI
2.23 [1.57, 3.15]
2.23 [1.57, 3.15]
Polypectomy Diagnostic hysteroscopy Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours diagnostic only Favours polyp removal  
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Hysteroscopic myomectomy 
We found one RCT on reproductive outcome in subfertile women treated 
with myomectomy versus expectant management (Casini et al, 2006). 
From an undetermined source population of women referred to a 
university fertility centre between January 1998 and April 2005, 193 
women with unexplained subfertility and with an ultrasonographic 
diagnosis of fibroids were included in the study. All study participants 
were younger than 35 years and had one ‘knot’ and/or fibroid smaller than 
4cm diagnosed by TVUS; we could not obtain any further clarification by 
the primary study authors on the definition of ‘knot’. The Italian study 
authors randomized 181 women to surgical treatment (laparotomy and/or 
operative hysteroscopy) or expectant management. Women in the 
intervention group were asked to abstain from having sexual intercourse 
for 3 months after the surgical procedure; those in the control group were 
allowed to have timed intercourse immediately after randomization. 
We analyzed only the data of women with submucous fibroids with or 
without intramural fibroids in the present systematic review. Data on the 
study characteristics are presented in table 1. It is unclear whether all 
women had a diagnostic hysteroscopy to confirm or exclude the presence 
of submucous fibroids. It is also not clear whether only intramural fibroids 
with uterine cavity deformation were included or not. Pregnancy was 
defined as the visualization of an embryo with cardiac activity at 6 to 7 
weeks of pregnancy. At 12 months after randomization pregnancy rates 
were almost doubled in the intervention group compared to the control 
group; the differences between both comparison groups were not 
statistically significant according to our computation (RR 1.9, 95% CI 
0.97 to 3.7, P=0.06) as opposed to the findings reported by the authors in 
the primary study publication which claim statistical significance (Figure 
3). The NNTB is 5 with a wide confidence interval (95% CI 3 to 100). No 
significant differences in pregnancy rates were found between the two 
comparison groups for a subgroup analysis including subfertile women 
with only submucous fibroids (RR 1.6, 95% CI 0.72 to 3.5, P=0.25). Our 
computation yielded different P values than those reported in the primary 
study publication. 
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Figure 3 Forest plot of comparison: Myomectomy versus expectant 
management in subfertile women with one knot* and/or one submucous 
fibroid with or without intramural fibroid smaller than 4 cm. Outcome: 
Clinical pregnancy. M-H: Mantel-Haenszel, fixed-effect model, CI: 
confidence interval. 
 
Study or Subgroup
Casini 2005
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.86 (P = 0.06)
Events
21
21
Total
52
52
Events
9
9
Total
42
42
Weight
100.0%
100.0%
M-H, Fixed, 95% CI
1.88 [0.97, 3.67]
1.88 [0.97, 3.67]
Myomectomy Expectant Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours expectant Favours myomectomy  
 
* The definition of knot is unclear; no further clarification could be 
obtained from the authors of the primary study. 
 
Hysteroscopic metroplasty 
We found two RCTs on hysteroscopic metroplasty; we excluded one 
study because there were no published data on the reproductive outcome 
(Vercellini et al, 1993). The other study randomly compared two methods 
of hysteroscopic treatment of uterine septa (resectoscopy versus 
Versapoint electrode) in a mixed population of 160 women with 
subfertility or recurrent pregnancy loss (Colacurci et al, 2007). The study 
characteristics are presented in table 1. There were no statistically 
significant differences in clinical pregnancy rates after hysteroscopic 
septoplasty with the Versapoint electrode versus the classical resectoscope 
(RR 1.1, 95% CI 0.90 to 1.3, P=0.36). Clinical pregnancy rate was defined 
by rising ß-hCG levels and visualization of a gestational sac. We 
calculated the data on the reproductive outcome in the subgroup of 
women suffering from primary subfertility compared to those with 
recurrent pregnancy loss. There were significantly fewer pregnancies after 
hysteroscopic metroplasty in the subgroup of women with primary 
subfertility versus those with recurrent pregnancy loss (RR 0.7, 95% CI 
0.5 to 0.9, P=0.01) (Figure 4). We could not study interaction (effect 
modification) formally because it was unknown which individual women 
with recurrent pregnancy loss also suffered from primary subfertility. 
Chapter 3 
 
 
60 
Figure 4 Forest plot of comparison: Primary subfertility versus recurrent 
pregnancy loss. Outcome: Pregnancy. M-H: Mantel-Haenszel, fixed-effect 
model, CI: confidence interval. 
 
Study or Subgroup
Colacurci 2007
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 2.47 (P = 0.01)
Events
26
26
Total
45
45
Events
73
73
Total
90
90
Weight
100.0%
100.0%
M-H, Fixed, 95% CI
0.71 [0.54, 0.93]
0.71 [0.54, 0.93]
Primary subfertility Recurrent pregnancy loss Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours subfertility Favours RPL  
 
Hysteroscopic synechiolysis  
No RCTs were retrieved on pregnancy rates after hysteroscopic 
synechiolysis in subfertile women with intrauterine adhesions. 
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Does diagnostic or operative hysteroscopy increase the pregnancy 
rate in subfertile women undergoing IVF? 
 
There are two RCTs on the effectiveness of hysteroscopy in women 
treated by IVF (Demirol and Gurgan, 2004; Rama Raju et al, 2006). The 
quality of these studies, their characteristics, and the participant and 
intervention characteristics are summarized in table 2. Both studies 
included 941 women with at least two failed IVF attempts in two tertiary 
non-university IVF clinics. All women suffered from primary subfertility 
and had a normal uterine cavity on hysterosalpingography (HSG). They 
were randomly allocated to two comparison groups using computer 
generated random numbers. Group I (n=476) did not undergo an office 
hysteroscopy prior to a subsequent IVF treatment cycle. In group II 
(n=465) office hysteroscopy was performed with a 5mm 30° 
hysteroscope. Group II was subdivided into group IIa (normal findings at 
office hysteroscopy; n=314) and group IIb (uterine pathology detected and 
treated by office hysteroscopy; n=151). Clinical pregnancy was defined by 
the visualization of fetal heart pulsation at 6 weeks. Office hysteroscopy 
before a next IVF cycle significantly increased the clinical pregnancy rate 
compared to women where IVF was started immediately without prior 
hysteroscopy (RR 1.6, 95% CI 1.3 to 1.9, P<0.00001) (Figure 5). There 
was no statistical heterogeneity beyond chance (Chi²=0.16, df=1(P=0.69); 
I²=0%). The NNTB is 7 (95% CI 5 to 12). In the intervention group, there 
were no statistically significant differences for the main outcome between 
women with normal findings (n=314) and women with uterine pathology 
(n=151) (RR 0.91, 95% CI 0.71 to 1.2, P=0.48) (Figure 6). 
 
Figure 5 Forest plot of comparison: Office hysteroscopy versus no 
hysteroscopy prior to subsequent IVF. Outcome: Clinical pregnancy. 
M-H: Mantel-Haenszel, fixed-effect model, CI: confidence interval. 
 
Study or Subgroup
Demirol and Gurgan 2004
Rama Raju 2006
Total (95% CI)
Total events
Heterogeneity: Chi² = 0.16, df = 1 (P = 0.69); I² = 0%
Test for overall effect: Z = 4.50 (P < 0.00001)
Events
67
108
175
Total
210
255
465
Events
45
69
114
Total
211
265
476
Weight
39.9%
60.1%
100.0%
M-H, Fixed, 95% CI
1.50 [1.08, 2.07]
1.63 [1.27, 2.09]
1.57 [1.29, 1.92]
Prior hysteroscopy Immediate IVF attempt Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
IVF without hysteroscopy Hysteroscopy prior to IVF  
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Figure 6: Forest plot of comparison: Pathology present versus normal. 
Outcome: Clinical pregnancy. M-H: Mantel-Haenszel, fixed-effect model, 
CI: confidence interval. 
 
Study or Subgroup
Demirol and Gurgan 2004
Rama Raju 2006
Total (95% CI)
Total events
Heterogeneity: Chi² = 0.02, df = 1 (P = 0.90); I² = 0%
Test for overall effect: Z = 0.71 (P = 0.48)
Events
17
38
55
Total
56
95
151
Events
50
71
121
Total
154
160
314
Weight
33.5%
66.5%
100.0%
M-H, Fixed, 95% CI
0.94 [0.59, 1.48]
0.90 [0.67, 1.22]
0.91 [0.71, 1.17]
Abnormal Normal Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours normal Favours abnormal  
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DISCUSSION 
 
Polyps 
The randomized trial on the effectiveness of hysteroscopic polypectomy 
in subfertile women with endometrial polyps treated subsequently with 
IUI (Perez-Medina et al, 2005) gives apparently straightforward results. 
The evidence is necessary but by itself not sufficient to establish a cause-
effect relationship between all endometrial polyps and subfertility. 
Moreover, the absence of blinding of women in this single study could 
have led to different sexual behavior among the study participants; 
therefore performance bias may be an alternative explanation for the 
findings of higher pregnancy rates after polypectomy, especially those 
observed in women who conceived spontaneously prior to IUI (Ankum, 
2005). 
Observational studies on hysteroscopic polypectomy in subfertile women 
fail to present consistent results (Valle, 1984; Hereter et al, 1998; 
Varasteh et al, 1999; Spiewankiewicz et al, 2003; Batioglu and Kaymak, 
2005; Annan and Amoah, 2006; Kassab et al, 2007). Therefore we should 
refrain from presenting recommendations based on the results of this 
single randomized trial.  
Several observational studies report higher pregnancy rates after the 
removal of tubocornual polyps suggesting that endometrial polyps in this 
region may have a substantial effect on reproductive function (Venturini 
et al, 1987; Brooks et al, 1990; Lee et al, 1997; Shokeir et al, 2004; 
Yanaihara et al, 2008). Other investigators have suggested that the 
observed association between endometrial polyps and subfertility may be 
alternatively explained by a confounding variable, namely concomitant 
endometriosis (Mc Bean et al, 1996; Kim et al, 2003). 
 
Fibroids 
The impact of fibroids on fertility remains controversial (Pritts, 2001; 
Lefebvre et al, 2003; Vilos, 2003; Griffiths et al, 2006; Somigliana et al, 
2007; Vimercati et al, 2007; Somigliana et al, 2008; Klatsky et al, 2008; 
Pritts et al, 2009).  
The only randomized trial comparing myomectomy to expectant 
management in women with fibroids and subfertility (Casini et al, 2006) 
was underpowered and not blinded. It is unclear whether hysteroscopy 
was used to screen systematically all the study participants. The inclusion 
criterion ‘knot’ is not defined properly, which is troublesome. More 
important, our own recalculation of the available data fails to demonstrate 
statistically significant differences for the pregnancy rates between both 
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comparison groups. This statistical error raises some concern about the 
validity of the published primary data. 
Observational epidemiological studies aimed at elucidating the causal 
relationship between fibroids and subfertility are equally not conclusive 
(Seoud et al, 1992; Narayan and Goswamy, 1994; Farhi et al, 1995; 
Lumbiganon et al, 1996; Eldar-Geva et al, 1998; Marshall et al, 1998; 
Ramzy et al, 1998; Stovall et al, 1998; Bulletti et al, 1999; Bajekal and Li, 
2000; Dietterich et al, 2000; Healy, 2000; Hart et al, 2001; Jun et al, 2001; 
Surrey et al, 2001; Wang et al, 2001; Check et al, 2002; Donnez and 
Jadoul, 2002; Ng and Ho, 2002; Yarali and Bukulmez, 2002; Bulletti et al, 
2004; Manyonda et al, 2004; Oliveira et al, 2004; Parazzini et al, 2004; 
Wang and Check, 2004; Wise et al, 2004; Benecke et al, 2005; Gianaroli 
et al, 2005; Ng et al, 2005; Rackow and Arici, 2005; Surrey et al, 2005; 
Khalaf et al, 2006; Klatsky et al, 2007). Overall the majority of the 
published studies are observational, often non-controlled and 
retrospective, with small sample sizes and a lack of adjustment of the 
results for important confounding variables such as maternal age.  
No data on a size effect relationship were retrieved. Non-controlled 
studies have suggested that the number, size and distortion effect of 
fibroids on the uterine cavity may be important (Bulletti et al, 1999; 
Varasteh et al, 1999; Bernard et al, 2000; Fernandez et al, 2001; Oliveira 
et al, 2005, Khalaf et al, 2006; Mukhopadhaya et al, 2007). 
The mechanism by which fibroids interfere with human reproduction is 
still unknown. Fibroids are believed to interfere with sperm migration, 
ovum transport and embryo implantation (Richards et al, 1998). This may 
be caused by altered contours of the uterine cavity resulting in altered 
mechanical pressure or abnormal uterine contractility (Bettocchi et al, 
2002; Farrugia et al, 2002; Oliveira et al, 2004). Local inflammation 
caused by the presence of submucous fibroids may cause focal 
endometrial vascular disturbances, chronic endometritis or secretion of 
vasoactive substances. Even an enhanced intrauterine androgen 
environment impairing gamete or zygote transport and embryo 
implantation has been suggested (Richards et al, 1998). It is biologically 
plausible that fibroids localized near the cervix may interfere with sperm 
transport whereas tubocornual fibroids may preferentially impair 
oocyte/embryo transport (Oliveira et al, 2004).  
 
Septate uterus 
Hysteroscopic metroplasty is frequently performed in women with 
recurrent miscarriage because a uterine septum is associated with an 
adverse pregnancy outcome. However, the effectiveness of hysteroscopic 
metroplasty in reducing miscarriage in women with septate uterus is at the 
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present not demonstrated by RCTs. A review of non-controlled studies 
suggests that the pregnancy outcome is more favorable after hysteroscopic 
metroplasty (Homer et al, 2000). However, the results of this review are 
biased because the reproductive outcomes were compared before and after 
metroplasty using women as their own controls; doing a before-after 
comparison will exaggerate the treatment effect of the intervention 
because the reason for the intervention has been the poor reproductive 
outcome in the index pregnancy (Christiansen et al, 2005). Although it 
could be considered unethical to design a RCT on the basis that a 
hysteroscopic metroplasty is technically easy to perform, a randomized 
trial is needed, and in fact is currently underway (http://www.studies-
obsgyn.nl/home/page.asp?page_id=596). The mechanism by which a 
septum may cause subfertility is not fully understood. It is biologically 
plausible that the endometrium of the septum may be unsuitable for 
blastocyst implantation. One author observed that the morphological 
development of endometrial septal specimens is suboptimal, using 
scanning electron microscopy (Fedele et al, 1996). The association 
between septate uterus and endometriosis, as reported in some non-
controlled studies, may explain the subfertility of at least some women 
with septate uterus but requires further research (Fayez, 1986; Fedele et 
al, 1993; Grimbizis et al, 1998; Nawroth et al, 2006).  
 
Intrauterine adhesions 
Randomized or clinical controlled studies on reproductive outcome after 
hysteroscopic synechiolysis are absent. The overall quality of the bulk of 
available observational studies on intrauterine adhesions is very poor 
(Sugimoto, 1978; Schenker and Margalioth, 1982; Fedele et al, 1986; 
Friedman et al, 1986; Parent et al, 1988; Valle and Sciarra, 1988; 
Pistofidis et al, 1996; Mc Comb and Wagner, 1997; Pabuçcu et al, 1997; 
Roge et al, 1997; Protopapas et al, 1998; Capella-Allouc et al, 1999; Feng 
et al, 1999; Preutthipan and Linasmita, 2000; Zikopoulos et al, 2004; 
Kodaman and Arici, 2007;Yu et al, 2008). Moreover, the results cannot be 
directly compared since different non-validated classification systems of 
the severity of disease are used (American Fertility Society, 1988; 
Wamsteker et al, 1998; Nasr et al, 2000).  
Subfertility in women with intrauterine adhesions may be caused by 
complete or partial occlusion of the tubal ostia, uterine cavity or the 
cervical canal, preventing the migration of sperm or the implantation of 
the embryo. Severe destruction of the endometrium may also lead to 
defective or absent implantation. 
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IVF 
The higher pregnancy rates in a subsequent IVF cycle after hysteroscopy 
in women suffering from primary subfertility with at least two failed IVF 
attempts even in the absence of intrauterine pathology is a somewhat 
unexpected but nevertheless biologically plausible observation. It is 
acceptable that cervical dilatation and/or direct hysteroscopic visualization 
of the uterine cavity may facilitate embryo transfer in this population (Mc 
Manus et al, 2000; Mansour and Aboulghar, 2002), Moreover, an 
immunological mechanism triggered by the hysteroscopic manipulation or 
by the effect of the distension medium on the endometrium, similar to the 
increased odds of spontaneous pregnancy after hysterosalpingography 
(Luttjeboer et al, 2007), might play a role. A new randomized trial on this 
subject is ongoing (Geslevich et al, 2006).  
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SUMMARY CONCLUSIONS 
 
Implications for clinical practice 
In women with primary subfertility and at least two failed IVF or ICSI 
attempts, diagnostic or operative hysteroscopy before a subsequent IVF or 
ICSI treatment is thought to improve reproductive outcome. Scarce 
evidence on the effectiveness of hysteroscopic surgery in subfertile 
women with polyps, fibroids, septate uterus or intrauterine adhesions 
suggests a potential benefit, but it is clear that more randomized trials are 
needed before evidence-based recommendations for the general subfertile 
target population can be given.  
 
Implications for further research 
Given the high costs of Assisted Reproductive Techniques (ART) it is 
imperative to study whether there is a benefit for doing a hysteroscopy in 
all women undergoing IVF or whether this benefit is limited to specific 
subgroups e. g. women with primary subfertility and at least two or more 
failed IVF treatment cycles. 
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ABSTRACT 
 
Background 
Observational studies suggest higher pregnancy rates after the 
hysteroscopic removal of endometrial polyps, submucous fibroids, uterine 
septum or intrauterine adhesions. 
 
Objectives 
To assess the effects of the hysteroscopic removal of endometrial polyps, 
submucous fibroids, uterine septum or intrauterine adhesions suspected on 
ultrasound, hysterosalpingography, diagnostic hysteroscopy or any 
combination of these methods in women with otherwise unexplained 
subfertility or prior to intrauterine insemination (IUI), in vitro fertilization 
(IVF) or intracytoplasmic sperm injection (ICSI). 
 
Search strategy 
We searched the Cochrane Menstrual Disorders and Subfertility 
Specialized Register (6 August 2012), the Cochrane Central Register of 
Controlled Trials (The Cochrane Library 2012, Issue 7), MEDLINE 
(1950 to October 2012), EMBASE (1974 to October 2012), CINAHL 
(from inception to October 2012) and other electronic sources of trials 
including trial registers, sources of unpublished literature and reference 
lists. We handsearched the American Society for Reproductive Medicine 
(ASRM) conference abstracts and proceedings (from January 2008 to 
October 2012) and we contacted experts in the field. 
 
Selection criteria 
Randomized comparisons between operative hysteroscopy versus control 
in women with otherwise unexplained subfertility or undergoing IUI, IVF 
or ICSI and suspected major uterine cavity abnormalities. Primary 
outcomes were live birth and hysteroscopy complications. Secondary 
outcomes were pregnancy and miscarriage. 
 
Data collection and analysis 
Two authors independently assessed studies for inclusion and risk of bias, 
and extracted data. We contacted study authors for additional information. 
 
Main results 
Two studies met the inclusion criteria. Neither reported the primary 
outcomes of live birth and complications from the procedure. In women 
with otherwise unexplained subfertility and submucous fibroids, there is 
no evidence of benefit with hysteroscopic myomectomy compared to 
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regular fertility-oriented intercourse during 12 months for clinical 
pregnancy (OR 2.4, 95% CI 0.97 to 6.2, P=0.06, 94 women) and 
miscarriage (OR 0.58, 95% CI 0.12 to 2.9, P=0.50, 30 clinical 
pregnancies, both very low-quality evidence). The hysteroscopic removal 
of polyps prior to IUI increases the odds of clinical pregnancy: the 
experimental event rate (EER) was 63% compared to the control event 
rate (CER) of 28% (OR 4.4, 95% CI 2.5 to 8.0, P< 0.00001, 204 women, 
high- quality evidence). 
 
Authors’ conclusions 
Hysteroscopic myomectomy might increase the odds of clinical pregnancy 
in women with unexplained subfertility and submucous fibroids, but the 
evidence is at present not conclusive. The hysteroscopic removal of 
endometrial polyps suspected on ultrasound in women prior to IUI might 
increase the clinical pregnancy rate. More randomized studies are needed 
to substantiate the effectiveness of the hysteroscopic removal of suspected 
endometrial polyps, submucous fibroids, uterine septum or intrauterine 
adhesions in women with unexplained subfertility or prior to IUI, IVF or 
ICSI. 
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BACKGROUND 
 
Description of the condition 
Subfertility is “a disease of the reproductive system defined by the failure 
to achieve a clinical pregnancy after 12 months or more of regular 
unprotected sexual intercourse” according to the International Committee 
for Monitoring Assisted Reproductive Technology (ICMART) and the 
World Health Organization (WHO) revised glossary of assisted 
reproductive technology (ART) (Zegers-Hochschild 2009). It is estimated 
that 72,400,000 women are subfertile and that 40,500,000 of these are 
currently seeking fertility treatment (Boivin 2007). Unexplained 
subfertility usually refers to a diagnosis (or lack of diagnosis) made in 
couples in whom all the standard investigations such as tests of ovulation, 
tubal patency and semen analysis are normal: it can be found in as many 
as 30% to 40% of subfertile couples (Ray 2012). 
The evaluation of the uterine cavity is a basic step in the investigation of 
subfertile women since the uterine cavity and its inner layer, the 
endometrium, are assumed to be important for the implantation of the 
human blastocyst. Nevertheless, the complex mechanisms leading to 
successful implantation are still poorly understood (Taylor 2008). Despite 
the huge investment in research and developments of the technologies and 
biology involved in medically assisted reproduction (MAR), the 
maximum implantation rate per embryo transferred still remains only 30% 
(Andersen 2008). The different phases of the implantation process are 
established by the complex interplay between the blastocyst and the 
endometrium (Singh 2011). 
Major uterine cavity abnormalities can be found in 10% to 15% of women 
seeking treatment for subfertility; they usually consist of the presence of 
excessive normal uterine tissue (Wallach 1972). The most common 
acquired uterine cavity abnormality is an endometrial polyp. This benign, 
endometrial stalk-like mass protrudes into the uterine cavity and has its 
own vascular supply. Depending on the population under study and the 
applied diagnostic test, endometrial polyps can be found in 1% to 41% of 
the subfertile population (Silberstein 2006). A fibroid is an excessive 
growth originating from the muscular part of the uterine cavity. Fibroids 
are present in 2.4% of subfertile women without any other obvious cause 
of subfertility (Donnez 2002). A submucous fibroid is located underneath 
the endometrium and is thought to interfere with fertility by deforming the 
uterine cavity. Intrauterine adhesions are fibrous tissue strings connecting 
parts of the uterine wall. They are commonly caused by inflammation or 
iatrogenic tissue damage (for example suction curettage after miscarriage) 
and are present in 0.3% to 14% of subfertile women (Fatemi 2010). A 
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septate uterus is a congenital malformation in which the longitudinal band 
separating the left and right Müllerian ducts, which form the uterus in the 
human female fetus, has not been entirely resorbed. A uterine septum is 
present in 1% to 3.6% of women with otherwise unexplained subfertility 
(Saravelos 2008). 
Ultrasonography (US), preferably transvaginally (TVUS), is used to 
screen for possible endometrium or uterine cavity abnormalities in the 
work-up of subfertile patients. This evaluation can be expanded with 
hysterosalpingography (HSG), saline infusion/gel instillation sonography 
(SIS/GIS) and diagnostic hysteroscopy. Diagnostic hysteroscopy is 
generally considered as being the gold standard procedure for the 
assessment of the uterine cavity since it enables direct visualization; 
moreover, treatment of intrauterine pathology can be done in the same 
setting (Bettocchi 2004). Nevertheless, even for experienced 
gynecologists the hysteroscopic diagnosis of the major uterine cavity 
abnormalities may be problematic (Kasius 2011). 
 
Description of the intervention 
Hysteroscopy is performed for the evaluation, or for the treatment of the 
uterine cavity, tubal ostia and endocervical canal in women with uterine 
bleeding disorders, Müllerian tract anomalies, retained intrauterine 
contraceptive devices or other foreign bodies, retained products of 
conception, desire for sterilization, recurrent miscarriage and subfertility. 
Most diagnostic and many operative procedures can be done in an office 
setting using local anesthesia and fluid distension media, while more 
complex procedures are generally performed as day surgery under general 
anesthesia (Clark 2005). Operative hysteroscopic procedures require a 
complex instrumentation set-up, special training of the surgeon and 
knowledge and skills in the adequate management of complications 
(Campo 1999). Complications from hysteroscopy are rare; a multicentre 
study including 13,600 diagnostic and operative hysteroscopic procedures 
performed in 82 centers reported a complication rate of 0.28% (Jansen 
2000). 
 
How the intervention might work 
It is plausible that major uterine cavity abnormalities may interfere with 
the factors that regulate the blastocyst-endometrium interplay, for 
example hormones and cytokines, precluding the possibility of pregnancy. 
Many hypotheses have been formulated in the literature of how 
endometrial polyps (Shokeir 2004; Silberstein 2006; Taylor 2008; 
Yanaihara 2008), submucous fibroids (Pritts 2001; Somigliana 2007; 
Taylor 2008), intrauterine adhesions (Yu 2008) and uterine septum 
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(Fedele 1996) are likely to disturb the implantation of the human embryo; 
nevertheless, the precise mechanisms of action by which each one of these 
major uterine cavity abnormalities affects the essential reproductive 
process of embryo implantation are poorly understood. 
For endometrial polyps, submucous fibroids, intrauterine adhesions and 
uterine septum, observational studies have suggested an improvement in 
the spontaneous pregnancy rate after the hysteroscopic removal of the 
abnormality (Taylor 2008). The chance for pregnancy is significantly 
lower in subfertile women with submucous fibroids compared to other 
causes of subfertility according to a systematic review and meta-analysis 
of 11 observational studies (Pritts 2001; Pritts 2009). Three observational 
studies found a major benefit for removing a uterine septum by 
hysteroscopic metroplasty in subfertile women with a uterine septum 
(Mollo 2009; Shokeir 2011; Tomaževič 2010). 
 
OBJECTIVES 
 
To assess the effects of the hysteroscopic removal of endometrial polyps, 
submucous fibroids, uterine septum or intrauterine adhesions suspected on 
ultrasound, hysterosalpingography, diagnostic hysteroscopy or any 
combination of these methods in women with otherwise unexplained 
subfertility or prior to intrauterine insemination (IUI), in vitro fertilization 
(IVF) or intracytoplasmic sperm injection (ICSI). 
 
METHODS 
 
Criteria for considering studies for this review 
 
Types of studies 
We included only trials that were either clearly randomized or claimed to 
be randomized.  
 
Types of participants 
• Women of reproductive age with otherwise unexplained subfertility and 
endometrial polyps, submucous fibroids, septate uterus or intrauterine 
adhesions. 
• Women of reproductive age with subfertility, undergoing IUI, IVF or 
ICSI with endometrial polyps, submucous fibroids, septate uterus or 
intrauterine adhesions. 
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Types of interventions 
• Randomized comparison between operative hysteroscopy versus control 
in women with otherwise unexplained subfertility and suspected major 
uterine cavity abnormalities. 
• Randomized comparison between operative hysteroscopy versus control 
in women undergoing IUI, IVF or ICSI with suspected major uterine 
cavity abnormalities. 
 
Types of outcome measures 
 
*Primary outcomes 
 
1. Effectiveness: live birth, defined as a delivery of a live fetus after 20 
completed weeks of gestational age that resulted in at least one live baby 
born. The delivery of a singleton, twin or multiple pregnancies was 
counted as one live birth (Zegers-Hochschild 2009). 
 
2. Adverse events: hysteroscopy complications, defined as any 
complication due to hysteroscopy. 
 
*Secondary outcomes 
 
3. Pregnancy 
• Ongoing pregnancy, defined as a pregnancy surpassing the first trimester 
or 12 weeks of pregnancy. 
• Clinical pregnancy, defined as a pregnancy diagnosed by US 
visualization of one or more gestational sacs or definitive clinical signs of 
pregnancy (Zegers-Hochschild 2009). 
 
4. Adverse events: miscarriage, defined as the spontaneous loss of a 
clinical pregnancy before 20 completed weeks of gestation, or if 
gestational age is unknown a fetus with a weight of 500 g or less (Zegers-
Hochschild 2009). 
 
Search methods for identification of studies 
 
Electronic searches 
We searched the Cochrane Central Register of Controlled Trials 
(CENTRAL) (The Cochrane Library 2012, Issue 7), the Menstrual 
Disorders and Subfertility Group (MDSG) Specialized Register, 
MEDLINE using Pub Med (1950 to 27 October 2012) and EMBASE 
using EMBASE.com (1974 to 27 October 2012). The search was not 
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limited by language, year of publication or document format. We also 
searched other electronic sources of trials in the Cochrane Database of 
Systematic Reviews (CDSR), the Database of Abstracts of Reviews of 
Effects (DARE) and the Health Technology Assessment Database (HTA 
Database) through the Centre for Reviews and Dissemination, National 
Guideline Clearinghouse, ISI Web of Knowledge, CINAHL and trial 
registers for ongoing and registered trials (Current Controlled Trials and 
the World Health Organization International Clinical Trials Registry). 
 
Searching other resources 
We handsearched the reference lists of reviews, guidelines, included and 
excluded studies and other related articles for additional eligible studies. 
We handsearched the American Society for Reproductive Medicine 
(ASRM) conference abstracts and proceedings. Moreover we contacted 
European experts in the field of hysteroscopic surgery. 
 
Data collection and analysis 
 
Selection of studies, data extraction and management 
We scanned titles and abstracts from the searches and obtained the full 
text of those articles that appeared to be eligible for inclusion. Two review 
authors independently assessed the studies that appeared to meet the 
inclusion criteria and extracted data by using a pilot-tested data extraction 
form. Any disagreements between the review authors were resolved by 
discussion or by a third review author. We contacted the authors of the 
primary study reports for clarification when required. 
 
Assessment of risk of bias in included studies 
Two authors independently assessed the risk of bias of the included 
studies by using the Cochrane ‘Risk of bias’ tool. 
 
Measures of treatment effect 
We used the numbers of events in both comparison groups of each study 
for the dichotomous data for live birth, pregnancy, miscarriage and 
hysteroscopy complications to calculate Mantel-Haenszel (M-H) odds 
ratios (OR). We presented 95% confidence intervals (95% CI) for all 
outcomes. 
 
Unit of analysis issues 
All primary and secondary outcomes were expressed as per woman 
randomized; per pregnancy data were included for the outcome 
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miscarriage. Multiple live births and multiple pregnancies were counted as 
one live birth or one pregnancy event. 
 
Dealing with missing data 
We aimed to analyze the data on an intention-to-treat basis. We tried to 
obtain as much missing data as possible from the original investigators. 
 
Assessment of heterogeneity 
Due to the limited number of included studies no formal assessment of 
heterogeneity by using the I² statistic combined with the Q-statistic was 
done. 
 
Assessment of reporting biases 
We planned to minimize the potential impact of publication bias, 
reporting bias and within-study reporting bias by ensuring a 
comprehensive search for eligible studies and by being alert in identifying 
duplication of data. Due to the low number of included studies we did not 
study reporting bias formally by a funnel plot. 
 
Data synthesis 
One review author carried out the statistical analysis of the data using 
Review Manager 5. Meta-analysis was not possible due to the limited 
number of included studies; therefore we presented a narrative overview 
as prespecified in the protocol of this Cochrane review (Bosteels 2011). 
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RESULTS 
 
Description of studies 
 
Results of the search  
See: Figure 1. PRISMA study flow diagram. 
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Included studies 
 
*Study design and setting 
 
Two parallel-design randomized controlled trials were included in the 
review. Both were single-centre studies, one conducted in Italy (Casini 
2006) and the other in Spain (Pérez-Medina 2005). 
 
*Participants 
 
One study (Casini 2006) included 94 women with submucous fibroids and 
otherwise unexplained subfertility. The number of study participants was 
52 in the intervention and 42 in the control group. The mean age was 31 
years (range 29 to 34 years) in the subgroup of women with submucous 
fibroids only and 32 years (range 30 to 35 years) in the subgroup with 
mixed intramural-submucous fibroids. All women underwent a complete 
fertility assessment. Transvaginal ultrasonography was done to detect 
uterine fibroids. All women with fibroids and no other causes of 
subfertility were invited to participate in the study. Only women aged≤35 
years with subfertility for at least one year and one fibroid of 
diameter≤40mm were selected for randomization. 
The second study (Pérez-Medina 2005) included 215 women with 
unexplained, male or female factor subfertility for at least 24 months 
bound to undergo IUI with a sonographic diagnosis of endometrial polyps. 
The number of women was 101 in the intervention and 103 in the control 
group; 11 study participants were lost to follow-up, six in the intervention 
and five in the control group. The mean age was 31 years (range 27 to 35 
years). All women had primary subfertility and underwent a complete 
fertility assessment. The sonographic diagnosis of endometrial polyps was 
established by the visualization of the vascular stalk of the polyp using 
color Doppler. Women older than 39 years of age or with anovulation, 
uncorrected tubal disease, previous unsuccessful use of recombinant FSH 
or a male partner with azoospermia were excluded. 
 
*Interventions 
 
In one trial (Casini 2006) the intervention group underwent hysteroscopic 
removal of the fibroids. After three months of sexual abstinence these 
women were asked to have regular fertility-oriented intercourse. Women 
in the control group were asked to start having regular fertility oriented 
intercourse immediately. Both groups were monitored for up to 12 months 
after study commencement. 
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In the second trial (Pérez-Medina 2005) all hysteroscopic interventions 
were done in an outpatient office setting under local anesthesia by one 
gynecologist. In the intervention group the endometrial polyps suspected 
on Doppler ultrasound were removed by hysteroscopy and sent for 
histopathological examination. The women of the intervention group were 
scheduled to receive four cycles of IUI using subcutaneous injections of 
recombinant follicle stimulating hormone (FSH) 50 IU daily from the 
third day of the cycle, starting three cycles after the operative 
hysteroscopy. In the control group the endometrial polyps suspected on 
Doppler ultrasound were left in place during diagnostic hysteroscopy; 
polyp biopsy was taken to establish a histopathological diagnosis. Ovarian 
stimulation was scheduled three cycles after the diagnostic hysteroscopy 
following the same regimen as in the intervention group. Four IUI cycles 
were attempted before finishing the trial. 
 
*Outcomes 
 
Neither of the two included studies reported data on the primary 
outcomes. 
 
Excluded studies 
 
We excluded 20 trials on hysteroscopic interventions for various reasons: 
see the PRISMA flow diagram (Figure 1). 
One study (Shokeir 2010) was retracted at the request of the editor of the 
publishing journal; another study (Pabuccu 2008) used an inadequate 
sequence generation based on the order of study entry. We excluded 18 
studies for not addressing the prespecified PICO research questions of this 
Cochrane review (Acunzo 2003; Aghahosseini 2012; Amer 2010; 
Colacurci 2007; Darwish 2008; De Iaco 2003; Demirol 2004; Di Spiezio 
Sardo 2011; El-Nashar 2011; Guida 2004; Lieng 2010a; Muzii 2007; 
Parsanezhad 2006; Rama Raju 2006; Shawki 2010; Tonguc 2008; van 
Dongen 2008; Vercellini 1993). 
 
Studies awaiting classification 
 
Two trials are awaiting classification (Pansky 2009; Trninić-Pjević 2011). 
 
Ongoing studies 
 
Six trials are ongoing (Broekmans 2010; El-Khayat 2012; El-Toukhy 
2009; Maramazi 2012; Revel 2011; Sohrabvand 2012). 
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Risk of bias in included studies 
 
Figure 2 ‘Risk of bias’ summary: review authors’ judgments about each 
risk of bias item for each included study. 
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Figure 3 ’Risk of bias’ graph: review authors’ judgments about each risk 
of bias item presented as percentages across all included studies. 
 
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
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Random sequence generation 
We judged both studies (Casini 2006; Pérez-Medina 2005) to be at low 
risk of selection bias related to random sequence generation: both used 
computerized random numbers tables. 
 
Allocation concealment 
We judged one study (Pérez-Medina 2005) to be at low risk for selection 
bias related to allocation concealment, as sequentially numbered, opaque, 
sealed envelopes were used. We judged the second trial (Casini 2006) to 
be at an unclear risk since the used method was not fully described. 
 
Blinding 
The risk of bias items ’blinding of participants and personnel’ and 
’blinding of outcome assessors’ were judged to be at unclear risk of bias 
for both studies; we were undetermined to score these items either at high 
risk (complete follow-up with ‘hard’ outcomes) or at low risk of bias (no 
blinding). The absence of blinding of women in both studies could have 
led to differences in sexual behavior, especially in the women in the 
control groups of both studies. We cannot exclude that bias related to 
absence of blinding might be an alternative explanation for the findings of 
higher pregnancy rates after myomectomy and polypectomy. 
 
Incomplete outcome data 
We judged both studies to be at low risk of attrition bias: one study 
(Casini 2006) reported outcome data of all randomized women and in the 
second study (Pérez-Medina 2005) the missing outcome data in 5% of the 
participants were balanced in numbers with similar reasons for missing 
data. 
 
Selective reporting 
We judged both studies (Casini 2006; Pérez-Medina 2005) to be at 
unclear risk of reporting bias because they both failed to include data for 
live birth: reasonably this primary outcome should have been reported in 
studies conducted over a seven-year (Casini 2006) and a four-year (Pérez-
Medina 2005) period. 
 
Other potential sources of bias 
We judged one study to be at unclear risk for this item due to potential 
imbalance in the baseline characteristics between both comparison groups 
(Casini 2006); we judged the second study (Pérez-Medina 2005) to be at 
low risk. 
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Effects of interventions 
 
Table 1 
1. Operative hysteroscopy compared with control for unexplained subfertility 
and suspected major uterine cavity abnormalities-submucous fibroids 
Patient or population: women with submucous fibroids and otherwise unexplained 
subfertility 
Settings: infertility centre in Rome, Italy 
Intervention: hysteroscopic removal of one submucous fibroid≤40 mm 
Comparison: regular fertility-oriented intercourse 
Outcomes Illustrative comparative 
risks* (95% CI)
Relative 
effect 
(95% CI)
N 
participant
(studies) 
Quality 
of the 
evidence
GRADE
 
Assumed 
risk 
Corresponding 
risk 
Control Myomectomy
Clinical 
pregnancy 
ultrasound1 
Follow-up: 12 
months 
Study population OR 2.44 
(0.97 to 
6.17) 
94 
(1 study) 
⊕⊝⊝
⊝ 
very 
low2-4 
 
214 
per1000 
 399 per 1000
 (209 to 627) 
Miscarriage 
ultrasound5 
Follow-up: 12 
months 
Study population OR 1.54 
(0.71 to 
5.00) 
94 
(1 study) 
⊕⊝⊝
⊝ 
very 
low2-4 
 
119           172 per 1000 
per 1000   (88 to 403) 
*The basis for the assumed risk is the control event rate in the primary study. The 
corresponding risk (and its 95% confidence interval) is based on the assumed risk in 
the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; OR: Odds ratio;  
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect.  
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate 
of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate 
of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
1 A clinical pregnancy was defined by the visualization of an embryo with cardiac activity at 6-7 weeks of 
pregnancy 
2 Unclear concealment of allocation 
3 Wide confidence intervals 
4 Unclear selective reporting and unclear whether there was imbalance in the baseline characteristics 
5 Miscarriage was defined by the clinical loss of an intrauterine pregnancy between the 7th and 12th weeks 
of gestation 
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Endometrial polyps 
No studies were retrieved. 
 
Submucous fibroids 
We retrieved one study (Casini 2006). See table 1. 
 
*Primary outcomes 
 
1.1. Live birth 
There were no data for this primary outcome. 
 
1.2. Adverse events: hysteroscopy complications 
There were no data for this primary outcome. 
 
*Secondary outcomes 
 
1.3. Clinical pregnancy 
In women with otherwise unexplained subfertility for at least one year and 
one submucous fibroid of diameter≤40 mm, there is no evidence of 
benefit with hysteroscopic myomectomy compared to regular fertility-
oriented intercourse for the secondary outcome of clinical pregnancy. The 
odds ratio (OR) was 2.4, 95% confidence interval (CI) 0.97 to 6.2, 
P=0.06, 1 study, 94 women) (Figure 4). 
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Figure 4 Forest plot of comparison: Hysteroscopic myomectomy versus 
regular fertility-oriented intercourse in women with unexplained 
subfertility and submucous fibroids. Outcome: Clinical pregnancy. M-H: 
Mantel-Haenszel, fixed-effect model, CI: confidence interval. 
 
Study or Subgroup
1.1.1 Removal of submucous fibroids only vs regular fertility-oriented intercourse
Casini 2006
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
1.1.2 Removal of mixed submucous-intramural fibroids vs regular fertility-oriented intercourse
Casini 2006
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Total (95% CI)
Total events
Heterogeneity: Chi² = 0.22, df = 1 (P = 0.64); I² = 0%
Test for overall effect: Z = 1.89 (P = 0.06)
Test for subgroup differences: Chi² = 0.22, df = 1 (P = 0.64), I² = 0%
Events
13
13
8
8
21
Total
30
30
22
22
52
Events
6
6
3
3
9
Total
22
22
20
20
42
Weight
66.2%
66.2%
33.8%
33.8%
100.0%
M-H, Fixed, 95% CI
2.04 [0.62, 6.66]
2.04 [0.62, 6.66]
3.24 [0.72, 14.57]
3.24 [0.72, 14.57]
2.44 [0.97, 6.17]
Operative hysteroscopy Control Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours intercourse Favours myomectomy  
 
1.4. Adverse events: miscarriage 
 
There is no evidence of benefit with the surgical intervention compared to 
regular fertility- oriented intercourse for the secondary outcome of 
miscarriage (OR 0.58, 95% CI 0.12 to 2.9, P=0.50, 1 study, 30 clinical 
pregnancies in 94 women) (Figure 5). 
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Figure 5 Forest plot of comparison: Hysteroscopic myomectomy versus 
regular fertility-oriented intercourse in women with unexplained 
subfertility and submucous fibroids. Outcome: Miscarriage. M-H: Mantel-
Haenszel, fixed-effect model, CI: confidence interval. 
 
Study or Subgroup
1.2.1 Removal of submucous fibroids only vs regular fertility-oriented intercourse
Casini 2006
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
1.2.2 Removal of mixed submucous-intramural fibroids vs regular fertility-oriented intercourse
Casini 2006
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Total (95% CI)
Total events
Heterogeneity: Chi² = 0.02, df = 1 (P = 0.90); I² = 0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Chi² = 0.02, df = 1 (P = 0.90), I² = 0%
Events
5
5
4
4
9
Total
13
13
8
8
21
Events
3
3
2
2
5
Total
6
6
3
3
9
Weight
63.5%
63.5%
36.5%
36.5%
100.0%
M-H, Fixed, 95% CI
0.63 [0.09, 4.40]
0.63 [0.09, 4.40]
0.50 [0.03, 7.99]
0.50 [0.03, 7.99]
0.58 [0.12, 2.85]
Operative hysteroscopy Control Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours intercourse Favours myomectomy  
 
*Subgroup analyses 
 
There is no evidence for a treatment effect favoring the hysteroscopic 
removal of one submucous fibroid≤40 mm in women with otherwise 
unexplained subfertility compared to regular fertility-oriented intercourse 
for the secondary outcome clinical pregnancy in the ‘submucous only’ 
subgroup (OR 2.0, 95% CI 0.62 to 6.7, P=0.24, 1 study 52 women) or the 
‘mixed submucous-intramural’ subgroup (OR 3.2, 95% CI 0.72 to 15, 
P=0.13, 1 study, 42 women); the test for subgroup differences 
demonstrated no significant difference (P=0.64). There were no 
differences for the secondary outcome miscarriage between the 
‘submucous only’ subgroup (OR 0.63, 95% CI 0.09 to 4.4, P=0.64, 1 
study, 19 clinical pregnancies in 52 women) versus the ’mixed 
submucous-intramural’ subgroup (OR 0.50, 95% CI 0.03 to 8.0, P=0.62, 1 
study, 11 clinical pregnancies in 42 women); the tests for subgroup 
differences demonstrated no statistical difference (P=0.90). 
 
*Sensitivity analyses 
 
Sensitivity analysis comparing the use of the risk ratio rather than the odds 
ratio as effect measure did not demonstrate an effect on the statistical 
significance of the main analysis for the secondary outcomes ‘clinical 
pregnancy’ (P=0.07) and ‘miscarriage’ (P=0.48). No effect was 
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demonstrated by a sensitivity analysis studying the effect of the choice to 
include women with mixed intramural-submucous fibroids rather than 
submucous fibroids only for the secondary outcomes ‘clinical pregnancy’ 
(P=0.06) and ‘miscarriage’ (P=0.64). 
 
Uterine septum 
No studies were retrieved. 
 
Intrauterine adhesions 
No studies were retrieved. 
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Table 2 
 
2. Operative hysteroscopy compared with control for suspected major uterine 
cavity abnormalities prior to medically assisted reproduction-polyps prior to 
IUI 
Patient or population: women with endometrial polyps diagnosed by 
ultrasonography prior to treatment with gonadotrophin and intrauterine insemination 
Settings: infertility unit of a university hospital in the Spanish capital Madrid 
Intervention: hysteroscopic polypectomy using a 5.5 mm continuous flow office 
hysteroscope with a 1.5 mm scissors and forceps 
Comparison: diagnostic hysteroscopy using a 5.5 mm continuous flow office 
hysteroscope and polyp biopsy 
Outcomes Illustrative comparative 
risks* (95% CI) 
Relative 
effect 
(95% CI) 
No of 
Participants
(studies) 
Quality of 
the 
evidence 
(GRADE) 
 
Assumed 
risk 
Corresponding 
risk 
Control Polypectomy 
Clinical 
pregnancy 
ultrasound1 
Follow-up: 
4 IUI cycles 
Low risk population 2 OR 4.41  
(2.45 to 
7.96) 
204 
(1 study) 
⊕⊕⊕⊕ 
high 5,6 
 
250 per 
1000
595 per 1000 
(450 to 726) 
Medium risk population 3 
366 per 
1000
718 per 1000 
(586 to 821) 
High risk population 4 
528 per 
1000
831 per 1000 
(733 to 899) 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. 
The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison 
group and the OR of the intervention (and its 95% CI). 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect.  
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate 
of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate 
of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
Chapter 4 
 
 
100 
1 Clinical pregnancy was defined by the presence of at least one gestational sac on ultrasound 
2 Based on the clinical pregnancy rate per woman after 4 cycles gonadotrophins and IUI for male 
subfertility based on data from Bensdorp 2007 
3 Based on the clinical pregnancy rate per woman after 4 cycles gonadotrophins and IUI for unexplained 
subfertility based on data from Veltman-Verhulst 2012 
4 Based on the clinical pregnancy rate per woman after 4 cycles gonadotropins and IUI for unexplained 
subfertility based on data from Spiessens 2003 
5 There was some potential for reporting bias 
6 Large treatment effect in the absence of plausible confounders. 
  
Endometrial polyps prior to intrauterine insemination (IUI) 
We retrieved one study (Pérez-Medina 2005). See table 2. 
 
*Primary outcomes 
 
2.1. Live birth 
There were no data for this primary outcome. 
 
2.2. Adverse events: hysteroscopy complications 
There were no data for this primary outcome. 
 
*Secondary outcomes 
 
2.3. Clinical pregnancy 
 
The hysteroscopic removal of polyps with a mean size of 16mm, detected 
by Doppler ultrasonography in women with unexplained, male or female 
factor subfertility for at least 24 months bound to undergo IUI, increases 
the odds of clinical pregnancy compared to diagnostic hysteroscopy and 
biopsy only (OR 4.4, 95% CI 2.5 to 8.0, P<0.00001, 1 study, 204 women) 
(Figure 6). The number needed to treat to benefit (NNTB) is 3 (95% CI 2 
to 4). These results are based on an ‘available data’ analysis. 
Hysteroscopy for suspected major uterine cavity abnormalities 
 
 
101 
Figure 6 Forest plot of comparison: Hysteroscopic removal of polyps 
versus diagnostic hysteroscopy and biopsy only prior to IUI. Outcome: 
Clinical pregnancy. M-H: Mantel-Haenszel, fixed-effect model, CI: 
confidence interval. 
 
Study or Subgroup
2.1.1 Hysteroscopic polypectomy vs diagnostic hysteroscopy and biopsy only prior to IUI
Pérez-Medina 2005
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 4.93 (P < 0.00001)
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 4.93 (P < 0.00001)
Test for subgroup differences: Not applicable
Events
64
64
64
Total
101
101
101
Events
29
29
29
Total
103
103
103
Weight
100.0%
100.0%
100.0%
M-H, Fixed, 95% CI
4.41 [2.45, 7.96]
4.41 [2.45, 7.96]
4.41 [2.45, 7.96]
Operative hysteroscopy Control Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours diagnostic only Favours polypectomy  
 
2.4. Adverse events: miscarriage 
 
There were no data for this secondary outcome. 
 
*Subgroup analyses 
 
A first prespecified subgroup analysis studied the effect of polyp size on 
the secondary outcome of clinical pregnancy. On histopathological 
examination the mean size of the polyps removed was 16mm (range 3 to 
24mm). In the primary study the effect of the polyp size on the clinical 
pregnancy rate was studied in the intervention group. The data were 
analyzed based on the size of the removed polyps, subdivided into four 
groups based in their quartiles (<5mm, 5 to 10mm, 11 to 20mm and 
>20mm); the differences between these four subgroups within this study 
were not statistically significant (P=0.32). There is no evidence of an 
effect of the polyp size on the outcome of clinical pregnancy, but these 
results should be interpreted with caution due to the limited numbers in 
this single study. There were no data on the estimated size of the polyps in 
the control group. 
The second subgroup analysis studied the effect of the timing of the IUI 
treatment after hysteroscopy on the secondary outcome clinical 
pregnancy. About 29% of women in the polypectomy group, compared to 
3% in the diagnostic hysteroscopy group became pregnant in the three-
month period after the hysteroscopy before the treatment with 
gonadotrophin and IUI was started; this was calculated from the Kaplan-
Meier survival analysis in the published report of the study (Pérez-Medina 
2005). Hysteroscopic polypectomy increases the odds of clinical 
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pregnancy compared to diagnostic hysteroscopy and polyp biopsy in 
women waiting to be treated with gonadotrophin and IUI (OR 13, 95%CI 
3.9 to 46, P<0.0001, 1 study, 204 women, available data analysis). The 
number needed to treat to benefit (NNTB) following the hysteroscopic 
removal of polyps before starting the treatment with gonadotrophin and 
IUI is 4 (95% CI 3 to 6). In women who started gonadotrophin and IUI 
treatment the pregnancy rates per woman were 49% and 26% in the 
intervention and control group respectively. Hysteroscopic polypectomy 
increases the odds of clinical pregnancy in women who started from three 
months after the surgical procedure with gonadotrophin and IUI treatment 
(OR 2.7, 95% CI 1.4 to 5.1, P=0.003, 1 study, 172 women, available data 
analysis). The NNTB when starting the treatment with gonadotrophin and 
IUI after a prior hysteroscopic polypectomy is 4 (95% CI 3 to 12). We 
judged this to be an honest and sensible post hoc analysis. Subgroup 
analysis according to the indication for IUI (ovulatory disorder, male 
factor or unexplained subfertility) was not possible because individual 
patient data linking outcomes to the indication for IUI were not available 
after contacting the study authors.  
 
*Sensitivity analyses 
 
A sensitivity analysis studying the choice of risk ratio rather than odds 
ratio as the effect measure demonstrated no effect on the statistical 
significance of the main analysis for the secondary outcome ’clinical 
pregnancy’ (P<0.00001). A sensitivity analysis comparing an intention-to-
treat analysis assuming that clinical pregnancies would not have occurred 
in participants with missing data, rather than an ‘available data’ analysis, 
did not affect the statistical significance of the main analysis for the 
secondary outcome ‘clinical pregnancy’ (OR 4.0, 95% CI 2.3 to 7.2, 
P<0.00001, 1 study, 215 women randomized). 
 
Endometrial polyps prior to IVF-ICSI 
No studies were retrieved. 
 
Submucous fibroids prior to IUI-IVF-ICSI 
No studies were retrieved. 
 
Uterine septum prior to IUI-IVF-ICSI 
No studies were retrieved. 
 
Intrauterine adhesions prior to IUI-IVF-ICSI 
No studies were retrieved. 
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DISCUSSION 
 
Summary of main results 
 
This Cochrane systematic review aimed to investigate whether the 
hysteroscopic treatment of suspected major uterine cavity abnormalities 
made a difference to the main outcomes of live birth or pregnancy and the 
adverse events - hysteroscopy complications and miscarriage - in women 
with otherwise unexplained subfertility or before IUI-IVF-ICSI. 
The first randomized comparison was operative hysteroscopy versus 
control in women with otherwise unexplained subfertility and suspected 
major uterine cavity abnormalities - stratified into endometrial polyps, 
submucous fibroids, intrauterine adhesions or septate uterus. 
The second randomized comparison was operative hysteroscopy versus 
control in subfertile women undergoing medically assisted 
reproduction(MAR) – categorized as IUI, IVF or ICSI - with suspected 
major uterine cavity abnormalities - stratified into endometrial polyps, 
submucous fibroids, intrauterine adhesions or septate uterus. 
We critically appraised one trial (Casini 2006) comparing hysteroscopic 
removal of one submucous fibroid with a diameter≤40 mm in women 
aged≤35 years with otherwise unexplained subfertility versus regular 
fertility-oriented intercourse for a period of 12 months. There is no 
evidence of a benefit with removing submucous fibroids compared to 
control for the secondary outcome of clinical pregnancy. 
We similarly retrieved one single trial (Pérez-Medina 2005) for the second 
category of randomized comparisons. There is a clinically relevant and 
statistically significant increase in the odds of clinical pregnancy favoring 
the hysteroscopic removal of polyps with a mean size of 16mm (range 3 
to 24mm) versus diagnostic hysteroscopy and biopsy in subfertile women 
with suspected endometrial polyps bound to undergo IUI. There were no 
data for the primary outcomes of live birth and hysteroscopy 
complications and the secondary outcome of miscarriage. The increase in 
clinical pregnancies after hysteroscopic polypectomy might be mainly due 
to a higher proportion of spontaneous conceptions before starting IUI and 
to a lesser- but still clinically relevant and statistically significant- extent 
to higher odds of conceiving after starting gonadotrophin treatment and 
IUI. The results of this sensible ‘post hoc’ subgroup analysis should 
nevertheless be interpreted with caution. There is no evidence for a dose-
effect relationship between the size of the polyps and the increase in the 
outcome clinical pregnancy, but no definitive conclusions can be drawn 
based on this subgroup analysis. 
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Overall completeness and applicability of the evidence 
 
Evidence on the effectiveness of treating suspected major uterine cavity 
abnormalities by operative hysteroscopy compared to a control 
intervention in women with otherwise unexplained subfertility is very 
limited. We found no RCTs on the hysteroscopic treatment of endometrial 
polyps, intrauterine adhesions or septa in women with otherwise 
unexplained subfertility. The only included study in this category fails to 
report on the primary outcomes for this review. 
Evidence on the effectiveness of operative hysteroscopy compared to 
control in subfertile women with associated major uterine cavity 
abnormalities prior to medically assisted reproduction is incomplete; our 
search retrieved only data for subfertile women with suspected 
endometrial polyps prior to IUI. No data were retrieved on the 
effectiveness of operative hysteroscopy in subfertile women with 
submucous fibroids, intrauterine adhesions or septa prior to IUI or other 
techniques such as IVF or ICSI for all outcomes. Moreover for the 
randomized comparison hysteroscopic polypectomy versus diagnostic 
hysteroscopy prior to IUI no data are available for the primary outcomes. 
The evidence retrieved is by consequence insufficient to address all the 
objectives of the present Cochrane review. 
The absence of evidence favoring the hysteroscopic removal of 
submucous fibroids in women with otherwise unexplained subfertility is 
in contrast with daily clinical practice: it is generally accepted that 
submucous fibroids are very likely to interfere with normal fertility (Pritts 
2001; Pritts 2009). In everyday practice most hysteroscopists will counsel 
subfertile women with submucous fibroids to undergo a hysteroscopic 
myomectomy since it does not seem reasonable to counsel timed 
intercourse with or without ovarian stimulation or proceed to IUI or 
IVF/ICSI without removing the fibroids; this clinical practice is based on 
observational evidence only and is therefore at risk of bias. 
The results of the trial on hysteroscopic polypectomy (Pérez-Medina 
2005) are very relevant for everyday practice. In this study one-third of 
the randomized women treated by IUI suffered from an isolated ovulatory 
disorder which is by itself not an indication for IUI in everyday clinical 
practice as opposed to mild male factor (Bensdorp 2007) or unexplained 
subfertility (Veltman-Verhulst 2012). 
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Quality of the evidence 
 
The present review included only two trials; neither reported the primary 
outcomes live birth or hysteroscopy complications. By using the GRADE 
tool (Grading of Recommendations Assessment, Development and 
Evaluation) we assessed the overall quality of the evidence of the first trial 
on hysteroscopic myomectomy (Casini 2006) as ‘very low’ and that of the 
second study on hysteroscopic polypectomy (Pérez-Medina 2005) as 
‘high’. 
 
Agreements and disagreements with other studies or reviews 
 
There are two systematic reviews on fibroids and subfertility (Pritts 2001; 
Pritts 2009). We refer to the data and conclusions reported in the most 
recent review because the MOOSE (Meta-analysis of Observational 
Studies in Epidemiology) guidelines for systematic reviews of 
observational studies were strictly followed (Pritts 2009). The review 
authors concluded that the fertility outcomes are decreased in women with 
submucous fibroids, and that the removal of the fibroids is likely to 
benefit the reproductive outcome. The results of the trial on the 
effectiveness of hysteroscopic polypectomy prior to IUI are consistent 
with the findings of two recently published observational studies. The first 
study planned to measure the effect of the presence of endometrial polyps 
on pregnancy rates and how polypectomy could affect pregnancy rates in 
171 women scheduled for IUI (Kalampokas 2012). The authors concluded 
that hysteroscopic polypectomy appears to improve fertility in women 
with otherwise unexplained subfertility. The second study, a prospective 
clinical controlled trial (CCT) including 120 women with endometrial 
polyps, aimed to measure whether polypectomy before IUI achieved 
better pregnancy outcomes than no intervention (Shohayeb 2011). The 
authors of this trial concluded that persistent endometrial polyps are likely 
to impair reproductive performance and that hysteroscopic polypectomy 
before IUI could be considered as an effective intervention. A systematic 
review (Lieng 2010b) included 11 studies in 935 subfertile women with 
endometrial polyps: one RCT (Pérez-Medina 2005), three CCTs and 
seven observational studies (three retrospective, one prospective and three 
undetermined). There was no evidence of a benefit with hysteroscopic 
polypectomy on the IVF outcomes according to two smaller observational 
studies but the authors nevertheless concluded that the limited evidence 
suggests a favorable outcome on pregnancy rates in subfertile women with 
endometrial polyps. The conclusion of this review should be interpreted 
with caution because there was substantial clinical diversity precluding 
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formal meta-analysis; moreover there are several methodological concerns 
(no study of the effect of confounders, no formal assessment of 
publication bias). 
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AUTHORS’CONCLUSIONS 
 
Implications for practice 
 
We cannot exclude nor confirm a benefit in favor of removing submucous 
fibroids in women with otherwise unexplained subfertility: the differences 
in clinical pregnancy rates between both comparison groups in the single 
retrieved RCT nearly reached statistical significance. The level of the 
evidence on this subject was very low. Before treating subfertile women 
with endometrial polyps with gonadotrophins combined with IUI for 
unexplained, mild male or female factor subfertility for at least 24 months, 
it may be recommended to do a hysteroscopic polypectomy to improve 
the chances of conceiving either spontaneously during a waiting period of 
three months or after starting IUI combined with gonadotrophins; the level 
of evidence of this study was high. 
 
Implications for research 
 
More well-designed RCTs are needed to assess whether the hysteroscopic 
removal of endometrial polyps, submucous fibroids, septa or intrauterine 
adhesions is likely to benefit women with otherwise unexplained 
subfertility or before treatment with IUI, IVF or ICSI. There are 
knowledge gaps on the effects of the number, size or extent and the 
localization of these four uterine cavity abnormalities on the main 
outcomes in women with otherwise unexplained subfertility or prior to 
MAR as well as on the time-effect relationship between the hysteroscopic 
intervention and subsequent IUI, IVF or ICSI treatment. Therefore more 
RCTs on these topics are needed to extend our present knowledge of the 
potential benefits of hysteroscopy for treating female subfertility. 
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ABSTRACT 
 
Study question 
To assess the effects of any anti-adhesion barrier gel used after 
hysteroscopy for treating subfertility. 
 
Summary answer 
Gynecologists might use any barrier gel following operative hysteroscopy 
in subfertile women for decreasing adhesion formation; the use of any 
barrier gel is associated with less severe adhesions and lower mean 
adhesion scores. Nevertheless subfertile women should be counseled that 
there is at the present no evidence for higher live birth or pregnancy rates. 
Data for the outcome miscarriage are absent. 
 
What is already known 
Preclinical studies suggest that the use of biodegradable surgical barriers 
decreases the incidence of postsurgical adhesions but observational 
studies in the human report conflicting results. 
 
Study design, size, duration 
We searched the Cochrane Menstrual Disorders and Subfertility 
Specialized Register (10 April 2013), the Cochrane Central Register of 
Controlled Trials (The Cochrane Library 2013, Issue 1), MEDLINE 
(1950 to 4 April 2013), EMBASE (1974 to 4 April 2013) and other 
electronic databases of trials including trial registers, sources of 
unpublished literature and reference lists. We handsearched the Journal of 
Minimally Invasive Gynecology (from 1 January 1992 to 13 April 2013); 
we also contacted experts in the field. 
 
Participants/materials, setting, methods 
Randomized comparisons between any anti-adhesion barrier gel versus 
another barrier gel, placebo or no adjunctive therapy following operative 
hysteroscopy. Primary outcomes were live birth rates and adhesion 
formation at second-look hysteroscopy. Secondary outcomes were 
pregnancy and miscarriage rates, mean adhesion scores and severity of 
adhesions at second-look hysteroscopy. Two authors independently 
assessed eligible studies for inclusion and risk of bias, and extracted data. 
We contacted primary study authors for additional information or other 
clarification. 
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Main results and the role of chance 
Five trials met the inclusion criteria. There is no evidence of benefit with 
the use of any barrier gel following operative hysteroscopy for the key 
outcome clinical pregnancy: the risk ratio (RR) was 3.0, 95% confidence 
interval (CI) was 0.35 to 26, P=0.32, 1 study, 30 women (very low quality 
evidence). There were no data for the outcomes live birth or miscarriage. 
The use of any gel following operative hysteroscopy decreases the 
incidence of adhesions at second-look hysteroscopy (RR 0.65, 95% CI 
0.45 to 0.93, P=0.02, 5 studies, 372 women, very low quality evidence). 
The number needed to treat to benefit (NNTB) is 9 (95% CI 5 to 33). The 
use of auto-cross-linked hyaluronic acid gel in women undergoing 
operative hysteroscopy for fibroids, endometrial polyps or uterine septa is 
associated with a lower mean adhesion score at second-look hysteroscopy 
at 3 months: the mean difference (MD) was -1.4, 95% CI -1.8 to -1.0, 
P<0.00001, 1 study, 24 women. The decrease in adhesion scores is greater 
in the subgroup of women treated for intrauterine adhesions (MD -3.3, 
95% CI -3.4 to -3.2, P<0.00001, 1 study, 19 women). When adhesions 
occur after hysteroscopic surgery the use of any gel following operative 
hysteroscopy is associated with more mild adhesions (RR 2.8, 95% CI 1.1 
to 7.0, P=0.03, 4 studies, 79 women) and less ’moderate or severe 
adhesions’ at second-look hysteroscopy (RR 0.25, 95% CI 0.10 to 0.67, 
P=0.006, 4 studies, 79 women). The NNTB is 2 with a 95% CI 1 to 2 for 
the former and 95% CI 1 to 4 for the latter outcome (all very low quality 
evidence). 
 
Limitations, reason for caution 
Only two trials included subfertile women, the proportion of participants 
with subfertility in the remaining three studies was unclear. Only one 
study reported on the effects of anti-adhesion barrier gels for the key 
outcome of pregnancy but the length of follow up was not reported. 
 
Wider implications of the findings 
More RCTs are needed to assess whether the use of any anti-adhesion gel 
affects the key reproductive outcomes in a target population of subfertile 
women. 
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BACKGROUND 
 
Intrauterine adhesions (IUAs) are fibrous strings at opposing walls of the 
uterus. The causes of IUAs are multifactorial; nearly 90% of cases are 
associated with postpartum or post abortion dilatation and curettage. The 
role of infection in the development of IUAs is undetermined with the 
exception of genital tuberculosis (Deans and Abbott, 2010). The 
pathophysiology and the mechanisms of tissue repair in the endometrium 
are poorly understood despite several theories on the source of cells 
involved in this process (Okulicz 2002). 
Intrauterine adhesion (IUA) formation is the major long-term 
complication of operative hysteroscopy in women of reproductive age. 
The incidence of postsurgical IUAs at second-look hysteroscopy varies 
according to the type of surgery as demonstrated by a RCT: 3.6% after 
polyp removal, 6.7% after resection of uterine septa, 31% after removal of 
a single fibroid and 45% after resection of multiple fibroids (Taskin et al, 
2000). The investigators of a prospective cohort study in 163 women 
undergoing operative hysteroscopy observed significantly more IUAs 
after septoplasty (14 of 16 women or 88 %) or adhesiolysis (34 of 45 
women or 76 %) compared to the removal of submucous fibroids (26 of 
65 women or 40 %) or endometrial polyps (0 of 37 women or 0%). They 
concluded that the full recovery of the endometrium may vary from one 
month after the removal of polyps to between two to three months 
following hysteroscopic myomectomy (Yang et al, 2013).  
Intrauterine adhesions may cause poor reproductive outcome. Firstly, 
IUAs have a negative impact on fertility as demonstrated by large review 
of observational studies: 922 of 2151 women with IUAs or 43% suffered 
from subfertility (Schenker and Margalioth, 1982). The hypothetical 
underlying mechanisms for subfertility due to IUAs are obstruction of 
sperm transport into the cervix, impaired embryo migration within the 
uterine cavity or failure of embryo implantation due to endometrial 
insufficiency (Deans and Abbott, 2010). Secondly, IUAs are often 
associated with recurrent miscarriage; the prevalence of IUAs in women 
suffering from this reproductive health problem ranges from 5 to 39% 
according to a narrative review of observational studies (Kodaman and 
Arici, 2007). Thirdly, the successful hysteroscopic treatment of severe 
IUAs may cause long term major obstetrical complications, such as 
placenta accreta/ increta and higher risks for preterm delivery, uterine 
rupture and peripartum hysterectomy (Deans and Abbott, 2010). 
Hyaluronic acid or hyaluronan (HA) is a water-soluble polysaccharide 
consisting of multiple disaccharide units of glucuronic acid and N-
acetylglucosamine, bound together by a ß1-3-type glycoside bond. 
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Solutions of HA have interesting visco-elastic properties which have led 
to the development of applications of HA in surgical procedures, for 
example in eye surgery. HA is not an ideal substance for all procedures, 
due to its limited residence time when applied to a surgical site. It quickly 
enters the systemic circulation and is cleared rapidly by catabolic 
pathways. Attempts to use hyaluronan for preventing postsurgical 
adhesions have therefore been met with variable success. Several 
chemically modified derivatives of HA have been developed to 
circumvent the disadvantages of HA. One such derivative is auto-cross-
linked polysaccharide (ACP). It is formed by cross-linking hyaluronan, by 
direct formation of covalent ester bonds between hydroxyl and carboxyl 
groups of the hyaluronan molecule. ACP can be prepared with various 
degrees of cross-linking, which allows tailoring of the viscosity properties 
of ACP gels (Renier et al, 2005). Carboxymethylcellulose (CMC) is a 
high molecular weight polysaccharide that has a viscosity greater than 
dextran 70. CMC can be used for adhesion prevention as a membrane 
barrier or a gel as a mixture of chemically derivative sodium hyaluronate 
and carboxymethylcellulose gel (HA-CMC) (Leach et al, 1998). 
The ideal anti-adhesion barrier for hysteroscopic surgery would be the 
application of a biologically active mechanical separator that achieves the 
suppression of intrauterine adhesion formation and promotes the healing 
of the endometrial tissue. The use of the biodegradable gel surgical 
barriers is based on the principle of keeping the adjacent wound surfaces 
as mechanically separate (Renier et al, 2005). Several preclinical studies 
in various animal models have reported the effectiveness of both ACP 
(Belluco et al, 2001; Binda et al, 2007; Binda et al, 2009; Binda et al, 
2010; De Iaco et al, 1998; Koçak et al, 1999; Shamiyeh et al, 2007; 
Wallwiener et al, 2006) and HA-CMC gels (Leach et al, 1998; Schonman 
et al, 2008) or HA-CMC membranes (Kelekci et al, 2004; Rajab et al, 
2010) for preventing postsurgical adhesions. Other preclinical studies in 
animal models suggest that HA gel remains in situ for more than 5 to 6 
days (Laurent and Fraser, 1992; Nimrod et al, 1992). Similarly, animal 
studies have demonstrated the persistence of HA-CMC for about 7 days 
after its application (Diamond et al, 1988). However, most of these studies 
were done in rodent models, and not in non-human primate models with 
reproductive anatomy similar to humans, like the baboon, a validated 
model for endometriosis research (D’Hooghe et al, 2009). 
The exact mechanisms by which ACP and HA-CMC are able to reduce 
adhesion reformation are not well known, but may be related to "hydro 
flotation" or "siliconizing" effects. One French clinical controlled trial 
(N=54 women) studied the effectiveness of the application of ACP gel 
(n=30) versus no gel (n=24) at the end of an operative hysteroscopic 
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procedure for treating fibroids, polyps, uterine septa or IUAs; there were 
no statistically significant differences for the rate of adhesion formation, 
the mean adhesion scores or the severity of the adhesions between both 
comparison groups (Ducarme et al, 2006). No data were available for the 
reproductive outcome. 
The health burden associated with subfertility, abdominal pain, or bowel 
obstruction due to adhesions is substantial (Renier et al, 2005; DeCherney 
et al, 1997; DiZerega, 1994); the total cost of adhesion-related morbidity 
in the US Health Care system exceeds $ 1 billion annually (Baakdah and 
Tulandi, 2005). To the best of our knowledge no economical studies on 
adhesion prevention after operative hysteroscopy have been conducted in 
a subfertile population. 
Postoperative adhesion formation is a determining factor influencing 
endometrial wound healing (Yang et al, 2013). At the present there is 
uncertainty whether the use of anti-adhesion barrier gels following 
operative hysteroscopy for preventing de novo adhesions or reformation 
of existing adhesions affects the pregnancy or live birth rates; this is the 
main objective of the present systematic review. 
 
METHODS 
Two review authors independently searched the Cochrane Menstrual 
Disorders and Subfertility Specialized Register (10 April 2013), the 
Cochrane Central Register of Controlled Trials (The Cochrane Library 
2013, Issue 1), MEDLINE (1950 to 4 April 2013), EMBASE (1974 to 4 
April 2013) using a combination of both index and free-text terms. We 
used no language restrictions. We searched other electronic databases 
including trial registers, sources of unpublished literature and reference 
lists. We handsearched the Journal of Minimally Invasive Gynecology 
(from 1 January 1992 to 13 April 2013) and contacted experts in the field.  
We included only studies that were clearly randomized or claimed to be 
randomized. Studies were selected if the source population included 
women of reproductive age suffering from subfertility, bound to undergo 
operative hysteroscopy before any infertility treatment or expectant 
management. Subfertility was defined as “a disease of the reproductive 
system defined by the failure to achieve a clinical pregnancy after 12 
months or more of regular unprotected sexual intercourse” (Zegers-
Hochschild et al, 2009). Studies were excluded if subfertility was 
explicitly reported among the exclusion criteria. We included the 
following types of randomized comparisons: any anti-adhesion barrier gel 
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versus placebo, no barrier gel or another type of barrier gel following 
operative hysteroscopy. 
We selected live birth and adhesion formation at second-look 
hysteroscopy as primary outcomes. Live birth was defined as a delivery of 
a live fetus after 20 completed weeks of gestational age that resulted in at 
least one live baby born. The delivery of a singleton, twin or multiple 
pregnancies was counted as one live birth (Zegers-Hochschild et al, 2009). 
Ongoing or clinical pregnancy, miscarriage and mean adhesion scores or 
severity of adhesions at second-look hysteroscopy were secondary 
outcomes. Ongoing pregnancy was defined as a pregnancy surpassing the 
first trimester or 12 weeks of pregnancy; clinical pregnancy was defined 
as a pregnancy diagnosed by the ultrasound visualization of one or more 
gestational sacs or definitive clinical signs of pregnancy (Zegers-
Hochschild et al, 2009). There are at the present seven reported 
classification systems for scoring the extent or severity of intrauterine 
adhesions (Deans and Abbott, 2010). Some classification systems have 
incorporated menstrual and obstetric history (Wamsteker and De Block, 
1998; AFS, 1988; Nasr et al, 2000); others rely exclusively on the 
hysteroscopic evaluation of the uterine cavity (March et al, 1978; Hamou 
et al, 1983; Valle and Sciarra, 1988; Donnez and Nisolle, 1994). None of 
these systems has been validated and therefore universally accepted 
(Deans and Abbott, 2010). We avoided pooling data from studies using 
different scoring systems. 
After screening the titles and abstracts, removing duplicates and after 
linking multiple reports of the same study together, two authors 
independently assessed the studies by examining the full text reports. We 
contacted the authors of the primary study report whenever additional 
information was required 
Two review authors independently assessed the risk of bias by using the 
Cochrane ‘Risk of bias’ tool assessing all six items. Any disagreements 
between the review authors for the selection, data extraction or risk of bias 
assessment were resolved by discussion or by a third author; any residual 
disagreement was reported in the final review. 
We used the numbers of events in both comparison groups of each 
included study to calculate the Mantel-Haenszel (M-H) risk ratios (RR) 
for the binary data for all the main outcomes; for the secondary outcome 
‘adhesion scores’ the mean values and the standard deviations (SD) were 
used to calculate the inverse variance (IV) mean differences (MD) and the 
95% confidence intervals (CI). We used Review Manager 5 for all the 
computations including the 95% CI. 
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All main outcomes were expressed as per woman randomized. Multiple 
live births and multiple pregnancies were counted as one event.  
We aimed to analyze the data on an intention-to-treat basis (ITT). We 
tried to obtain missing data after contacting the primary study authors. If 
missing data could not be obtained, we undertook imputation of individual 
values for the primary outcomes only by assuming that live births or 
adhesions would not have occurred in participants without a reported 
primary outcome. For all other main outcomes we used an available data 
analysis. We subjected any imputation of missing data for the primary 
outcomes to sensitivity analyses; any substantial difference in the imputed 
ITT analyses compared to available data analyses was incorporated in the 
interpretation of the study findings and the discussion. 
Meta-analysis was done to provide a meaningful summary when enough 
studies were available that were sufficiently similar with respect to the 
clinical and methodological characteristics. A formal assessment of 
statistical heterogeneity was done by using the Q-statistic and the I² 
statistic. If there was evidence of substantial heterogeneity beyond chance, 
we aimed to explore possible explanations for this heterogeneity instead 
of pooling studies that were too clinically diverse. 
We aimed to do the search for eligible studies as comprehensively as 
possible and by being alert in identifying duplicated reports of trials in 
order to minimize the potential impact of reporting and publication bias. 
Since we retrieved only a small number of studies, we did not study 
publication bias or other forms of small study effects by creating a funnel 
plot. 
One review author entered the study data and carried out the statistical 
analysis using Review Manager 5. We considered the outcomes live birth 
and pregnancy to be positive outcomes of effectiveness and by 
consequence higher numbers of these events as a benefit. The outcomes 
miscarriage, adhesion formation and adhesion scores were on the contrary 
considered as negative outcomes and higher numbers as harmful. We 
aimed to combine data from primary studies in a meta-analysis with 
Review Manager 5 using the risk ratio as a summary outcome measure 
using a random-effects model (RE) if enough studies were retrieved and 
after significant clinical diversity and substantial statistical heterogeneity 
were confidently ruled out.  
We aimed to carry out subgroup analyses according to the extent or the 
severity of the uterine abnormality treated and for studies that reported 
both ‘live birth’ and ‘pregnancy’ in order to assess any overestimation of 
the treatment effect. We planned to do sensitivity analyses for the primary 
outcomes to investigate whether the results and conclusions were robust to 
arbitrary decisions regarding the eligibility and analysis. These sensitivity 
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analyses included consideration whether conclusions would have differed 
if the eligibility was restricted to studies without high risk of bias versus 
all studies or if alternative imputation strategies were adopted, e.g. using 
odds ratio rather than risk ratio for the summary effect measure or a fixed-
effect rather than a random-effects as the analysis model. 
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FINDINGS 
 
Description of studies 
 
Results of the search 
 
The search and selection process is presented in figure 1: we retrieved 14 
potentially eligible randomized studies; we included five trials, six trials 
were excluded and three are ongoing. 
 
Figure 1.PRISMA flow chart of the search and selection process. 
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Included studies 
*Study design and setting 
 
Five single-centre parallel group RCTs were included in the present 
systematic review: four were conducted in Italy (Acunzo et al, 2003; De 
Iaco et al, 2003; Di Spiezio Sardo et al, 2011; Guida et al, 2004) and one 
in Israel (Pansky et al, 2011). All five trials used two comparison groups. 
Only one trial (Di Spiezio Sardo et al, 2011) reported a statistical power 
calculation for one of the primary outcomes (incidence of adhesion 
formation). The protocol of all included trials was approved by the 
Institutional Review Board (IRB). The protocol of the trial from Israel 
(Pansky et al, 2011) was registered in a clinical trial registry (See 
NCT01377779 in Clinical Trials.gov). None of the trials reported on 
funding or other potential conflicts of interest. 
 
*Participants 
 
Two of the four Italian trials included subfertile women: 34 women out of 
92 participants (Acunzo et al, 2003) and 21 out of 110 participants (Di 
Spiezio Sardo et al, 2011). The characteristics and data from these 
subfertile women were not available for individual patient data (IPD) 
meta-analysis. In the remaining two studies including 60 women (De Iaco 
et al, 2003) and 138 women (Guida et al, 2004) it is not clear whether and 
how many participants suffered from subfertility. We could not obtain 
further clarification from the study authors. The study from Israel 
included 30 women who were trying to conceive after miscarriage. The 
proportion of women suffering from subfertility was not reported; this 
could not be clarified (Pansky et al, 2011). Three of the four Italian trials 
(Acunzo et al, 2003; Di Spiezio Sardo et al, 2011; Guida et al, 2004) were 
conducted in the same university hospital; several co-authors participated 
in the clinical research of all three trials. The in- and exclusion criteria 
were similar in these three studies; one trial included only women with 
intrauterine adhesions (Acunzo et al, 2003), the other trials included 
women with fibroids, polyps or uterine septa (Guida et al, 2004) or 
women with single or multiple intrauterine lesions except intrauterine 
adhesions or suffering from dysfunctional uterine bleeding (Di Spiezio 
Sardo et al, 2011). The description of the source population was not 
adequate in the fourth Italian study (De Iaco et al, 2003). The fifth 
included study was conducted in a source population of women with 
retained products of conception after miscarriage (Pansky et al, 2011). 
The mean age of the participants was below 35 years in one study 
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(Acunzo et al, 2003). In two trials the mean patient age in both 
comparison groups was above 35 years (Di Spiezio Sardo et al, 2011; 
Guida et al, 2004). The other two studies reported a range between 18 to 
65 years (De Iaco et al, 2003) or 18 to 50 years (Pansky et al, 2011) 
without reporting data on the mean ages and SD in both comparison 
groups. 
 
*Interventions 
 
All trials randomly compared the intrauterine application of an anti-
adhesion gel versus no gel following operative hysteroscopy. In three 
studies ACP gel was used (Acunzo et al, 2003; De Iaco et al, 2003; Guida 
et al, 2004); the other two (Di Spiezio Sardo et al, 2011; Pansky et al, 
2011) used polyethylene oxide-sodium CMC gel for the intervention. In 
three trials the gel was administered into the uterine cavity through one of 
the flow channels of the resectoscope; the procedure was judged to be 
adequate when under hysteroscopic control the gel seemed to have 
replaced the liquid medium, filling the cavity from the fundus to the 
internal ostium of the cervix (Acunzo et al, 2003; Di Spiezio Sardo et al, 
2011; Guida et al, 2004). In one of these three studies (Acunzo et al, 
2003) ultrasonographic data demonstrated that the anti-adhesive gel was 
able to keep the uterine walls separated for at least 72 hours. In one study 
(De Iaco et al, 2003) the gel was applied using the cannula in a blind way 
without using hysteroscopic visualization; for another trial (Pansky et al, 
2011) the method of application of the anti-adhesion gel is not clear. 
 
*Outcomes 
 
The primary outcome of live birth was reported in none of the included 
studies; the incidence of adhesions was reported in all five studies. The 
following secondary outcomes were reported as follows: clinical 
pregnancy (Pansky et al, 2011), mean adhesion scores (Acunzo et al, 
2003; Guida et al, 2004) and severity of the adhesions (Acunzo et al, 
2003; De Iaco et al, 2003; Di Spiezio Sardo et al, 2011; Guida et al, 2004; 
Pansky et al, 2011). The definition of pregnancy and the time period 
during which this secondary outcome was assessed in one trial (Pansky et 
al, 2011) was not described. Four studies (Acunzo et al, 2003 Di Spiezio 
Sardo et al, 2011; Guida et al, 2004; Pansky et al, 2011) used the 1988 
AFS classification system for scoring intrauterine adhesions at second-
look hysteroscopy; one trial (De Iaco et al, 2003) used the ASRM 
modified scoring system. In all five studies the incidence and the severity 
of adhesion formation was measured at one time point only, ranging from 
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4 to 12 weeks after the operative hysteroscopy (Acunzo et al, 2003; De 
Iaco et al, 2003; Di Spiezio Sardo et al, 2011; Guida et al, 2004; Pansky et 
al, 2011). 
 
Risk of bias in included studies 
Allocation (selection bias) 
We judged four of the five trials to be at low risk for selection bias related 
to random sequence generation (Acunzo et al, 2003; De Iaco et al, 2003; 
Di Spiezio Sardo et al, 2011; Guida et al, 2004). One trial (Pansky et al, 
2011) did not describe the method of random sequence generation; no 
further clarification could be obtained. We judged all five studies to be at 
unclear risk for selection bias related to allocation since they did not 
adequately describe the method of allocation concealment (Acunzo et al, 
2003; De Iaco et al, 2003; Di Spiezio Sardo et al, 2011; Guida et al, 2004; 
Pansky et al, 2011). 
 
Blinding (performance bias and detection bias) 
In all five trials the method of blinding of the outcome assessors was not 
described (Acunzo et al, 2003; De Iaco et al, 2003; Di Spiezio Sardo et al, 
2011; Guida et al, 2004; Pansky et al, 2011).We judged this risk of bias 
item to be important for the outcomes ‘incidence of adhesions’, ‘mean 
adhesion scores’ and ‘severity of adhesions’ but less relevant for the 
outcomes of ‘live birth’, ‘ongoing’ or ‘clinical pregnancy’ and 
‘miscarriage’ unless the follow up period was not long enough. 
 
Incomplete outcome data (attrition bias) 
We judged four trials to be at low risk for attrition bias (Acunzo et al, 
2003; Di Spiezio Sardo et al, 2011; Guida et al, 2004; Pansky et al, 
2011).We judged one study to be at high risk for attrition bias related to 
incomplete outcome data; the loss to follow up in this study of 33% (20 
out of 60 enrolled women) is high and thus very likely to cause substantial 
attrition bias (De Iaco et al, 2003). 
 
Selective outcome reporting (reporting bias) 
We judged all trials to be at low risk of reporting bias; no evidence for 
selective outcome reporting was retrieved in any of the included studies 
when comparing abstract, methods and results section. 
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Other potential sources of bias 
We judged three studies to be at low risk for other potential sources of 
bias (Acunzo et al, 2003; Di Spiezio Sardo et al, 2011; Guida et al, 2004). 
We judged one study to be at an unclear risk for other potential sources of 
bias (Pansky et al, 2011); the other study (De Iaco et al, 2003) was judged 
to be at high risk of bias due to likely imbalance of patient characteristics, 
imbalanced distribution of co-treatment and other methodological study 
flaws. 
 
Figure 2 Risk of bias summary: review authors' judgments about each 
risk of bias item for each included study. 
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Figure 3 Risk of bias graph: review authors' judgments about each risk of 
bias item presented as percentages across all included studies. 
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of outcome assessment (detection bias): outcome: live birth or pregnancy
Blinding of outcome assessment (detection bias): outcome: adhesions
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
 
Effects of interventions 
Any gel versus no gel 
 
*Primary outcomes 
1. Live birth 
There were no data for this primary outcome. 
2. Incidence of adhesion formation at second-look hysteroscopy 
 
The use of any gel after operative hysteroscopy decreases the incidence of 
adhesions (RR 0.65, 95% CI 0.45 to 0.93, P=0.02, 5 studies, 372 women) 
The NNTB is 9 (95% CI 5 to 33) (Figure 4). 
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Figure 4 Forest plot of comparison: Any anti-adhesion gel versus no gel. 
Outcome 2: Incidence of adhesions at second-look hysteroscopy. M-H: 
Mantel-Haenszel, random-effects model, CI: confidence interval. 
Study or Subgroup
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Di Spiezio Sardo 2011
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Subtotal (95% CI)
Total events
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Test for overall effect: Z = 0.40 (P = 0.69)
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De Iaco 2003
Subtotal (95% CI)
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Heterogeneity: Not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.01; Chi² = 7.31, df = 7 (P = 0.40); I² = 4%
Test for overall effect: Z = 2.35 (P = 0.02)
Test for subgroup differences: Chi² = 5.69, df = 5 (P = 0.34), I² = 12.2%
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1
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6
8
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3
8
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6
6
3
3
6
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7
7
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7
8
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Weight
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1.6%
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16.0%
16.0%
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13.1%
13.1%
100.0%
M-H, Random, 95% CI
0.31 [0.04, 2.68]
0.48 [0.17, 1.39]
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Not estimable
0.32 [0.07, 1.49]
0.32 [0.07, 1.49]
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Chapter 5 
 
 
132 
*Secondary outcomes 
3. Pregnancy 
There is no evidence for a benefit with the use of polyethylene oxide-
sodium CMC gel following operative hysteroscopy for suspected retained 
products of conception for the outcome of clinical pregnancy (RR 3.0, 
95% CI 0.35 to 26, P=0.32, 1 study, 30 women) (Figure 5). 
Figure 5 Forest plot of comparison: Any anti-adhesion gel versus no gel. 
Outcome 3: Pregnancy. M-H: Mantel-Haenszel, random-effects model, 
CI: confidence interval. 
Study or Subgroup
Pansky 2011
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Events
3
3
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Weight
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0.01 0.1 1 10 100
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4. Miscarriage 
There were no data for this secondary outcome. 
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*Other secondary outcomes 
5.1. Mean adhesion score at 3 months in women with fibroids, polyps or 
uterine septa 
The use of ACP gel in women undergoing operative hysteroscopy for 
fibroids, endometrial polyps or uterine septa is associated with a lower 
mean adhesion score at second-look hysteroscopy at 3 months (MD -1.4, 
95% CI -1.8 to -1.0, P<0.00001, 1 study, 24 women) (Figure 6). 
Figure 6 Forest plot of comparison: Auto-cross-linked hyaluronic acid gel 
versus no gel. Outcome 5: mean adhesion score AFS 1988 at 3 months in 
women with myomas, polyps or uterine septa. IV: inverse variance, 
random-effects model, CI: confidence interval. 
Study or Subgroup
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IV, Random, 95% CI
-4 -2 0 2 4
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5.2. Mean adhesion score at 3 months in women with intrauterine 
adhesions 
There are statistically significant differences in the mean adhesion scores 
at second-look hysteroscopy at 3 months after the use of ACP gel 
compared to operative hysteroscopy only in women undergoing operative 
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hysteroscopy for intrauterine adhesions (MD -3.3, 95% CI -3.4 to -3.2, 
P<0.00001, 1 study, 19 women) (Figure 7). 
Figure 7 Forest plot of comparison: Auto-cross-linked hyaluronic acid gel 
versus no gel. Outcome 5 mean adhesion score AFS 1988 at 3 months in 
women with intrauterine adhesions. IV: inverse variance, random-effects 
model, CI: confidence interval. 
Study or Subgroup
Acunzo 2003
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 47.91 (P < 0.00001)
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5.3. Severity of adhesions at second-look hysteroscopy when using any gel 
At second-look hysteroscopy there are more mild adhesions when using 
any gel following operative hysteroscopy (RR 2.8, 95% CI 1.1 to 7.0, 
P=0.03, 4 studies, 79 women) (Figure 8). Statistical heterogeneity beyond 
chance was high (Chi2=12.30, df=3 (P=0.006); I2=76%). The NNTB is 2 
(95% CI 1 to 4). 
Figure 8 Forest plot of comparison: Any anti-adhesion gel versus no gel. 
Outcome 5: AFS 1988 stage I (mild) adhesions at second- look 
hysteroscopy. M-H: Mantel-Haenszel, random-effects model, CI: 
confidence interval. 
Study or Subgroup
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There is an effect favoring the use of any gel following operative 
hysteroscopy for the outcome of AFS 1988 stage II (moderate) adhesions 
at second-look hysteroscopy (RR 0.26, 0.09 to 0.80, P=0.02, 3 studies, 58 
women) (Figure 9). The NNTB is 2 (95% CI 1 to 2). 
Figure 9 Forest plot of comparison: Any anti-adhesion gel versus no gel. 
Outcome 5: AFS 1988 stage II (moderate) adhesions at second-look 
hysteroscopy. M-H: Mantel-Haenszel, random-effects model, CI: 
confidence interval. 
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There is no evidence for an effect in favor of any gel versus no gel 
following operative hysteroscopy for the outcome of AFS 1988 stage III 
(severe) adhesions at second-look hysteroscopy (RR 0.46, 95% CI 0.03 to 
7.2, P=0.58, 3 studies, 58 women) (Figure 10). 
Figure 10 Forest plot of comparison: Any anti-adhesion gel versus no gel. 
Outcome 5: AFS 1988 stage III (severe) adhesions at second-look 
hysteroscopy. M-H: Mantel-Haenszel, random-effects model, CI: 
confidence interval. 
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For the composite outcome ’moderate or severe adhesions’ there are 
statistically significant differences favoring the use of any gel following 
operative hysteroscopy (RR 0.25, 95% CI 0.10 to 0.67, P=0.006, 4 
studies, 79 women) (Figure 11). The NNTB is 2 (95% CI 1 to 4). 
 
Figure 11 Forest plot of comparison: Any anti-adhesion gel versus no gel. 
Outcome 5: AFS 1988 stage II (moderate) or stage III (severe) adhesions 
at second-look hysteroscopy. M-H: Mantel-Haenszel, random-effects 
model, CI: confidence interval. 
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*Subgroup analyses 
 
We conducted a subgroup analysis according to the type of pathology 
treated by operative hysteroscopy. The use of any gel following operative 
hysteroscopy for fibroids (RR 0.44, 95% CI 0.17 to 1.1, P=0.09, 2 studies, 
80 women), endometrial polyps (RR 0.32, 95% CI 0.07 to 1.5, P=0.15, 2 
studies, 109 women), uterine septa (RR 0.26, 95% CI 0.05 to 1.3, P=0.11, 
2 studies, 29 women), intrauterine adhesions (RR 0.44, 95% CI 0.18 to 
1.0, P=0.06, 1 study, 84 women), retained products of conception (RR 
0.91, 95 % CI 0.57 to 1.4, P=0.69, 1 study, 30 women) or 'not specified' 
(RR 0.87, 95% CI 0.33 to 2.3, P=0.78, 1 study, 40 women) consistently 
tends to decrease the incidence of adhesions at second-look hysteroscopy. 
The fact that the differences between both comparison groups within each 
subgroup were not statistically significant is a common problem with 
subgroup analyses due to smaller numbers. There is no evidence for 
substantial subgroup differences (Chi²=5.7, df=5 (P=0.34), I²=12%) as 
shown in figure 4. The data of this sensible predefined subgroup analysis 
should not be over interpreted. 
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*Sensitivity analyses 
A sensitivity analysis was done to study the impact of the study quality on 
the treatment effect for the primary outcomes. If we excluded the single 
study at high risk of bias (De Iaco et al, 2003) in a sensitivity analysis, the 
use of any gel following operative hysteroscopy was still beneficial for 
decreasing the incidence of adhesions but the treatment effect was larger 
(RR 0.56, 95% CI 0.35 to 0.90, P=0.02, 4 studies, 332 women). A second 
sensitivity analysis to study the influence of the choice for the analysis 
model (fixed-effect rather than random-effects model) did not demonstrate 
any impact on the treatment effect (RR 0.55, 95% CI 0.38 to 0.79, 
P=0.001, 5 studies, 372 women). The choice of the summary effect 
measure (RR rather than OR) did not have a substantial effect on the 
magnitude or the direction of the estimated treatment effect nor on the 
statistical significance of the differences between the comparison groups 
(OR 0.40, 95% CI 0.23 to 0.70, P=0.001, 5 studies, 372 women). 
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SUMMARY OF MAIN RESULTS 
Table 1 
Any anti-adhesive barrier gel following operative hysteroscopy for treating 
female subfertility 
Outcomes No of 
Participants
(studies) 
Follow up 
Quality of the 
evidence 
(GRADE) 
Relative 
effect 
(95% 
CI) 
Anticipated absolute 
effects
Risk 
with 
Control 
Risk difference 
with Anti-
adhesion 
barrier gels 
(95% CI) 
Incidence of 
adhesions 
hysteroscopy 
372 
(5 studies) 
1 to 3 months
⊕⊝⊝⊝ 
VERY 
LOW1,2 
due to risk of 
bias, 
indirectness 
RR 0.65 
(0.45 to 
0.93) 
Study population
292 per 
1000 
102 fewer per 
1000 
(from 20 fewer 
to 161 fewer) 
Medium risk
510 per 
1000 
179 fewer per 
1000 
(from 36 fewer 
to 280 fewer) 
High risk
880 per 
1000 
308 fewer per 
1000 
(from 62 fewer 
to 484 fewer) 
Clinical 
pregnancy 
30 
(1 study) 
unknown 
⊕⊝⊝⊝ 
VERY 
LOW3,4 
due to 
indirectness, 
imprecision 
RR 3.00 
(0.35 to 
26) 
67 per 
1000 
133 more per 
1000 
(from 43 fewer 
to 1000 more) 
*The basis for the assumed medium risk for the outcome ‘incidence of  adhesions’ is the average risk 
(51%)of adhesions for the different pathologies reported in the prospective cohort study by Yang et 
al,2013. The assumed high risk is based on the incidence of adhesions following septum resection 
(88%) reported by Yang et al, 2013. The corresponding risk (and its 95% confidence interval) is 
based on the assumed risk in the comparison group and the risk ratio of the intervention (and its 95% 
CI).CI: Confidence interval; RR: Risk ratio. 
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GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect.  
Moderate quality: Further research is likely to have an important impact on our confidence in the 
estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the 
estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
1 The study by De Iaco 2003 was at high risk for attrition bias 
2 In two of the four included trials 19% (Di Spiezio Sardo 2011) and 37% (Acunzo 2003) of the 
participants suffered from subfertility; for a third Italian trial (Guida 2004) it is unclear whether 
subfertile women were included. The proportion of women suffering from subfertility in the Israeli 
study (Pansky 2011) is not reported. 
3 The number of women suffering from subfertility was not reported 
4 The 95% confidence interval is very wide 
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DISCUSSION 
This systematic review aimed to appraise critically whether the use of any 
anti-adhesion barrier gel following operative hysteroscopy in subfertile 
women made a difference for the main outcomes of live birth, incidence 
of adhesion formation, pregnancy, miscarriage, mean adhesions scores or 
severity of adhesions at second-look hysteroscopy. We searched for RCTs 
on anti-adhesion barrier gels versus other barrier gels, placebo or no anti-
adhesion barrier gels following operative hysteroscopy. We critically 
appraised five studies randomly comparing the use of any anti-adhesion 
gel versus no gel in women of reproductive age treated by operative 
hysteroscopy for fibroids, polyps, septa, adhesions or retained products of 
conception (Acunzo et al, 2003; De Iaco et al, 2003; Di Spiezio Sardo et 
al, 2011; Guida et al, 2004; Pansky et al, 2011). We judged a statistical 
pooling of the results of these five studies to be sensible given that 
substantial clinical diversity and statistical heterogeneity could 
confidently be ruled out. We refer to table 1 on the previous page for a 
summary of findings for the key outcomes clinical pregnancy and 
incidence of adhesions at second-look hysteroscopy (Table 1). 
According to our meta-analysis there is evidence for a benefit with the use 
of any anti-adhesive gel following operative hysteroscopy for decreasing 
the incidence of adhesions at second-look hysteroscopy. The benefit for 
this outcome tends to be consistently present across different subgroups 
according to the type of pathology treated. The treatment effect for 
decreasing adhesions at second-look hysteroscopy is robust; the direction 
of the treatment effect and the statistical significance of the differences 
between the comparison groups are independent from the study quality 
and the choices made for the analysis model and the summary effect 
measure. 
The use of ACP gel in women undergoing operative hysteroscopy for 
fibroids, endometrial polyps, uterine septa or intrauterine adhesions is 
associated with a lower mean adhesion score at second-look hysteroscopy 
at 3 months; the clinical relevance of this finding is unclear since only 
non-validated classification systems for scoring IUAs are used at the 
present. When adhesion formation is observed at second-look 
hysteroscopy, there are more mild adhesions and less moderate or severe 
adhesions by using any anti-adhesion gel after operative hysteroscopy. 
There is no evidence for a benefit with the use of polyethylene oxide-
sodium CMC gel versus no gel in women treated by operative 
hysteroscopy for suspected retained products of conception for the 
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outcome of pregnancy (Pansky et al, 2011). Although there was a 
beneficial trend when using the anti-adhesion gel, the differences between 
both comparison groups were not statistically significant. This may be a 
type II error: to detect a difference between both comparison groups of 
13% in the clinical pregnancy rate with a statistical power of 80% at a 
confidence level of 95% (α=0.05 and β=0.20) and under the assumption of 
a loss to follow up of 10%, a sample size of 120 would be required; 
meaning 240 rather than 30 participants as in this single centre study. 
Overall completeness and applicability of evidence 
The evidence of the effectiveness of using any anti-adhesion gel versus no 
gel in women of reproductive age treated by operative hysteroscopy for 
fibroids, polyps, septa or intrauterine adhesions is limited: no data on live 
birth, pregnancy or miscarriage rate were retrieved. In women of 
reproductive age treated by operative hysteroscopy for retained products 
of conception, the use of polyethylene oxide-sodium CMC gel tends to 
increase the clinical pregnancy rate; the differences between both 
comparison groups were not statistically significant due to the inadequate 
statistical power of the trial. Moreover, the proportion of the women 
suffering from subfertility in both comparison groups was not reported 
and the trial was at unclear risk of bias for several items. 
There are at the present two ongoing trials on the use of anti-adhesion 
barrier gels after operative hysteroscopy. The first is a parallel group 
randomized study on the effectiveness of applying Oxiplex/AP Gel 
(Intercoat) for preventing intrauterine adhesions in women aged 18 to 50 
years following hysteroscopic surgery. This study is at the present not yet 
recruiting (NCT01637974). The second trial will address the effectiveness 
of hyaluronic acid gel in women older than 18 years following 
hysteroscopic surgery; this trial will not answer the research question in 
the present review since the primary and only outcome measured is the 
patient satisfaction rate two months after the gel application 
(NCT01464528). 
There is some reason for concern about the applicability of the evidence 
retrieved: most trials were conducted in a target population including -but 
not limited to- women suffering from subfertility: two trials (Acunzo et al, 
2003; Di Spiezio Sardo et al, 2011) included variable proportions of 
women suffering from subfertility, miscarriage or risk of preterm delivery, 
for two studies ( De Iaco et al, 2003; Guida et al, 2004) it is unclear 
whether and how many participants suffered from subfertility while the 
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final fifth included study (Pansky et al, 2011) included a source 
population of women with proven fertility trying to conceive after 
miscarriage. It is unlikely that the mechanisms of adhesion formation 
might be different in subfertile compared to a general or fertile target 
population; nevertheless, we judge the overall applicability of the 
retrieved best available evidence in a more general source population to a 
target population of subfertile women to be limited. 
Quality of the evidence 
We graded the evidence for the randomized comparison between any anti-
adhesion barrier gel versus no gel following operative hysteroscopy for 
the outcomes of pregnancy and incidence of adhesions as very low. 
Agreements and disagreements with other studies or reviews 
Two reviews support the use of anti-adhesive gel for reducing adhesion 
formation following operative hysteroscopy. The first review (Deans and 
Abbott, 2010) is a narrative review reporting the results and conclusions 
of one RCT included in the present systematic review (Acunzo et al, 
2003). The second review (Mais et al, 2012) is a systematic review and 
meta-analysis studying the effectiveness of auto-cross-linked hyaluronan 
gel for adhesion prevention in laparoscopic and hysteroscopic surgery. 
The data of three RCTs included in the present systematic review (Acunzo 
et al, 2003; De Iaco et al, 2003; Guida et al, 2004) were pooled: the 
proportion of women with adhesions at second-look was significantly 
lower in women who received ACP gel than in the control group of 
women undergoing operative hysteroscopy without ACP gel (RR 0.50, 
95% CI 0.31 to 0.85, P=0.009, 3 studies, 256 women). The authors used 
an older methodological tool (the Jadad scale) for assessing the validity of 
the included trials. The “scale” methodology is at the present no longer 
supported by the Cochrane Collaboration which recommends using a 
more formal assessment by means of the ‘Risk of bias’ tool. This different 
methodology explains the discrepancy between the statement of Mais et al 
that all the included trials in their systematic review were judged to be of a 
high quality which contrasts with our judgment of “very low quality 
evidence” for the outcomes of pregnancy and incidence of de novo 
adhesions.  
One French small comparative study (n=54 women with uterine 
pathology) has studied the efficacy of auto-cross-linked hyaluronic acid 
gel in the prevention of adhesions following operative hysteroscopy 
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(Ducarme et al, 2006). The authors concluded that the use of auto-cross-
linked hyaluronic acid gel does not reduce the incidence and the severity 
of intrauterine adhesions after hysteroscopic surgery. According to a more 
recent review of the literature (Revaux et al, 2008) -with the first author of 
the French comparative study (Ducarme et al, 2006) as co-author- the 
majority of the limited published studies until 2008 only evaluated the 
anatomic efficiency of anti-adhesion agents after hysteroscopic surgery. 
The authors concluded that the available data for the key reproductive 
outcomes were not convincing to promote the widespread clinical use of 
anti-adhesive barrier agents as an effective treatment strategy for infertile 
women treated by operative hysteroscopy; hence their conclusion that 
additional RCTs are needed. 
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AUTHORS’ CONCLUSIONS 
Implications for practice 
Gynecologists should counsel their patients that intrauterine adhesion 
formation is the major long-term complication of operative hysteroscopy 
in women of reproductive age. The use of any barrier gel following 
operative hysteroscopy for suspected uterine cavity abnormalities in 
subfertile women might be considered: its use may decrease adhesion 
formation (very low quality evidence). If adhesion formation occurs, there 
are less moderate or severe adhesions and more mild adhesions by using 
any anti-adhesion gel; the mean adhesion scores at second-look 
hysteroscopy are lower after using ACP gel. Subfertile women 
nevertheless should be counseled that there is no evidence for higher live 
birth or pregnancy rates by using any barrier gel following operative 
hysteroscopy (very low quality evidence). There are no data at the present 
of the effects on the miscarriage rates. 
Implications for research 
The very low quality evidence retrieved from the small number of RCTs 
in a general source population including, but not restricted to subfertile 
women, is at the present not sufficient to draw robust conclusions in favor 
of any barrier as an adjunctive therapy following operative hysteroscopy 
for the key reproductive outcomes; more adequately powered and well-
designed management RCTs are needed to assess whether the use of any 
anti-adhesion gel affects the live birth, the pregnancy and miscarriage 
rates in a target population of subfertile women. There are no data on a 
dose-response relationship between the size, the number or the severity of 
the treated pathology and the corresponding magnitude of the increase in 
effectiveness or decrease in the adverse outcomes that were defined in the 
present systematic review. A universally accepted classification system 
for scoring intrauterine adhesions validated for the prediction of 
spontaneous pregnancy is needed; this is a research priority that should be 
addressed by inception cohort studies. 
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BACKGROUND 
 
Description of the interventions for preventing intrauterine adhesions 
Observational studies have suggested that several different anti-adhesion 
strategies might be used for preventing intrauterine adhesions following 
operative hysteroscopy. 
 
IUD or Foley catheter balloon 
An intrauterine device (IUD) may provide a physical barrier between the 
uterine walls, separating the endometrial layers after lysis of IUAs. Its 
insertion as an adjunctive therapy has been recommended in at least 13 
observational studies (Deans 2010). The use of a Foley catheter balloon 
has been reported as an alternative for similar purposes in eight 
observational studies (Deans 2010). 
 
Hormone therapy 
In 1964, Wood and Pena suggested to prescribe estrogen therapy to 
stimulate the regeneration of the endometrium after the surgical treatment 
of IUAs (Wood 1964). 
 
Barrier gels 
Hyaluronic acid or hyaluronan (HA), is a water soluble polysaccharide: it 
consists of multiple disaccharide units of glucuronic acid and N-acetyl 
glucosamine, bound together by a ß1-3-type glycoside bond. Solutions of 
HA have visco-elastic properties which have led to interests in developing 
applications of HA in surgical procedures, for example in ocular surgery 
and prevention of postsurgical adhesions. However, HA may not be the 
ideal substance for all procedures, due to its limited residence time when 
applied to a surgical site. It quickly enters the systemic circulation and is 
then cleared rapidly by catabolic pathways. Attempts to use hyaluronan 
for preventing postsurgical adhesions have therefore been met with 
variable success. Chemically modified derivatives of HA have been 
developed to circumvent the disadvantages of HA. One such derivative is 
auto-cross-linked polysaccharide (ACP). It is formed by cross linking 
hyaluronan, via direct formation of covalent ester bonds between hydroxyl 
and carboxyl groups of the hyaluronan molecule. ACP can be prepared 
with various degrees of cross linking, which allows tailoring of the 
viscosity properties of ACP gels (Renier 2005). Carboxymethylcellulose 
(CMC) is a high-molecular-weight polysaccharide that has a viscosity 
greater than Dextran 70. CMC can be used for adhesion prevention as a 
membrane barrier or a gel as a mixture of chemically derivative sodium 
hyaluronate and carboxymethylcellulose gel (HA-CMC) (Leach 1998). 
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Human amnion membrane grafting 
Over the last three decades, the surgical community has become aware of 
the increasing potential of human amnion membrane (HAM) as an 
adjunctive anti-adhesion intervention. The use of whole human fetal 
membranes or amnion alone in surgery has primarily developed to aid the 
repair of surface epithelial defects in the skin, eye, abdominal wall and 
peritoneum. HAM grafting has not been very popular in the field of 
obstetrics and gynecology: its clinical use is limited to the use as a graft in 
forming an artificial vagina or as a barrier to prevent postoperative intra-
abdominal adhesion formation or finally as a biological dressing 
following radical vulvectomies and groin dissections (Amer 2006). 
 
How these interventions might work 
The hypothetical underlying mechanisms of subfertility associated with 
IUAs are obstruction of sperm transport into the cervix, impaired embryo 
migration within the uterine cavity or failure of embryo implantation due 
to endometrial insufficiency (Deans 2010). The ideal anti-adhesion 
adjunctive therapy following operative hysteroscopy would be the 
application of a biologically active mechanical separator that achieves the 
suppression of intrauterine adhesion formation and promotes the healing 
of the endometrium. The bulk of evidence on how the different 
interventions might work is derived from animal studies-largely in rodents 
and not in validated animal models for the study of human reproduction- 
or observational studies. 
 
IUD or Foley catheter balloon 
The use of an IUD (13 observational studies) or a Foley catheter balloon 
(8 observational studies) (Deans 2010) is often recommended following 
the hysteroscopic treatment of IUAs or septoplasty to act as a physical 
barrier separating the opposing walls of the uterine cavity. The type of 
IUD may be important; copper-containing IUDs provoke an inflammatory 
reaction with probably detrimental effects whereas T-shaped IUDs might 
have too small a surface area to be truly effective in providing an efficient 
physical barrier. The loop IUD (e.g. Lippes loop) is generally considered 
the IUD of choice when treating IUAs; it is however no longer available 
in many countries (Kodaman 2007). One controlled clinical trial (CCT) 
(Orhue 2003) compared the use of a Foley catheter balloon for 10 days 
(N=59) versus the insertion of an IUD during three months (N=51); the 
fertility rates were equally poor in both the IUD group (20/59 or 34%) and 
the Foley catheter group (14/51 or 28%)(P=0.47). 
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Hormone therapy 
Many studies recommend the use of a cyclical estrogen and progestogen 
treatment regimen following the hysteroscopic treatment of IUAs to 
promote the regeneration of the endometrium (Deans 2010). Various 
regimens have been proposed consisting of estrogen (e.g. a typical daily 
dose of 2.5 mg of conjugated equine estrogen twice daily for 30 days) 
with or without a progestin (e.g. 10 mg medroxyprogesterone acetate for 
10 days) (Kodaman 2007); no comparative studies have been performed 
on dosage, administration, or combination of hormones (Deans 2010). In a 
randomized study (Farhi 1993) 60 women undergoing dilation and 
curettage during the first trimester of pregnancy were allocated to receive 
estrogen and progestin or no treatment. Women in the intervention group 
had a significantly thicker endometrium (8.4 vs. 6.7mm, P=0.02) 
compared with the control group. The authors concluded that 
postoperative hormone treatment may be beneficial for intrauterine 
adhesion prevention following surgical trauma to the uterine cavity. 
Nevertheless, no data were available on pregnancy outcome or 
intrauterine adhesion formation or recurrence (Farhi 1993). A systematic 
review of observational studies concluded that hormonal therapy, 
particularly estrogen therapy, may be beneficial to women with IUAs but 
as an adjunctive therapy combined with other anti-adhesion strategies 
(Johary 2013). 
 
Barrier gels 
The use of the biodegradable gel surgical barriers is based on the principle 
of keeping the adjacent wound surfaces as mechanically separate (Renier 
2005). Several preclinical studies in various animal models have 
demonstrated the effectiveness of both ACP (Belluco 2001; Binda 2007; 
Binda 2009; Binda 2010; De Iaco 1998; Koçak 1999; Shamiyeh 2007; 
Wallwiener 2006) and HA-CMC gels (Leach 1998; Schonman 2008) or 
HA-CMC membranes (Kelekci 2004; Rajab 2010) for preventing 
postsurgical adhesions. Other preclinical studies in animal models suggest 
that HA gel remains in situ for more than 5 to 6 days (Laurent 1992; 
Nimrod 1992). Similarly, animal studies demonstrate the persistence of 
HA-CMC for about seven days after its application (Diamond 1988). The 
precise mechanisms by which ACP and HA-CMC are able to reduce 
adhesion reformation are not well known, but may be related to "hydro 
flotation" or "siliconizing" effects. One French CCT (N=54 women) 
compares the application of ACP gel (n=30) versus no gel (n=24) at the 
end of an operative hysteroscopic procedure for treating myomas, polyps, 
uterine septa or IUAs; there are no statistically significant differences for 
the rate of adhesion formation between both comparison groups nor for 
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the mean adhesion scores or the severity of the adhesions (Ducarme 
2006). There were no data on the reproductive outcome. 
 
Human amnion membrane grafting 
The preclinical data on the effectiveness of HAM grafting in different 
animal models present conflicting results: one trial (Szabo 2002) 
demonstrates a beneficial effect in preventing de novo adhesions whereas 
in two other animal studies (Arora 1994; Badawy 1989) HAM grafting 
fails to prevent de novo adhesion formation. One observational study 
reports on the use of a fresh amnion graft over an inflated Foley catheter 
to prevent recurrence of intrauterine adhesions after hysteroscopic lysis in 
25 women with moderate to severe Asherman syndrome: minimal 
adhesion reformation was demonstrated in 48% of study participants with 
severe adhesions. The authors conclude that HAM grafting might be 
promising as an adjunctive therapy following hysteroscopic adhesiolysis; 
it acts as a biologically active mechanical barrier suppressing adhesion 
formation and promoting endometrial healing (Amer 2006). Fresh HAM 
graft preserves its viability for 21 days following its application in the 
pelvic cavity (Trelford Sauder 1977). In addition to being an anatomical 
barrier HAM may promote the regeneration of epithelium by acting as a 
basement membrane substrate; HAM may facilitate the migration of 
epithelial cells, reinforce the adhesion of the basal epithelium, promote 
epithelial cell differentiation (Meller 1999) and prevent cellular apoptosis 
(Hori 2006). Human amnion epithelial cells produce factors or create a 
microenvironment for effective tissue repair and endometrial regeneration, 
possibly by stimulating endogenous stem cells (Padykula 1991). 
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OBJECTIVES 
 
To assess the effectiveness of anti-adhesion therapy versus placebo, no 
therapy or an alternative anti-adhesion therapy following operative 
hysteroscopy for the treatment of female subfertility. 
 
METHODS 
 
Criteria for considering studies for this review 
 
Types of studies 
Published and unpublished parallel group randomized controlled trials 
(RCTs) will be eligible for inclusion. We will exclude non-randomized 
studies (e.g. studies with evidence of inadequate sequence generation such 
as alternate days, patient numbers) as they are associated with a high risk 
of bias. We will include crossover trials if individually randomized 
women are the unit of analysis; only data from the first phase will be 
included in meta-analyses, as the crossover is not a valid study design in 
the context of subfertility. 
 
Types of participants 
Women of reproductive age undergoing operative hysteroscopy for 
subfertility associated with suspected or unsuspected intrauterine 
pathology before spontaneous conception or any subfertility treatment. 
Studies excluding women wishing to conceive will not be eligible. 
 
Types of interventions 
We will include the following randomized comparisons: 
• Anti-adhesion therapy versus placebo or no active anti-
adhesion therapy following operative hysteroscopy. 
• Anti-adhesion therapy A versus anti-adhesion therapy B 
following operative hysteroscopy. 
 
Types of outcome measures 
 
*Primary outcomes 
 
1. Effectiveness: live birth, defined as a delivery of at least one live fetus 
after 20 weeks of gestational age that resulted in at least one live baby 
born; we will count the delivery of singleton, twin or multiple pregnancies 
as one live birth. 
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2. Adverse event: incidence of adhesion formation at second-look 
hysteroscopy. 
 
*Secondary outcomes 
 
3. Effectiveness: clinical pregnancy, defined as a pregnancy diagnosed 
by ultrasonographic visualization of one or more gestational sacs or 
definitive clinical signs of pregnancy; it includes ectopic pregnancy. 
We will count multiple gestational sacs as one clinical pregnancy. 
 
4. Adverse event: miscarriage; mean adhesion scores and severity of 
adhesions at second look hysteroscopy. A miscarriage is the 
spontaneous loss of a clinical pregnancy that occurs before 20 
completed weeks of gestational age (18 weeks post fertilization) or, if 
gestational age is unknown, the loss of an embryo/fetus of less than 
400 grams. 
 
We will avoid excluding studies on the basis of their reported outcome 
measures. Eligible studies that could have measured the outcomes of 
interest will be reviewed; we will report any lack of data for the key 
outcomes in the final review. 
We aim to follow the ICMART terminology (International Committee for 
Monitoring Assisted Reproductive Technologies) for the key reproductive 
outcomes (live birth, pregnancy and miscarriage) as much as possible 
(Zegers-Hochschild 2009); we will contact the primary study authors for 
clarification in case of unclear definitions. We will report any 
discrepancies in the final review. 
There are at the present seven reported classification systems for scoring 
the extent or severity of intrauterine adhesions. None of these systems has 
been validated or universally accepted (Deans 2010). We will therefore 
avoid pooling data from studies using different scoring systems; we will 
ask clarification from the primary study authors if necessary. 
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Search methods for identification of studies 
 
We will search for all published and unpublished RCTs of anti-adhesion 
therapies following operative hysteroscopy in subfertile women, without 
language restriction and in consultation with the Menstrual Disorders and 
Subfertility Group (MDSG) Trials Search Co-ordinator. 
 
Electronic searches 
We will search the following electronic databases, trial registers and web 
sites using the search strategies in the appropriate appendices: the 
Cochrane Central Register of Controlled Trials (CENTRAL), the 
Menstrual Disorders and Subfertility Group (MDSG) Specialized 
Register, MEDLINE using OVID and EMBASE using EMBASE.com 
from inception till the present. 
The search strategy will combine both index and free-text terms. 
• Cochrane Database of Systematic Reviews (CDSR). 
• Database of Abstracts of Reviews of Effects (DARE) and the 
Health Technology Assessment Database (HTA Database) 
through the Centre for Reviews and Dissemination. 
• National Guideline Clearinghouse. 
• BIOSIS previews through ISI Web of Knowledge. 
• Trial registers for ongoing and registered trials: 'Current 
Controlled Trials' and the World Health Organization 
International Clinical Trials Registry. 
• Citation indexes: Science Citation Index through Web of Science. 
• Conference abstracts and proceedings on the ISI Web of 
Knowledge. 
• LILACS database, which is a source of trials from the Spanish 
and Portuguese speaking world. 
• European grey literature through Open Grey database. 
• General search engines: Turning Research into Practice (TRIP) 
database, Google Scholar and Scirus. 
 
Searching other resources 
Two review authors (JB and JK) will handsearch reference lists of articles 
retrieved by the search and contact experts in the field to obtain additional 
data. We will contact the first or corresponding authors of included studies 
to ascertain if they are aware of any ongoing or unpublished trials. We 
will also handsearch relevant journals and conference abstracts that are 
not covered in the MDSG register, in liaison with the Trials Search Co-
ordinator. The search process will be reported in a PRISMA (Preferred 
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Reporting Items for Systematic Reviews and Meta-Analyses) flow 
diagram in the review. 
 
Data collection and analysis 
 
Selection of studies 
After an initial screen of titles and abstracts retrieved by the search, 
conducted by JB, the full texts of all potentially eligible studies will be 
retrieved. Two review authors (FB and TD) will independently examine 
these full-text articles for compliance with the inclusion criteria and select 
studies eligible for inclusion in the review. We will correspond with study 
investigators as required, to clarify study eligibility. Disagreements as to 
study eligibility will be resolved by discussion or by a third review author 
(BWM). We will classify the study as ’awaiting classification’ if 
disagreements between review authors cannot be resolved and will report 
the disagreement in the final review. 
 
Data extraction and management 
Two review authors (JB and SW) will independently extract data from 
eligible studies using a data extraction form designed and pilot-tested by 
the authors. Any disagreements will be resolved by discussion or by a 
third review author (BWM). Data extracted will include study 
characteristics and outcome data. Where studies have multiple 
publications, the main trial report will be used as the reference and 
additional details derived from secondary papers. We will correspond with 
study investigators for further data on methods and/or results, as required. 
We will include studies irrespective of whether outcomes are reported in a 
“usable” way. In multi-arm studies, data from arms that do not meet 
eligibility criteria will be excluded. 
 
Assessment of risk of bias in included studies 
Two reviewers (JB and SW) will independently assess the included 
studies for risk of bias using the ‘Risk of bias’ tool. We will resolve 
disagreements by discussion or by arbitration from a third review author 
(BWM). We will describe all judgments fully and present the conclusions 
in the ‘Risk of bias’ table, which will be incorporated into the 
interpretation of review findings by means of sensitivity analyses. 
Selective reporting is a type of reporting bias that affects the internal 
validity of an individual study. It refers to the selective reporting of some 
outcomes (e.g. positive outcomes) and the failure to report others (e.g. 
adverse events). We will take care to search for within-trial selective 
reporting, such as trials failing to report obvious outcomes, or reporting 
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them in insufficient detail to allow inclusion. We will seek published 
protocols and compare the outcomes between the protocol and the final 
published study. Where identified studies fail to report the primary 
outcome of live birth, but do report interim outcomes such as pregnancy, 
we will undertake informal assessment as to whether the interim values 
(e.g. pregnancy rates) are similar to those reported in studies that also 
report live birth. If there are outcomes defined in the protocol or the study 
report with insufficient data to allow inclusion, the review will indicate 
this lack of data and suggest that further clinical trials need to be 
conducted to clarify these knowledge gaps. 
 
Measures of treatment effect 
For dichotomous data (e.g. live birth or clinical pregnancy rates) we will 
use the numbers of events in the two comparison groups of each study to 
calculate Mantel-Haenszel odds ratios (ORs). We will treat ordinal data 
(e.g. adhesion scores) as continuous data. For ordinal data (e.g. adhesion 
scores), if all studies report exactly the same outcomes we will calculate 
mean difference (MDs) between treatment groups. If similar outcomes are 
reported on different scoring scales we will not calculate the standardized 
mean difference (SMD) because the seven different adhesion score 
classifications have not been validated. We will reverse the direction of 
effect of individual studies, if required, to ensure consistency across trials. 
We will present 95% confidence intervals for all outcomes. We will make 
contact with the corresponding or first authors of all included trials that 
report data in a form that is not suitable for meta-analysis, for example 
time-to-pregnancy data (TTP). We will report the data of those reports 
that fail to present additional data that could be analyzed under ’other 
data’. We will not include TTP data in any meta-analysis. Where data to 
calculate ORs or MDs are not available, we will utilize the most detailed 
numerical data available that may facilitate similar analyses of included 
studies (e.g. test statistics, P-values). We will compare the magnitude and 
direction of effect reported by studies with how they are presented in the 
review, taking account of legitimate differences. 
 
Unit of analysis issues 
The primary analysis will be per woman randomized; per pregnancy data 
will be included for some outcomes (e.g. miscarriage). If studies report 
only “per cycle” data, we will contact the primary study authors and 
request “per woman” data. If these are not available, the "per cycle" data 
will be briefly summarized in an additional table and will not be meta-
analyzed. Multiple live births (e.g. twins or triplets) will be counted as one 
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live birth event. Only first-phase data from crossover trials will be 
included. 
 
Dealing with missing data 
We will analyze the data on an intention-to-treat basis as much as 
possible; if needed, attempts will be made to obtain missing data from the 
original researchers. Where these are unobtainable, imputation of 
individual values will be undertaken for the beneficial primary outcome 
(live birth) only: we will assume that live births would not have occurred 
in women without a reported outcome. For all other outcomes, we will 
only analyze the available data. Any imputation undertaken for missing 
data on the primary outcomes will be subjected to sensitivity analysis. If 
studies report sufficient detail to calculate mean differences but no 
information on associated standard deviation (SD), the outcome will be 
assumed to have standard deviation equal to the highest SD from other 
studies within the same analysis. 
 
Assessment of heterogeneity 
We will consider whether the clinical and methodological characteristics 
of the included studies are sufficiently similar for meta-analysis to provide 
a clinically meaningful summary. We will carry out a formal assessment 
of statistical heterogeneity by using the I² statistic combined with the Q-
statistic. Cochran’s Q test, a kind of Chi² statistic, is the classical measure 
to test significant heterogeneity. Cochran’s Q test is calculated as the 
weighted sum of squared differences between individual study effects and 
the pooled effect across studies. The Q-statistic follows Chi² distribution 
with k-1 degree of freedom where k is the number of studies. Q > k-1 
suggests statistical heterogeneity. A low P value of Cochran’s Q test 
means significant heterogeneous results among different studies; usually, 
the P value at 0.10 is used as the cut-off. The Q-statistic has low power as 
a comprehensive test of heterogeneity especially when the number of 
studies is small. The Q-statistic informs us about the presence or absence 
of heterogeneity; it does not report on the extent of such heterogeneity. 
The I² statistic describes the percentage of variation across studies due to 
significant heterogeneity rather than random chance. It measures the 
extent of heterogeneity. An I² measurement greater than 50% will be 
taken to indicate substantial heterogeneity (Higgins 2003). We will 
explore possible explanations if substantial heterogeneity is detected. 
 
Assessment of reporting biases 
Reporting biases arise when the dissemination of research findings is 
influenced by the nature and direction of results. Some types of reporting 
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bias (e.g. publication bias, multiple publication bias, language bias etc) 
reduce the likelihood that all studies eligible for a review will be retrieved. 
The review may be biased if not all eligible studies are retrieved. In view 
of the difficulty of detecting and correcting for publication bias and other 
reporting biases, we will aim to minimize their potential impact by 
ensuring a comprehensive search for eligible studies and by being alert for 
duplication of data. If there are ten or more studies in an analysis, we will 
use a funnel plot to explore the possibility of small study effects (a 
tendency for estimates of the intervention effect to be more beneficial in 
smaller studies). 
 
Data synthesis 
One review author (JB) will enter the data and carry out the statistical 
analysis of the data in Review Manager 5. If the studies are sufficiently 
similar and substantial statistical heterogeneity can be confidently ruled 
out, we will combine the data from the primary studies in a meta-analysis 
with Review Manager 5 software using the summary Mantel-Haenszel 
(M-H) odds ratios (ORs) and a random-effects model (REM) for the 
following comparisons: 
• Anti-adhesion therapy versus placebo or no active anti-adhesion 
therapy following operative hysteroscopy. 
• Anti-adhesion therapy A versus anti-adhesion therapy B 
following operative hysteroscopy. 
The outcomes 'live birth' and 'clinical pregnancy' are considered positive 
outcomes of effectiveness and by consequence, higher numbers will be 
considered as a benefit. The outcomes 'incidence of adhesion formation', 
'miscarriage', 'mean adhesion scores' and 'severity of adhesions' at second-
look hysteroscopy are negative effects and higher numbers will be 
considered harmful. An increase in the odds of a particular outcome, 
which may be beneficial (e.g. live birth) or detrimental (e.g. de novo 
adhesions), will be displayed graphically in the meta-analyses to the right 
of the centre-line and a decrease in the odds of an outcome to the left of 
the centre-line. 
We will aim to define analyses that are comprehensive and mutually 
exclusive, so that all eligible study results can be slotted into only one 
stratum of the two predefined categories of randomized comparisons, and 
so that trials within the same stratum can be pooled. Stratification is not a 
requirement, but allows consideration of effects within each stratum as 
well as, or instead of, an overall estimate for the comparison. The use of 
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the REM instead of a fixed-effect analysis model (FEM) is justified by the 
fact that the results of a similar surgical treatment may be different across 
studies; despite rigorous standardization, there might be inevitably 
differences in surgical skill among the different surgeons involved in the 
trials. If no RCTs are retrieved for some comparisons, the review will 
indicate their absence identifying knowledge gaps which need further 
research. We will undertake a narrative overview if meta-analysis is not 
appropriate. 
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Subgroup analysis and investigation of heterogeneity 
Where enough data are available, we will conduct subgroup analyses to 
determine the separate evidence within the following subgroups: 
• Studies that report both ‘live birth’ and ‘clinical pregnancy’ in 
order to assess any overestimation of the treatment effect and 
reporting bias. 
• According to the type, extent or severity of the uterine 
abnormality treated. 
We will report the interpretation of any subgroup analysis restrictively 
even if enough data were available; subgroup analysis is by its nature an 
observational study which can be helpful in generating or exploring 
hypotheses. Moreover the interpretation of the statistical analysis for 
subgroups is not without problems. 
 
Sensitivity analysis 
We will conduct sensitivity analyses for the primary outcomes to 
determine whether the conclusions are robust to arbitrary decisions made 
regarding the eligibility and analysis. These analyses will include 
consideration of whether the review conclusions would have differed if: 
• Eligibility were restricted to studies without high risk of bias 
versus all studies  
• A fixed-effect rather than a random-effects model had been 
adopted. 
• Alternative imputation strategies had been implemented. 
• The summary effect measure was relative risk rather than odds 
ratio.  
 
Grading the evidence 
We will generate a “Summary of findings” table for the primary outcomes 
'live birth' and 'incidence of adhesion formation at second-look 
hysteroscopy' using GRADEPRO software. This table will evaluate the 
overall quality of the body of evidence for these two key outcomes, using 
GRADE criteria (study limitations (i.e. risk of bias), consistency of effect, 
imprecision, indirectness and publication bias). Judgments about evidence 
quality (high, moderate or low) will be justified, documented, and 
incorporated into reporting of results for each outcome.  
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ABSTRACT 
 
Background 
In 1996 the CONSORT statement (Consolidated Standards Of Reporting 
Trials) was published to develop a new scale for assessing the quality of 
published reports of randomized studies. We aimed to appraise if there has 
been any progress in evidence-based practice in reproductive surgery by 
studying the number and the quality of published reports of randomized 
controlled studies (RCTs) of surgical interventions in subfertile women. 
 
Methods 
We searched MEDLINE, EMBASE and The Cochrane Library for RCTs 
evaluating laparoscopic or hysteroscopic interventions in subfertile 
women reporting pregnancy and/or live birth as the main outcomes. Two 
review authors independently assessed eligible studies for inclusion and 
risk of bias, and extracted data. We compared the quality of the trials 
based on the composite outcome measure "all six items for risk of bias" in 
the Cochrane ‘Risk of bias’ tool between a post-CONSORT (≥1999) and a 
pre-CONSORT (≤1995) group. Studies between 1996 and 1998 were 
excluded from the analysis for the assessment of study quality. 
 
Results 
We retrieved 64 RCTs. Our findings demonstrated a steady increase from 
1970- 2010 in the number of RCTs per decade. We excluded 10 studies 
between 1996 and 1998 for the assessment of study quality. About 61% of 
the 54 RCTs had an adequate random sequence generation and nearly 
39% had adequate allocation concealment. The proportion of trials with 
adequate random sequence generation was higher in the post- (≥1999) 
(33/38) versus pre- (≤1995) (7/16) CONSORT group; the risk ratio (RR) 
was 2.0 (95% confidence interval (CI) 1.1 to 3.5, P=0.02, 54 studies). 
Similar trends were seen for the risk of bias items ‘adequate allocation 
concealment’ (RR 2.2, 95% CI 0.90 to 5.4, P=0.08), ‘incomplete outcome 
data’ (RR 1.4, 95% CI 0.92 to 2.3, P=0.11), ‘selective outcome reporting’ 
(RR 1.3, 95% CI 0.94 to 1.7, P=0.12) and ‘other potential sources of bias’ 
(RR 2.1, 95% CI 0.52 to 8.5, P=0.30) but nor for ‘blinding’ (RR 0.42, 
95% CI 0.12 to 1.5, P=0.18). There was a higher proportion of items 
judged to be at low risk of bias for the composite outcome ‘all six risk of 
bias items’ favoring the post-CONSORT group (RR 1.5, 95% CI 1.2 to 
1.9, P=0.001).  
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Conclusions 
There has been an increase in the number of published reports of RCTs on 
reproductive surgical interventions in subfertile women measuring live 
birth or pregnancy rate; more importantly, there has been an improvement 
in the overall methodological quality of these publications since the 
publication of the CONSORT statement in 1996. 
 
BACKGROUND 
 
In 1996 the CONSORT statement was published (Schulz et al, 2010). 
CONSORT stands for CON solidated Standards Of Reporting Trials; 
originally started in 1993 in Ottawa, Canada as a meeting of medical 
journal editors, clinical trialists, epidemiologists and methodologists this 
initiative aimed to develop a new scale for assessing the quality of 
published reports of randomized studies. Two revisions of the CONSORT 
statement have been published in 2001 and 2010. The statement refers to 
the use of a checklist consisting of 25 items selected because empirical 
evidence indicates that not reporting the information is associated with 
biased estimates of treatment effect, or because the information is 
essential to judge the reliability or relevance of the findings. A systematic 
review has demonstrated that the use of the CONSORT checklist is 
associated with an improvement in the reporting of RCTs (Plint et al, 
2006). We aimed to investigate if a similar improvement in the quality of 
the published reports of RCTs on reproductive surgery could be 
demonstrated as an indicator for progress in evidence-based practice in the 
field of reproductive surgery. 
 
MATERIALS AND METHODS 
 
Search methods for identification of studies 
 
We aimed to identify RCTs on reproductive surgery in subfertile women 
with pregnancy or live birth rate as the main outcomes. We searched The 
Cochrane Library (1970 to June 1st 2010) for relevant trials in the CDSR, 
DARE, CENTRAL or HTA databases. We also searched EMBASE (1974 
to June 1st 2010) and MEDLINE through Pub Med using a combination 
of text words and MeSH terms for “laparoscopy”, “hysteroscopy” 
,“infertility”, “pregnancy rate” and “live birth rate” (1966- June 1st 2010). 
We also searched the Current Controlled Trials (metaRegister); the last 
up-dated search was done on June 1st 2010. The search was done 
independently by two review authors. Language restrictions were not 
applied. 
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Data collection and analysis 
 
Selection of studies 
We included RCTs on reproductive surgical interventions in subfertile 
women reporting the main outcomes of pregnancy or live birth. We 
excluded non-randomized trials, studies not reporting pregnancy or live 
birth, studies in a source population with gynecological problems other 
than subfertility, trials on diagnostic accuracy, technical feasibility and 
patient compliance. Study selection was done by two authors 
independently based on reviewing the full-text manuscript. Any 
disagreement was solved by discussion or by a third review author. 
 
Data extraction and management 
The characteristics of the different study populations, the control and 
study intervention as well as other relevant study characteristics were 
extracted from the full-text articles by using standardized work sheets for 
quality assessment of RCTs from the website of the Dutch Cochrane 
Centre. We contacted the corresponding authors in case of unclear study 
methodology or to obtain missing data. Two review authors independently 
extracted relevant study data. To test the study hypothesis that quality of 
studies changed over time after the publication of the CONSORT 
statement, we made two comparison groups using the year of publication 
of the CONSORT statement (1996) as a time marker (Begg et al, 1996); 
we excluded the studies between 1996 and 1998 to allow a reasonable 
time period for the implementation of the CONSORT statement. We 
compared post-CONSORT (≥1999) versus pre-CONSORT (≤1995). 
 
Assessment of risk of bias in included studies 
We estimated the risk of bias by using the ‘Risk of bias’ tool provided by 
the Cochrane Collaboration based on all six items: random sequence 
generation, allocation concealment, blinding of participants, personnel and 
outcome assessors, completeness of outcome data, selective outcome 
reporting and other potential sources of bias. This was done independently 
by two review authors; any disagreement was solved by discussion or by a 
third review author. 
 
Measures of treatment effect and statistical analysis 
The methodological quality was assessed based on the composite outcome 
measure "all six items for risk of bias" in the Cochrane ‘Risk of bias’ tool. 
For the analysis we defined the reported use of allocation concealment as 
‘low risk’ of bias against the other concealment categories i.e. unclear, 
inadequate or concealment not used. The same principle was used for all 
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other risk of bias items. The number of items judged as "at low risk of 
bias" was considered as a positive outcome of effectiveness and higher 
numbers were considered as a benefit. Statistical analysis was done using 
Review Manager 5. The dichotomous data (number of items judged as 
‘low risk’ versus ‘other’) were extracted in 2x2 tables. The results of 
individual trials and of the meta-analysis were expressed as Mantel-
Haenszel (M-H) risk ratios (RR) with 95% confidence limits (95% CI) 
using a fixed-effect model.  
 
Subgroup analysis and investigation of heterogeneity 
We defined a sensible ‘a priori’ subgroup analysis based on each of the 
six items in the Cochrane ‘Risk of bias’ tool. We aimed to avoid over 
interpretation; subgroup analysis is by its nature an observational study 
within a study and the interpretation of the statistical significance of 
subgroup differences is not without problems. Statistical heterogeneity 
was assessed with the Chi² test and the I² test. 
 
Sensitivity analysis 
We planned to conduct sensitivity analyses for the composite outcome ‘all 
six risk of bias items’ to investigate whether the review conclusions would 
have differed if the item ‘blinding’ was excluded or not. Blinding of 
participants and personnel is very often problematical in the design of 
randomized studies in surgery. Other sensitivity analyses studied the 
effect of the choice of a fixed-effect rather than a random-effects model 
and the use of an odds ratio rather than the risk ratio as the effect measure.
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RESULTS 
 
Results of the search 
 
The findings are presented in detail in the two primary published reports 
(Bosteels et al, 2010; Bosteels et al, 2011). The process of literature 
search and selection is described in figure 1: we included 64 RCTs on 
reproductive surgical techniques and pregnancy outcome; 16 RCTs in the 
pre-CONSORT group, 38 RCTs in the post-CONSORT group and 10 
RCTs between 1996 and 1998. These latter 10 trials were taken into 
account for the quantitative but not the qualitative assessment of the 
research question. 
 
Figure 1 PRISMA flow diagram: systematic review of benefit after 
reproductive surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through Cochrane Library 
(n=170), MEDLINE (n=106) and EMBASE 
(n=334)  
(N=609) 
Additional records identified through Current  
Controlled Trials  
 
(N=37) 
Records screened after duplicates removed 
(n=592) 
Records excluded 
(n=495) 
Excluded: n=33  
Full-text articles assessed for eligibility 
(n=97) 
Studies included in quantitative synthesis  
(n=64) 
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An overview of the included trials and a summary of findings grouped 
according to the specific pathology or clinical setting are presented in 
table 1. 
 
Table 1 Overview of included trials. 
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Table 1 Overview of included trials (continued). 
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Table 1 Overview of included trials (continued). 
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Table 1 Overview of included trials (continued). 
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Table 1 Overview of included trials (continued). 
 
 
 
Progress in evidence-based practice in reproductive surgery 
 
 
179 
Effects of interventions 
 
An overview of the RRs of all included trials is presented in figure 2. The 
mean value of the effect measure was 1.47 ± SD 1.51. The RR of the 
included studies had a range from 0.33 to 12. In the majority of studies the 
treatment effect was moderate: the log (RR) varies from -0.3 to 0.3, 
corresponding with 0.5<RR < 2. 
 
Figure 2 Risk ratios across all included studies 
 
 
 
The number and the quality of RCTs post- versus pre-CONSORT  
 
Our findings demonstrate a steady increase from 1970- 2010 in the 
number of published reports of randomized studies on reproductive 
surgical interventions per decade (Figure 3). 
 
Figure 3 Evolution of the number of published reports of RCTs on the 
effectiveness of reproductive surgery. 
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There is a significant increase in the proportion of trials with adequate 
random sequence generation favoring the post-CONSORT group (RR 2.0; 
95% CI 1.1 to 3.5, P=0.02) (Figure 4). 
 
Figure 4 Forest plot of comparison: Post-CONSORT versus pre-
CONSORT. Outcome: Number of risk of bias items judged as ‘low risk’. 
M-H: Mantel-Haenszel, fixed-effect model, CI: confidence interval.  
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Similarly there is a consistent trend for a higher proportion of studies 
favoring the post-CONSORT group for the outcome of number of risk of 
bias items judged as ‘low risk’ for ‘adequate allocation concealment’ (RR 
2.2, 95% CI 0.90 to 5.4, P=0.08), ‘completeness of outcome data’ (RR 
1.4, 95% CI 0.92 to 2.3, P=0.11), ‘selective outcome reporting’ (RR 1.3, 
95% CI 0.94 to 1.7, P=0.12), ‘other potential sources of bias’ (RR 2.1, 
95% CI 0.52 to 8.5, P=0.30) but not for ‘blinding’ (RR 0.42, 95% CI 0.12 
to 1.5, P=0.18). The tests for subgroup differences demonstrated no 
statistically significant differences between the different subgroups 
according to the risk of bias item (Chi²=6.8, df=5 (P=0.24), I²=26%). 
Overall, there is an effect in favor of the post-CONSORT group for the 
composite measure ‘all six risk of bias items’ (RR 1.5, 95% CI 1.2 to 1.9, 
P=0.001, 324 items from 54 studies). A sensitivity analysis did not 
demonstrate statistically significant differences between both comparison 
groups when the item ‘blinding’ was excluded from the data synthesis 
(RR=1.6, 95% CI 1.3 to 2.1, P=0.0001). Two other sensitivity analyses 
demonstrated similarly that the data are robust concerning the choice of 
the effect measure: odds ratio (OR) versus risk ratio (P=0.0004) and 
random-effects (RE) model rather than a fixed-effect model (P=0.02). 
Live birth was reported as the primary outcome measure in 13 out of 54 
studies (24%) of the pre + post-CONSORT RCTs. In the post-CONSORT 
group 13 out of 38 studies (34%) either explicitly referred to the 
CONSORT statement or used a study flow diagram as proposed in the 
checklist. 
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DISCUSSION 
 
The results of the present systematic review show a steady increase in the 
number of published RCTs on reproductive surgical interventions 
measuring live birth or pregnancy as main outcome in subfertile women. 
Moreover we were able to demonstrate an improvement in the quality of 
the published reports of RCTs on reproductive surgical interventions in 
the post-CONSORT group. Our findings are consistent with those 
reported earlier by other review authors, both for non-gynecological (Plint 
et al, 2006) and gynecological RCTs (Selman et al, 2008); the latter 
authors reported a significant increase of the proportion of studies 
reporting adequate allocation concealment after CONSORT, as well as a 
trend towards improvement in precision of the estimation of the treatment 
effect over time (Selman et al, 2008). There were nevertheless differences 
in methodology. Selman and co-workers only retrieved studies from the 
Cochrane Database of Systematic Reviews. Moreover these authors 
focused only on one risk of bias item (allocation concealment) while we 
examined all six items of risk of bias assessment. 
A limitation of the present review is that we included only RCTs reporting 
live birth and/or pregnancy as main outcome; this means that some RCTs 
might not have been included, likely causing selection bias. Moreover we 
have only demonstrated a time-effect relationship rather than a cause-
effect relationship between the publication of CONSORT and the 
improved methodological quality. The uptake of the study flow diagrams 
in the published reports since 1996 can be considered as an indirect proof 
that the implementation of the CONSORT might have been a causal factor 
for this improvement. Our findings demonstrate that gynecology has 
evolved to becoming a specialty in which the interventions are 
increasingly exposed to the gold standard of RCTs (Johnson et al, 2003). 
Reproductive surgery seems not to have “missed the boat”. Not all 
methodological problems of RCTs on reproductive surgery have been 
solved at the present. The methodological quality of surgical trials could 
be improved further by adequate training of surgeons in clinical 
epidemiology and evidence-based medicine or employing epidemiologists 
in surgical units where clinical research is being carried out (Urschel et al, 
2001; Madhok et al, 2002). More research is needed on the willingness of 
reproductive surgeons to change practice for improving the outcomes that 
matter to subfertile women. 
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SUMMARY CONCLUSION 
 
Clinical research in the field of reproductive surgery should be guided by 
high-quality RCTs. The limited and mediocre quality evidence provided 
by 64 RCTs indicates a positive role for some surgical reproductive 
interventions. There has been a steady increase in the number of published 
reports of RCTs on reproductive surgery in the last decade. Overall the 
methodological quality of the RCTs published after the CONSORT 
statement in 1996 has improved, likely because of this methodological 
initiative and the uptake of its implementation by the leading journals in 
reproductive medicine. In conclusion, we agree with others: “Evidence-
based reproductive surgery is no passing fad” (Johnson et al, 2008). 
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SUMMARY 
 
In 1987, only one year before his death, ‘Archie’ Cochrane referred to a 
systematic review of RCTs of care during pregnancy and childbirth as “a 
real milestone in the history of randomized trials and in the evaluation of 
care” (Chalmers et al, 1989). Surely, to his judgment, from that moment 
there was no longer any reason to leave the notorious wooden spoon 
described in chapter 1 in the possession of Obstetrics. But is this true for 
reproductive surgery as well? We summarize the findings of our thesis on 
evidence-based practice in reproductive surgery by answering the three 
predefined research questions. We also discuss the implications for 
clinical practice and future research. We briefly reflect on the future of 
evidence-based practice in reproductive surgery. 
Chapter 2 discusses the position of laparoscopy in current fertility 
practice. Although Assisted Reproductive Technology (ART) is steadily 
replacing tubal surgery as the first-line treatment for tubal infertility a 
randomized comparison between both treatment options is lacking. We 
retrieved limited evidence on the effectiveness of laparoscopy for treating 
female subfertility in some settings. The treatments for which we found 
evidence are summarized in the next alinea. 
The Canadian ENDOCAN trial has demonstrated a benefit with the 
laparoscopic treatment of minimal and/or mild endometriosis for the 
outcome ‘ongoing pregnancy at 20 weeks or live birth’ in women with 
otherwise unexplained subfertility: odds ratio (OR) 2.0, 95% confidence 
interval (CI) was 1.2 to 3.3, P=0.01, 341 women. In the smaller Gruppo 
Italiano trial there was no evidence for such a benefit (OR 0.85, 95% CI 
0.32 to 2.3, P=0.75, 96 women). Laparoscopic ovarian drilling (LOD) in 
women with clomiphene-resistant polycystic ovaries is at least as effective 
as gonadotrophin treatment - the odds ratio (OR) was 1.0, 95% CI 0.63 to 
1.6, P=0.95, 4 studies, 304 women- but LOD carries a substantially lower 
risk for multiple pregnancy (OR 0.13, 95% CI 0.03 to 0.59, P=0.008, 4 
studies, 154 women). Doing a laparoscopy before a first or after several 
failed cycles of IUI does not affect the pregnancy rates (OR 0.81, 95% CI 
0.43 to 1.5, P=0.52, 1 study, 154 women) nor the incidence of clinically 
relevant pelvic pathology (OR 0.72, 95% CI 0.28 to 1.9, P=0.51, 1 study, 
89 women). The removal of hydrosalpinges visible on ultrasound may 
increase the delivery rate after in vitro fertilization (IVF) - the risk ratio 
(RR) was 2.4, 95% CI 1.1 to 5.3, P=0.038, 1 study, 75 women- especially 
when bilaterally detectable (RR 3.5, 95% CI 1.1 to 11, P=0.019, 1 study, 
39 women). In conclusion, there is no evidence-based fundament for the 
shift from tubal reconstructive surgery to ART. The limited evidence on 
the role of laparoscopy in the treatment of female subfertility and the 
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availability of reliable alternative methods for detecting tuboperitoneal 
subfertility are nevertheless two important reasons to question the practice 
of doing laparoscopy in all subfertile women as the final step in the 
fertility work-up.  
Chapter 3 aims to clarify the position of hysteroscopy in current fertility 
practice by a non-Cochrane systematic review of the literature. The Royal 
College of Obstetricians and Gynecologists (RCOG) and the European 
Society for Human Reproduction and Embryology (ESHRE) do not 
recommend hysteroscopy as a first-line procedure for screening all 
subfertile women. We aimed to summarize and appraise the evidence on 
the effectiveness of hysteroscopy in subfertile women for improving 
reproductive outcome. We retrieved five RCTs. The hysteroscopic 
removal of endometrial polyps with a mean diameter of 16mm detected 
by ultrasound may double the pregnancy rates in women undergoing 
intrauterine insemination (IUI) compared to diagnostic hysteroscopy only 
(RR 2.2, 95% CI 1.6 to 3.1, P<0.00001, 1 study, 215 women). There is no 
proof for a benefit with hysteroscopic myomectomy compared to timed 
intercourse in women with one submucous fibroid <4cm and otherwise 
unexplained subfertility, although the point estimate is almost statistically 
significant (RR 1.9, 95% CI 0.97 to 3.7, P=0.06, 1 study, 94 women). 
Hysteroscopic metroplasty for a septate uterus may be less effective in a 
target population of women with primary subfertility versus those with 
recurrent miscarriage (RR 0.7, 95% CI 0.5 to 0.9, P=0.01, 1 study, 160 
women). Hysteroscopy before a next IVF attempt may nearly double the 
pregnancy rate in women with primary subfertility and at least two failed 
IVF attempts compared to starting IVF without prior hysteroscopy (RR 
1.6, 95% CI 1.3 to 1.9, P<0.00001, 2 studies, 941 women) irrespective of 
whether pathology was present or not (RR 0.91, 95% CI 0.71 to 1.2, 
P=0.48, 2 studies, 465 women). In conclusion, there is limited evidence 
for doing hysteroscopy in some but not all subfertile women. 
Chapter 4 illustrates the added value of doing a Cochrane systematic 
review for identifying knowledge gaps to direct future primary research. 
We aimed to assess the effects of the hysteroscopic removal of 
endometrial polyps, submucous fibroids, uterine septum or intrauterine 
adhesions suspected on ultrasound, hysterosalpingography, diagnostic 
hysteroscopy or any combination of these methods in women with 
otherwise unexplained subfertility or prior to IUI, IVF or ICSI. We found 
no RCTs on the hysteroscopic removal of endometrial polyps, intrauterine 
adhesions or uterine septa in women with otherwise unexplained 
subfertility. The only included study in women with otherwise 
unexplained subfertility and fibroids moreover failed to report data on the 
predefined primary outcomes for this Cochrane review (live birth for 
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positive and procedure-related complications for negative outcome). We 
similarly found no RCTs on the effectiveness of operative hysteroscopy in 
subfertile women with suspected submucous fibroids, intrauterine 
adhesions or uterine septa prior to IUI, IVF or ICSI. The only included 
study for this second category of randomized comparisons (endometrial 
polyps before IUI) also did not present data for the primary outcomes. 
Moreover we found no data on the effects of the number, size/extent or 
the localization of the uterine cavity abnormalities on the main outcomes 
for both categories of randomized comparisons or on a possible time-
effect relationship between the timing of the hysteroscopic intervention 
and subsequent IUI or ART. In conclusion, we have identified many 
knowledge gaps in our current understanding of the effects of 
hysteroscopic interventions on reproductive outcome in subfertile women. 
This is an opportunity for future research. 
Chapter 5 examines the role of anti-adhesion barrier gels following 
operative hysteroscopy for treating female subfertility. We aimed to assess 
the effects of any anti-adhesion barrier gel used after hysteroscopy for 
treating subfertility by a systematic review of the literature. We retrieved 
five studies. We assessed the risk of bias and performed a meta-analysis 
for some randomized comparisons. There is no evidence for a benefit with 
the use of any anti-adhesion barrier gel following operative hysteroscopy 
for the main outcomes live birth or clinical pregnancy (RR 3.0, 95% CI 
0.35 to 26, P=0.32, 1 study, 30 women). The use of any gel decreases the 
incidence of adhesions at second-look hysteroscopy (RR 0.65, 95% CI 
0.45 to 0.93, P=0.02, 5 studies, 372 women). The number needed to treat 
to benefit (NNTB) is 9 (95% CI 5 to 33). The use of auto-cross-linked 
hyaluronic acid (ACP) gel in women undergoing operative hysteroscopy 
for submucous fibroids, endometrial polyps or uterine septa is associated 
with a decrease in the mean adhesion scores at second-look hysteroscopy: 
the mean difference (MD) was -1.4, 95% CI -1.8 to -1.0, P<0.00001, 1 
study, 24 women. The largest decrease is demonstrated in women treated 
by ACP gel after hysteroscopic adhesiolysis (MD -3.3, 95% CI -3.4 to -
3.2, P<0.00001, 1 study, 19 women). When adhesions occur following 
operative hysteroscopy, the use of any anti-adhesion barrier gel is 
associated with more ‘mild’ adhesions (RR 2.8, 95% CI 1.1 to 7.0, 
P=0.03, 4 studies, 79 women) and less ‘moderate or severe adhesions’ at 
second-look hysteroscopy (RR 0.25, 95% CI 0.10 to 0.67, P=0.006, 4 
studies, 79 women). The NNTB is 2 with a 95% CI 1 to 2 for the former 
and a 95% CI 1 to 4 for the latter outcome. The quality of the evidence 
retrieved was graded as very low. In conclusion, gynecologists should 
counsel women wishing to become pregnant that intrauterine adhesion 
formation is the major long-term complication of operative hysteroscopy 
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in women of reproductive age. The use of any anti-adhesion barrier gel 
might be considered after operative hysteroscopy because its use might 
decrease the incidence of adhesions and if these do occur, they tend to be 
more ‘mild’ and less ‘moderate or severe’. We retrieved only very low 
quality evidence from a limited number of RCTs in a general source 
population including- but not restricted to- subfertile women. Moreover 
subfertile women should be counseled that there is at the present no 
evidence for a benefit for the outcomes of pregnancy or live birth. 
Chapter 6 studies the effectiveness of different anti-adhesion strategies 
following operative hysteroscopy in subfertile women. Intrauterine 
adhesions are associated with a poor reproductive outcome due to a high 
incidence of subfertility or recurrent miscarriage and due to major 
obstetric complications as the endpoint of a successful hysteroscopic 
treatment of severe intrauterine adhesions. Therefore several preventive 
strategies were proposed in the literature, based on observational 
evidence. We aimed to summarize and appraise the evidence on the 
effectiveness of inserting an intrauterine device or a Foley catheter 
balloon, prescribing postoperative hormone therapy, using anti-adhesion 
barrier gels or human amnion membrane grafting by conducting a 
Cochrane systematic review. 
Chapter 7 aims to examine if there has been any progress in evidence-
based practice in reproductive surgery. In 1996 the CONSORT statement 
was launched as a methodological initiative to improve the standards of 
reporting of clinical trials. We aimed to study the effect of the CONSORT 
statement on the number and the quality of published reports of RCTs on 
reproductive surgery in subfertile women. After a systematic review of the 
literature we retrieved 64 RCTs on reproductive surgical interventions in 
subfertile women measuring pregnancy or live birth rates: we classified 16 
studies in the pre-CONSORT group (≤1995) and 38 studies in the post-
CONSORT group (≥1999). We excluded 10 studies published between 
1996 and 1998 for the assessment of the research question on the quality 
of RCTs to allow a reasonable time period for the implementation of the 
CONSORT statement by the scientific community. The number of RCTs 
reporting pregnancy or live birth as main outcome (N=32) in the last 
decade (2000-2010) equals the number of all RCTs published in the 
previous three decades (1970 to 1999). We compared the methodological 
quality post- versus pre-CONSORT by counting the number of items 
judged as low risk of bias by using the Cochrane ‘Risk of bias’ tool. We 
found a consistent trend for an improvement favoring the post-CONSORT 
studies for the items of random sequence generation (RR 2.0, 95% CI 1.1 
to 3.5, P=0.02, 54 studies), allocation concealment (RR 2.2, 95% CI 0.90 
to 5.4, P=0.08, 54 studies), completeness of outcome data (RR 1.4, 95% 
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CI 0.92 to 2.3, P=0.11, 54 studies), selective outcome reporting (RR 1.3, 
95% CI 0.94 to 1.7, P=0.12, 54 studies) and other potential sources of bias 
(RR 2.1, 95% CI 0.52 to 8.5, P=0.30, 54 studies) but not for blinding (RR 
0.42, 95% CI 0.12 to 1.5, P=0.18, 54 studies). We found a significant 
improvement in the overall methodological quality defined by the 
composite outcome ‘all six risk of bias items’ favoring the post-
CONSORT studies (RR 1.5, 95% CI 1.2 to 1.9, P=0.001, 54 studies). In 
conclusion, recent years have witnessed more and better reports on 
reproductive surgical interventions in subfertile women. 
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DISCUSSION 
 
Our search did not retrieve any randomized comparison of tubal surgery 
versus expectant management or IVF measuring live birth or pregnancy in 
women with tubal infertility. This is consistent with the findings of two 
Cochrane reviews (Pandian et al, 2008; Johnson et al, 2010). This answers 
the first research question of the present thesis. 
Our appraisal of the evidence on the effectiveness of hysteroscopy in 
treating subfertile women has identified limited evidence for a benefit in 
women with endometrial polyps before IUI and in women with primary 
subfertility and at least two failed IVF attempts; moreover many 
knowledge gaps have been identified. The use of any barrier gel following 
operative hysteroscopy in subfertile women might be considered: its use 
may decrease the formation of adhesions as well as their extent and 
severity but data on the key reproductive outcomes are lacking. This 
answers the second research question of our thesis. 
Our research has demonstrated an increase in the number and an 
improvement in the methodological quality of published RCTs on 
reproductive surgery over recent years. This answers part of the third 
research question of the present thesis. Our findings are consistent with 
those of a recently published opinion paper on ‘Twenty years of Cochrane 
reviews in Menstrual Disorders and Subfertility’ (Farquhar et al, 2013). 
The number of RCTs on the treatment of subfertility has increased from 
fewer than 2000 in 1997 to over 5000 in 2013. There is a move towards 
identifying and accumulating the highest quality evidence; inevitably, this 
should lead to a greater use of this evidence in the field and bridge the gap 
between evidence and daily clinical practice.  
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1. IMPLICATIONS FOR CLINICAL PRACTICE 
 
• Laparoscopic surgery for treating female subfertility 
 
At the present we can no longer recommend doing a laparoscopy as the 
final step in the fertility work-up of all subfertile women: to attain a 100% 
level of certainty about the status of the tubes would increase the pool of 
women with minimal pelvic pathology of questionable prognostic 
significance leading to an inflation of health care costs (Collins and Van 
Steirteghem, 2004). HSG and laparoscopy are comparable for predicting 
natural conception in a general subfertile population (Verhoeve et al, 
2011). Subfertile women with a history of PID, complicated appendicitis, 
pelvic surgery, ectopic pregnancy and endometriosis have a higher risk of 
having tuboperitoneal pathology (Luttjeboer et al, 2009) and should be 
offered a diagnostic laparoscopy early in the fertility work-up (NICE 
2004; ASRM 2006). CAT by using the microimmunofluorescence test is 
the test of first choice in the initial screening for tubal pathology (Broeze 
et al, 2011). The combination of medical history taking and CAT testing 
has a higher predictive value in the selection of subfertile women for 
diagnostic laparoscopy than either of both alone and as a triage has the 
potential to decrease the number of ‘unnecessary laparoscopies’ by 82% 
compared to doing a laparoscopy in all cases (Coppus et al, 2007) . HSG 
is a useful test for screening tubal patency in all subfertile women (Broeze 
et al, 2011; the Practice Committee of the American Society for 
Reproductive Medicine, 2012). The combination of medical history 
taking, CAT and HSG has the best performance for the diagnosis of 
bilateral tubal pathology (Broeze et al, 2012). Routine diagnostic tubal 
patency tests in the fertility work-up are not cost-effective if considered 
only from the viewpoint of health policy management; when there is a 
need for information on the tubal status to make clinical decisions for the 
health of individual women, HSG followed by a tailored treatment or a 
diagnostic laparoscopy if HSG shows no tubal patency is more cost-
effective than diagnostic laparoscopy (Verhoeve et al, 2013). 
LOD followed by CC and gonadotrophins if anovulation persists is an 
attractive alternative for the second-line treatment of CC-resistant PCOS 
women mainly since it lowers the risk of multiple pregnancies for at least 
equal effectiveness compared to starting gonadotrophin treatment 
immediately. Moreover a long-term follow-up study demonstrated that 
LOD by electrocautery significantly reduced the need for ovulation 
induction or ART for a first live born baby and increases the chance for a 
second child (Nahuis et al, 2011). Health-related quality of life was not 
affected for both LOD or gonadotrophin treatment except in a subanalysis 
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of women without ongoing pregnancy that had more depressive symptoms 
in the gonadotrophin treatment arm compared to the electrocautery 
strategy group (van Wely et al, 2004). The total treatment costs up to an 
ongoing pregnancy are comparable for both treatment strategies (van 
Wely et al, 2004) but data from a long-term follow-up have demonstrated 
that the mean treatment costs per live birth within 8 to 12 years after 
initial treatment were significantly lower for the strategy starting with 
electrocautery compared to starting immediately with gonadotrophin 
treatment (Nahuis et al, 2012). Therefore starting with LOD first followed 
by clomiphene citrate and gonadotrophins when anovulation persists 
should be recommended as a rational second-line treatment in CC-
resistant PCOS patients. 
Tubal reconstructive surgery was the only available treatment option for 
tubal infertility in the pre-ART era. It offers women the potential to 
achieve more than one conception by a one-time minimally invasive 
intervention, avoiding ART and its associated risks. The disadvantages of 
reconstructive surgery include the risks associated with surgery/anesthesia 
and recurrence of hydrosalpinx. In case of bilateral irreparable 
hydrosalpinges there is good-quality evidence for recommending 
salpingectomy or tubal occlusion to improve the pregnancy rates after IVF 
(Johnson et al, 2010; Johnson et al, 2011). Young women without other 
reasons for subfertility might be counseled to undergo laparoscopic 
fimbrioplasty or neosalpingostomy for restoring tubal pathology with a 
good fertility prognosis e.g. phimosis and adhesions (Mol et al, 1999); 
bilateral salpingectomy in these cases would eradicate the potential for 
spontaneous pregnancy (Johnson et al, 2011). Microsurgical or 
laparoscopic reanastomosis by a skilled reproductive surgeon might be 
recommended after prior tubal sterilization (the Practice Committee of the 
American Society for Reproductive Medicine, 2012). 
 
• Hysteroscopic surgery for treating female subfertility 
 
Doing a hysteroscopy prior to a subsequent IVF/ICSI treatment cycle in 
women with primary subfertility and at least two failed IVF/ICSI attempts 
may increase the likelihood of a successful reproductive outcome. A 
systematic review and meta-analysis of five observational studies and one 
randomized trial has suggested that a hysteroscopy before a first IVF 
attempt might improve the clinical pregnancy and live birth rates; the data 
should be interpreted with caution because of substantial clinical diversity 
and statistical heterogeneity across the included studies (Pundir et al, 
2013). A hysteroscopy before a first IVF attempt might be cost-effective 
as shown by a cost-decision model (Kasius et al, 2013). More research is 
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needed before hysteroscopy prior to a first ART treatment cycle can be 
firmly recommended. 
 
• Anti-adhesion therapy after hysteroscopic surgery 
 
Gynecological surgeons should inform women still wishing to conceive 
that intrauterine adhesion formation is the major long-term complication 
of operative hysteroscopy in women of reproductive age. A recent survey 
in the Netherlands has indicated that adhesion awareness among Dutch 
gynecologists seems limited and that counseling is provided inadequately 
(Meuleman et al, 2013). Using barrier gels after operative hysteroscopy 
may decrease the incidence and the extent/severity of adhesions but the 
effects on reproductive outcome are not documented by high-quality 
evidence similarly to the use of barrier gels after laparoscopic 
myomectomy (Pellicano et al, 2005). This absence of evidence should not 
be neglected in the process of counseling. 
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2. IMPLICATIONS FOR FUTURE RESEARCH 
 
• Laparoscopic surgery for treating female subfertility 
 
Additional randomized studies are needed to assess the effectiveness of 
HyCoSy to predict a spontaneous pregnancy; one RCT has found no 
evidence for a benefit with HyCoSy for improving clinical pregnancy 
rates in subfertile women (Lindborg et al, 2009). 
Several prospective comparative studies suggest a high correlation of the 
findings of transvaginal hydrolaparoscopy (THL) with those of 
conventional laparoscopy (Campo et al, 1999; Casa et al, 2002; Darai et 
al, 2000; Nawroth et al, 2001). In a prospective cohort study similar FRRs 
for one-sided tubal pathology, two sided tubal pathology and 
adhesions/endometriosis were found; this suggests that the capacity of 
THL to predict spontaneous ongoing pregnancy may be comparable to 
that of laparoscopy (van Tetering et al, 2007). Definitive evidence can 
only be derived from additional pragmatic RCTs comparing THL and 
laparoscopy in the same group of participants with a short time interval 
between both procedures. The value of clinical prediction models for tubal 
disease and endometriosis (all stages versus stage III or IV) in the 
selection of women with unexplained subfertility for THL as an outpatient 
screening procedure under local anesthesia should be studied. 
Several authors have indicated that the ongoing parallel debate on the 
economics of ART treatment to define the most appropriate funding 
framework for providing safe, equitable and cost-effective treatment is 
complex (Mol et al, 2000; Connolly et al, 2010; Berg Brigham et al, 2012; 
Chambers et al, 2013). Cost-effectiveness studies comparing restorative 
tubal surgery with expectant management and reproductive tubal surgery 
as an alternative or preliminary to ART in women with tubal infertility 
should be placed on top of the research agenda, especially in countries 
with a high ART utilization, like Belgium; the comparison between both 
interventions for the outcomes of adverse events and health-related quality 
of life should be considered as well. A major barrier for conducting this 
research might be that the clinical community in reproductive medicine 
seems reluctant to question the perceived success of ART (Kamphuis et 
al, 2014). We admit that there are major limitations in the practicability of 
designing such a study e.g. the availability of sufficient surgical expertise 
in tubal restorative surgery (Pandian et al, 2008) and a sufficiently high 
burden of tubal disease (Sabatini and Davis, 2005). A priori defined 
subgroup analyses should be done to study the cost-effectiveness of tubal 
restorative surgery compared to ART in specific subgroups (e.g. older 
versus younger women, poor responders, previous tubal ligation…). 
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• Hysteroscopic surgery for treating female subfertility 
 
We agree with others that there is currently no evidence from adequately 
powered high-quality RCTs for a benefit with hysteroscopic myomectomy 
for improving pregnancy or live birth rates in women with otherwise 
unexplained subfertility or prior to ART (Metwally et al, 2012). The 
findings of a systematic review of observational studies (Pritts et al, 2009) 
have suggested a negative impact of submucous fibroids on reproductive 
outcome and a benefit with their hysteroscopic removal. As reproductive 
surgeons we therefore face a difficult choice: either take this non-evidence 
based (biased) research for granted or follow the scientific path to prove 
the effectiveness and safety of hysteroscopic myomectomy for treating 
women with otherwise unexplained subfertility or before IUI/ART. Not 
removing the fibroids might be considered unethical by some, to proceed 
with ovarian stimulation, IUI or ART might be thought inappropriate by 
others but there is the third and overlooked possibility of asking informed 
consent for inclusion in a pragmatic multicentre RCT. Data from 
randomized studies on a plausible dose-response or location relationship 
and the corresponding increase in benefit or decrease in adverse events are 
needed as part of investigating a causal relationship. More RCTs are 
needed to clarify the relationship between the timing of the hysteroscopic 
intervention and the effects on pregnancy or live birth rates. Additional 
high-quality RCTs are needed to investigate whether hysteroscopy in the 
preceding cycle may benefit all women undergoing IVF/ICSI or should be 
restricted to subgroups such as women with primary subfertility and 
unexplained recurrent implantation failure. A recently published 
systematic review and meta-analysis of four RCTs and three observational 
studies (Potdar et al, 2012) and a Cochrane review (Nastri et al, 2012) 
have reported a benefit with endometrial injury (including endometrial 
biopsy/scratch and diagnostic hysteroscopy) during the cycle preceding 
ART treatment on the live birth and clinical pregnancy rates. If the 
endometrial injury was made on the day of oocyte retrieval, a decrease in 
the ongoing and clinical pregnancy rates was demonstrated (Nastri et al, 
2012). The beneficial effect of repetitive endometrial sampling was first 
observed in a study aiming to investigate the pattern of endometrial 
expression of a gap junction protein. The hypothesis that local injury of 
the endometrium might increase the receptivity for implantation was 
proven by a randomized study (Barash et al, 2003). A randomized 
comparison between hysteroscopy in the cycle preceding ART versus on 
the day of oocyte retrieval could investigate a similar time-effect 
relationship of hysteroscopy before ART. Moreover additional research is 
needed to investigate whether the benefit of endometrial injury by 
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scratch/biopsy or hysteroscopy in the cycle preceding ART is different 
according to the phase of the cycle. Since the duration of this beneficial 
effect is not known, more research is needed to investigate whether repeat 
interventions are required in cases of persistent treatment failure. This 
may increase costs as well as patients’ stress and discomfort; the issues of 
cost-effectiveness and health-related quality of life should therefore be 
taken into account. For the outcome of clinical pregnancy the benefit with 
endometrial scratch/biopsy was greater compared to hysteroscopy (Potdar 
et al, 2012); this result of the meta-analysis should be interpreted with 
great caution because all cases of operative hysteroscopy were excluded 
from the statistical pooling on the a priori assumption that operative 
hysteroscopy for unsuspected uterine anomalies is likely to improve ART 
success rates (Potdar et al, 2012); therefore additional RCTs are needed to 
measure the cost-effectiveness of endometrial biopsy/scratch versus 
diagnostic and/or operative hysteroscopy. Finally more basic research is 
needed to study the underlying biological mechanisms that may increase 
the endometrial receptivity during the window of implantation in the 
human. In 1907 a report was published on the observation of a rapid 
growth of endometrial stromal cells provoked by injury caused by 
scratching of the progestational guinea-pig uterus (Loeb, 1907). An 
increased influx of macrophages and dendritic cells playing a key role in 
decidualization of human endometrial stromal cells (HESCs) and 
implantation (Gnainsky et al, 2010), an increased release of pro-
inflammatory cytokines and growth factors, especially leukemia-
inhibitory factor (LIF), interleukin-1β (IL) and heparin-binding epidermal 
growth factor-like growth factor (HB-EGF) (Paria et al, 2002), modulated 
gene expression in the endometrium with up regulation of pro-
implantation proteins (Kalma et al, 2009) and synchronization of 
endometrial and embryo development (Zhou et al, 2008) might be 
plausible explanations. The basic research on the hypothetical 
mechanisms for the increased endometrial receptivity should assist 
clinicians to unravel what extent of endometrial injury is required to 
improve reproductive outcomes. 
 
• Anti-adhesion therapy after hysteroscopic surgery 
 
Our research on the effectiveness of barrier gels for preventing 
intrauterine adhesions is in agreement with the findings of a Cochrane 
systematic review (Metwally et al, 2006) but the effects of using 
hyaluronic acid barrier gels following operative hysteroscopy in subfertile 
women on the key reproductive outcomes are unknown and should be 
studied.
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RANDOM REFLECTIONS (*) ON THE FUTURE OF EVIDENCE-
BASED PRACTICE IN REPRODUCTIVE SURGERY 
 
There is little doubt on the validity of using a rigorously scientific 
approach (i.e. a RCT) to measure the efficacy of an intervention under 
ideal experimental conditions; the RCT offers the potential of the least 
biased measure of the true treatment effect. A well-designed RCT has 
therefore a high internal validity. This means that the estimates of the 
treatment effect for the conditions, intervention and the population 
described in the experiment are highly reliable. But is this equally true for 
all subfertile women? Or at least for those under the care of the 
reproductive surgeon who consults the findings of an “experimental” RCT 
to propose a treatment based on the best available evidence but in 
circumstances wholly different from the “experimental” condition 
described in the RCT? The applicability of the study findings to a general 
or target population constitutes the external validity of a trial. Recently 
there has been an emerging interest in ‘real life’ studies. In one review 
(Saturni et al, 2014) the trade-off between internal and external validity of 
a trial was erroneously simplified to the distinction between 
‘experimental’ RCTs measuring efficacy versus ‘real life’ studies 
measuring effectiveness; this disregards the fact that explanatory 
(efficacy) and management trials (effectiveness) are a continuum rather 
than a dichotomy (Haynes et al, 2006). In psychiatry criticism on the 
rigorous approach of the ‘experimental’ RCT has led to the introduction 
of ‘practice based evidence’ aiming to improve the prediction of outcomes 
at the individual level (Margison et al, 2000). Practice based evidence is 
defined as the ability to use our clinical skills and past experience to 
rapidly identify each patient’s unique health state and diagnosis, their 
individual risks and benefits of potential interventions, and their personal 
values and expectations. The ‘conscientious, explicit, and judicious use of 
the current best evidence in making decisions about the care of individual 
patients’ stands for the integration of individual expertise of the clinician 
with the best available evidence from systematic research taking into 
account the patient’s unique values and preferences. Practice based 
evidence is therefore a part of evidence base practice. 
The scientific approach of EBM might be less appealing for the practicing 
clinician who may be reluctant to follow the challenging path of finding 
valid proof for a given intervention rather than to continue offering non-
evidence based therapy (Kamphuis et al, 2014). We agree with others that 
the strength of a well-conducted RCT consists of its high internal validity; 
this enables the clinician to distinguish between effective, undetermined, 
ineffective or even possibly harmful interventions (Johnson et al, 2003; 
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Johnson et al, 2008; Farquhar et al, 2013). We agree that there are many 
barriers for designing RCTs in surgery. Many of these have been 
identified by others (McCulloch et al, 2002; McLeod, 1999) e.g. the 
problems of the surgical learning curve and differences in surgical 
expertise (Devereaux et al, 2005), the difficulty to standardize surgical 
interventions (Kapiteijn et al, 1999), the problem of blinding in surgical 
trials (Moseley et al, 2002), the presence of co-interventions (Haynes et al, 
2006), problems of recruitment (Haynes et al, 2006) and issues of 
statistical power calculation (Dimick et al, 2001). Recently there has been 
a growing recognition of the problem of implementing EBM: the 
biomedical knowledge grows exponentially but the integration of research 
into practice is slow (Oude Rengerik et al, 2011). Clinical practice 
guidelines based on the best available evidence have the potential to 
decrease undesirable variation in care between settings and may facilitate 
the implementation of evidence-based practice. Attempts have been made 
to study the effectiveness of multi-faceted strategies to promote change 
and clinical daily practice implementation by using a RCT as study design 
(Mourad et al, 2011). It is clear that evidence-based practice is necessary 
but not sufficient to fulfill the needs of the caretakers and the women 
under their care. Recent years have witnessed the appearance of patient-
centeredness in fertility care (Dancet et al, 2010). The framework for 
patient-centered fertility treatment places the patient/woman in the central 
position while taking into account effectiveness, safety, costs and burden 
of fertility treatment (Dancet et al, 2014). It is clear from the definitions of 
patient-centered care and evidence-based medicine that both are part of a 
continuum rather than being competitive or mutually exclusive. 
Clinicians might be tempted to consider the evidence provided by 
observational studies as an ethical basis to discard the need for additional 
high-quality research, as in the cases of submucous fibroids in women 
with otherwise unexplained subfertilitity or a uterine septum in women 
suffering from recurrent miscarriage (Kowalik et al, 2010). This 
“certainty” based on the findings of studies with an inherent risk of bias 
should nevertheless be put aside in deference to the reasoned uncertainty 
existing within the larger community of experts (Haynes et al, 2006). The 
true uncertainty on the part of the expert professional community about 
the benefit to harms balance of two or more treatments for a well- defined 
study population has been termed “clinical equipoise” (Freedman, 1987). 
The balance between the clinical equipoise and the ‘certainty’ based on 
studies of lesser methodological quality should be the standard to judge 
whether or not additional RCTs should be conducted to study the 
effectiveness of an intervention. To our opinion, the possibility of 
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participation in a RCT is therefore not only a third and often overlooked 
alternative but a real ‘treatment’ option if the balance is undetermined. 
The final question is whether there is any proof that the use of EBM 
indeed improves practice. Has there been any proof that evidence-based 
care does improve outcomes that matter for patients (Dobbie et al, 2000)? 
To solve this crucial question scientifically by randomly comparing 
evidence-based versus non-evidence-based practice would truly be a 
daunting challenge. An alternative but to our opinion valid answer comes 
from data derived from outcomes research studies. Outcomes research-the 
study of the end results of health services that takes patients’ experiences, 
preferences, and values into account-is intended to provide scientific 
evidence relating to decisions made by all who participate in health care 
(Clancy and Eisenberg, 1998). Many data from outcomes research studies 
have proven that patients who received evidence-based treatment often 
had better outcomes than those who did not in several domains of 
medicine (Krumholz et al, 1996; Krumholz et al, 1998) including 
reproductive medicine (Twisk et al, 2006; Pandian et al, 2013; 
Mastenbroek et al, 2011) and reproductive surgery (Johnson et al, 2008; 
Johnson et al, 2010). We agree with others that “demanding rigorous 
evidence in evaluating the effectiveness of medical interventions is a good 
thing” (Imrie and Ramey, 2008). This applies equally to reproductive 
surgery: true progress in the field of reproductive surgery is based upon 
surgical skills, innovation in techniques and instruments, basic research 
and the exposure of the clinical practice research to the validity of the 
RCT. If the balance of effectiveness is undetermined reproductive 
surgeons should follow the guiding principle of clinical equipoise rather 
than hide behind false certainty or pseudo-ethical objections as an excuse 
for not changing clinical practice or being reluctant to do additional 
clinical research. There couldn’t have been a more fitting end for the story 
of the wooden spoon in the introduction of this thesis than the powerful 
“Old English” words of one of Cochrane’s greatest countrymen (**): 
“Now this is not the end. It is not even the beginning of the end. But it is, 
perhaps, the end of the beginning”. 
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SAMENVATTING 
 
'Archie' Cochrane verwees in 1987, één jaar voor zijn dood, naar een 
systematisch literatuuroverzicht van gerandomiseerde studies over de zorg 
tijdens zwangerschap en bevalling als "een mijlpaal in de geschiedenis 
van gerandomiseerde studies en de evaluatie van zorg" (Chalmers et al, 
1989). Van dan af was er voor hem geen reden meer om de beruchte 
houten lepel beschreven in hoofdstuk 1 nog verder in het bezit te laten 
van de discipline Obstetrie. Maar geldt dit ook voor reproductieve 
chirurgie? Wij vatten de bevindingen van dit proefschrift over ‘evidence-
based’ praktijkvoering in de reproductieve chirurgie samen door de drie 
onderzoeksvragen te beantwoorden. We bespreken tevens de implicaties 
voor de klinische praktijk en toekomstig onderzoek. We besluiten met 
enkele korte beschouwingen over de toekomst voor ‘evidence-based’ 
praktijkvoering in het domein van de reproductieve chirurgie. 
Hoofdstuk 2 bespreekt de positie van de laparoscopie in de hedendaagse 
vruchtbaarheidskliniek. Hoewel ART geleidelijk aan tubaire chirurgie als 
eerstelijns behandeling van tubaire onvruchtbaarheid lijkt te vervangen, is 
er geen gerandomiseerde vergelijking van de beide behandelingen. We 
hebben beperkt bewijs gevonden voor de doeltreffendheid van de 
laparoscopie voor de behandeling van vrouwelijke onvruchtbaarheid in 
bepaalde klinische indicaties. Deze werd samengevat in de onderstaande 
alinea. 
De Canadese ENDOCAN studie heeft een voordeel aangetoond voor de 
laparoscopische behandeling van minimale en/of milde endometriose voor 
de uitkomstmaat 'doorgaande zwangerschap na 20 weken of 
levendgeboorte' bij vrouwen met overigens onverklaarde 
onvruchtbaarheid: odds ratio (OR) 2.0, 95% betrouwbaarheidsinterval 
(BI) was 1.2 tot 3.3, P=0.01, 341 vrouwen. De kleinere Gruppo Italiano 
studie kon echter geen bewijs leveren voor dergelijk voordeel (OR 0.85, 
95% BI 0.32 tot 2.3, P=0.75, 96 vrouwen). Laparoscopische kapseldrilling 
bij vrouwen met CC-resistente polycysteuze ovaria is minstens even 
effectief als behandeling met gonadotrofines: de odds ratio (OR) was 1.0, 
95% BI 0.63 tot 1.6, P=0.95, 4 studies, 304 vrouwen. De kans op 
meerlingzwangerschap was beduidend lager (OR 0.13, 95% BI 0.03 tot 
0.59, P=0.008, 4 studies, 154 vrouwen). Het doen een laparoscopie voor 
een eerste of na verscheidene mislukte cycli van intra-uteriene inseminatie 
(IUI) lijkt de kans op zwangerschap (OR 0.81, 95% BI 0.43 tot 1.5, 
P=0.52, 1 studie, 154 vrouwen) noch het voorkomen van klinisch 
belangrijke pathologie van het kleinbekken niet beduidend te beïnvloeden 
(OR 0.72, 95% BI 0.28 tot 1.9, P=0.51, 1 studie, 89 vrouwen). De 
verwijdering van echoscopisch zichtbare hydrosalpinges vergroot de kans 
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op bevalling na IVF –het relatief risico (RR) was 2.4, 95% BI 1.1 tot 5.3, 
P=0.038, 1 studie, 75 vrouwen- vooral zo bilateraal echoscopisch 
zichtbaar (RR 3.5, 95% BI 1.1 tot 11, P=0.019, 1 studie, 39 vrouwen). 
Samengevat lijkt er geen ‘evidence-based’ basis te bestaan voor de 
verschuiving van reconstructieve tubachirurgie naar ART. De beperkte 
evidentie over de rol van de laparoscopie in de behandeling van 
vrouwelijke onvruchtbaarheid en de beschikbaarheid van betrouwbare 
alternatieve methoden voor het opsporen van tuboperitoneale 
onvruchtbaarheid zijn niettemin twee belangrijke redenen om de praktijk 
van het uitvoeren van een laparoscopie bij alle gevallen van 
onvruchtbaarheid als de laatste stap in de exploratie in vraag te stellen.  
Hoofdstuk 3 tracht de plaats van de hysteroscopie in de 
vruchtbaarheidskliniek te verduidelijken door een non-Cochrane 
systematisch literatuuroverzicht. De Royal College of Obstetricians and 
Gynecologists en the European Society for Human Reproduction and 
Embryology bevelen hysteroscopie niet als een eerstelijns onderzoek aan 
voor het systematisch screenen van alle subfertiele vrouwen. Onze 
doelstelling was om de effectiviteit van de hysteroscopie bij subfertiele 
vrouwen voor het verbeteren van de reproductieve uitkomst samen te 
vatten en kritisch te beoordelen. Wij vonden vijf gerandomiseerde studies. 
De hysteroscopische verwijdering van endometriumpoliepen met een 
gemiddelde doormeter van 16mm zichtbaar via echoscopie kan de kans op 
zwangerschap verdubbelen in vergelijking met een louter diagnostische 
hysteroscopie bij vrouwen die een behandeling met IUI moeten ondergaan 
(RR 2.2, 95% BI 1.6 tot 3.1, P < 0.00001, 1 studie, 215 vrouwen). Er is 
geen bewijs voor enig voordeel voor het hysteroscopisch verwijderen van 
myomen versus gerichte sexuele activiteit bij vrouwen met één 
submuceus fibroom < 4cm en onverklaarde onvruchtbaarheid hoewel de 
puntschatting net niet statistisch significant is (RR 1.9, 95% BI 0.97 tot 
3.7, P=0.06, 1 studie, 94 vrouwen). Hysteroscopische septumresectie voor 
een uterus septus lijkt minder doeltreffend bij vrouwen met primaire 
onvruchtbaarheid dan bij vrouwen met habitueel miskraam (RR 0.7, 95% 
BI 0.5 tot 0.9, P=0.01, 1 studie, 160 vrouwen). Hysteroscopie vóór een 
volgende IVF poging kan de kans op zwangerschap bij vrouwen met 
primaire subfertiliteit en minstens twee mislukte IVF pogingen bijna 
verdubbelen vergeleken met het opstarten van een volgende IVF poging 
zonder voorafgaande hysteroscopie (RR 1.6, 95% BI 1.3 tot 1.9, P< 
0.00001, 2 studies, 941 vrouwen) en dit ongeacht of er pathologie was of 
niet (RR 0.91, 95% BI 0.71 tot 1.2, P=0.48, 2 studies, 465 vrouwen). 
Samengevat blijkt er bewijs om over te gaan tot een exploratie via 
hysteroscopie bij sommige subfertiele vrouwen voor enkele beperkte 
indicaties. 
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Hoofdstuk 4 illustreert de toegevoegde waarde van een Cochrane review 
voor het opsporen van kennis lacunes omdat dit toelaat om toekomstig 
primair onderzoek te oriënteren. Wij trachten de effecten te bestuderen 
van de hysteroscopische verwijdering van endometriumpoliepen, 
submuceuze myomen, uteriene septa of intra-uteriene adhesies 
opgespoord via een echoscopie, hysterosalpingografie, diagnostische 
hysteroscopie of een combinatie van deze onderzoeken bij vrouwen met 
onverklaarde subfertiliteit of voorafgaand aan behandeling met IUI, IVF 
of ICSI. Wij vonden geen gerandomiseerde studies over de 
hysteroscopische verwijdering van endometriumpoliepen, intra-uteriene 
adhesies of uteriene septa bij vrouwen met onverklaarde 
onvruchtbaarheid. De enige studie bij vrouwen met onverklaarde 
onvruchtbaarheid en myomen rapporteert bovendien geen gegevens over 
de vooraf bepaalde primaire uitkomstmaten voor deze Cochrane review 
(levendgeboorte als positieve en procedure gerelateerde verwikkelingen 
als negatieve uitkomst). We vonden evenmin gerandomiseerde studies 
over de doeltreffendheid van operatieve hysteroscopie bij onvruchtbare 
vrouwen met gediagnosticeerde submuceuze myomen, intra-uteriene 
adhesies of uteriene septa voorafgaand aan behandeling met IUI, IVF of 
ICSI. De enige studie in deze tweede categorie van gerandomiseerde 
vergelijkingen (behandeling van endometriumpoliepen vóór IUI) 
rapporteerde evenmin gegevens voor de primaire uitkomstmaten. 
Bovendien vonden we geen gegevens over de effecten van het aantal, de 
grootte/uitgebreidheid of de lokalisatie van de uteriene afwijkingen op de 
hoofduitkomsten voor beide categorieën van gerandomiseerde 
vergelijkingen of over een verband tussen het tijdstip van de 
hysteroscopische interventie en effecten hiervan op de uitkomsten van een 
daaropvolgende behandeling met IUI of ART. Wij concluderen dat er nog 
vele lacunes zijn in onze huidige kennis over de effecten van 
hysteroscopische interventies op de reproductieve uitkomst van subfertiele 
vrouwen. Dit is een opportuniteit voor verder onderzoek. 
Hoofdstuk 5 onderzoekt de rol van het gebruik van anti-adhesieve gels na 
operatieve hysteroscopie voor de behandeling van vrouwelijke 
onvruchtbaarheid. De bedoeling van dit systematisch literatuuroverzicht 
was om de doeltreffendheid te onderzoeken van het gebruik van anti-
adhesieve barrière gels na een hysteroscopische interventie voor 
onvruchtbaarheid. Wij vonden vijf studies. Na beoordeling van het risico 
op systematische vertekening besloten wij om een meta-analyse te doen 
voor sommige gerandomiseerde vergelijkingen. Er lijkt geen bewijs te zijn 
voor enig voordeel voor het gebruik van gelijk welke anti-adhesieve gel 
na operatieve hysteroscopie voor de hoofduitkomsten levendgeboorte of 
klinische zwangerschap (RR 3.0, 95% BI 0.35 tot 26, P=0.32, 1 studie, 30 
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vrouwen). Het gebruik van een anti-adhesieve gel vermindert wel de 
incidentie van intra-uteriene adhesies bij een second-look hysteroscopie 
(RR 0.65, 95% BI 0.45 tot 0.93, P=0.02, 5 studies, 372 vrouwen). De 
NNTB is 9 (95% BI 5 tot 33). Het gebruik van ACP gel bij vrouwen die 
een operatieve hysteroscopie ondergaan voor submuceuze myomen, 
endometriumpoliepen of uteriene septa is geassocieerd met lagere 
gemiddelde adhesiescores bij second-look hysteroscopie (MD -1.4, 95% 
BI -1.8 tot -1.0, P<0.00001, 1 studie, 24 vrouwen); de grootste daling kan 
worden aangetoond bij vrouwen behandeld met ACP gel na 
hysteroscopische adhesiolyse (MD -3.3, 95% BI -3.4 tot -3.2, P<0.00001, 
1 studie, 19 vrouwen). Als er toch intra-uteriene adhesies ontstaan na 
operatieve hysteroscopie, dan blijkt het gebruik van een anti-adhesieve gel 
meer met ”milde” adhesies (RR 2.8, 95% BI 1.1 tot 7.0, P = 0.03, 4 
studies, 79 vrouwen) en minder met ”matige of ernstige adhesies” bij 
second-look hysteroscopie geassocieerd te zijn (RR 0.25, 95% BI 0.10 aan 
0.67, P = 0.006, 4 studies, 79 vrouwen). De NNTB is 2 met een 95% BI 1 
tot 2 voor de eerstgenoemde en een 95% BI 1 tot 4 voor de 
laatstgenoemde uitkomst. De kwaliteit van de gevonden evidentie is zeer 
laag. Samengevat zouden gynaecologen vrouwen met kinderwens moeten 
informeren dat intra-uteriene adhesies de belangrijkste langetermijn 
verwikkeling is van operatieve hysteroscopie bij vrouwen in de 
reproductieve periode. Men kan het gebruik van anti-adhesieve gel na 
operatieve hysteroscopie steeds overwegen omdat dit de incidentie van 
intra-uteriene adhesies vermindert en als er toch vergroeiingen ontstaan 
dan blijken deze meer ‘mild' en minder 'matig of ernstig'. Wij vonden 
enkel bewijs van zeer lage methodologische kwaliteit uit een beperkt 
aantal gerandomiseerde studies in een algemene populatie die niet beperkt 
was tot vrouwen met subfertiliteit. Bovendien moeten onvruchtbare 
vrouwen worden geïnformeerd dat er momenteel geen bewijs is voor een 
voordeel voor het gebruik van anti-adhesieve gels voor de uitkomstmaten 
zwangerschap of levendgeboorte. 
Hoofdstuk 6 bestudeert de doeltreffendheid van verschillende anti-
adhesie strategieën na operatieve hysteroscopie bij subfertiele vrouwen. 
Intra-uteriene adhesies hebben een slechte reproductieve uitkomst door 
een hoge incidentie van onvruchtbaarheid of habitueel miskraam en door 
ernstige obstetrische verwikkelingen als eindpunt van een succesvolle 
hysteroscopische behandeling van uitgebreide intra-uteriene adhesies. 
Daarom stelt de literatuur verschillende preventieve strategieën voor maar 
vaak zijn deze enkel gebaseerd op observationeel onderzoek. Onze 
Cochrane systematische literatuurstudie tracht om de doeltreffendheid van 
verschillende preventieve maatregelen zoals het achterlaten van een IUD 
of een Foley katheter ballon, het voorschrijven van postoperatieve 
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hormoontherapie, het aanbrengen van anti-adhesieve gels of enten van 
menselijk amnion membraan samen te vatten en kritisch te beoordelen. 
Hoofdstuk 7 heeft als doel na te gaan of er enige vooruitgang is geboekt 
in de ‘evidence-based’ praktijkvoering in reproductieve chirurgie. In 1996 
werd de CONSORT verklaring gepubliceerd als een methodologisch 
initiatief om de normen van de rapportering van klinische studies te 
verhogen. Het doel van ons onderzoek was om de effecten van 
CONSORT op het aantal en de kwaliteit van de wetenschappelijke 
publicaties van gerandomiseerde studies in het domein van de 
reproductieve chirurgie bij subfertiele vrouwen te onderzoeken. Via een 
systematische literatuurstudie vonden wij 64 gerandomiseerde studies 
over chirurgische ingrepen bij onvruchtbare vrouwen met zwangerschap 
of levendgeboorte als uitkomstmaat: 16 studies behoren tot de pre 
CONSORT groep (≤1995) en 38 studies tot de post CONSORT groep 
(≥1999). Voor de beoordeling van het kwalitatieve luik van de 
onderzoeksvraag werden 10 studies gepubliceerd tussen 1996 en 1998 
uitgesloten om een redelijke termijn toe te laten voor het implementeren 
van de CONSORT verklaring. Het aantal gerandomiseerde studies die 
zwangerschap of levendgeboorte als hoofd uitkomstmaat hebben 
gerapporteerd tijdens 2000-2010 (N=32) is hetzelfde als dat van alle 
gerandomiseerde studies die tijdens de periode 1970-1999, zijnde drie 
decennia werden gepubliceerd. Wij hebben de methodologische kwaliteit 
post versus pre CONSORT met elkaar vergeleken door het aantal punten 
beoordeeld als laag risico op bias te tellen via de Cochrane 'Risk of bias 
tool’. We hebben een consistente trend gevonden voor een verbetering in 
het voordeel van de post CONSORT studies voor de punten ‘genereren 
van willekeurige volgorde’ (RR 2.0, 95% BI 1.1 tot 3.5, P=0.02, 54 
studies), ‘blinderen van toewijzing’ (RR 2.2, 95% BI 0.90 tot 5.4, P = 
0.08, 54 studies), ‘volledigheid van uitkomst gegevens’ (RR 1.4, 95% BI 
0.92 tot 2.3, P= 0.11, 54 studies), ‘selectieve uitkomst rapportering’ (RR 
1.3, 95% BI 0.94 tot 1.7, P=0.12, 54 studies) en ‘andere mogelijke 
oorzaken van systematische vertekening’ (RR 2.1, 95% BI 0.52 tot 8.5, 
P=0.30, 54 studies), maar niet voor het punt ‘blindering’ (RR 0.42, 95% 
BI 0.12 tot 1.5, P=0.18, 54 studies). Er blijkt een belangrijke verbetering 
in de globale methodologische kwaliteit omschreven door de composiet 
uitkomstmaat 'alle zes punten voor risico voor systematische vertekening' 
in het voordeel van de post CONSORT studies (RR 1.5, 95% BI 1.2 tot 
1.9, P=0.001, 54 studies). Wij besluiten dat er de laatste jaren een 
duidelijke toename is geweest in zowel het aantal als de kwaliteit van de 
wetenschappelijke publicaties over reproductieve chirurgie bij vrouwen 
met vruchtbaarheidsproblematiek. 
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DISCUSSIE 
 
Onze systematische literatuurstudie kon geen gerandomiseerde 
vergelijking van reconstructieve tuba chirurgie met expectatief beleid of 
ART vinden in een doelpopulatie van vrouwen met tubaire 
onvruchtbaarheid waarbij levendgeboorte of zwangerschap werd 
bestudeerd als hoofduitkomstmaat. Dit stemt overeen met de bevindingen 
van twee Cochrane reviews (Pandian et al, 2008; Johnson et al, 2010). Dit 
beantwoordt de eerste onderzoeksvraag van dit proefschrift. 
Onze beoordeling van de beschikbare evidentie over de doeltreffendheid 
van hysteroscopie voor het behandelen van onvruchtbare vrouwen kon 
een beperkt positief effect aantonen bij vrouwen met 
endometriumpoliepen vóór IUI en bij vrouwen met primaire subfertiliteit 
en minstens twee gefaalde IVF pogingen vóór een volgende poging IVF. 
Bovendien hebben wij tal van lacunes in de kennis opgemerkt. Het 
gebruik van anti-adhesie barrière gels kan worden overwogen na 
operatieve hysteroscopie bij subfertiele vrouwen omdat dit de incidentie, 
de ernst en de uitgebreidheid van adhesies kan verminderen; gegevens 
over de effecten op de belangrijkste reproductieve uitkomsten ontbreken 
echter. Dit beantwoordt de tweede onderzoeksvraag van ons proefschrift 
Ons onderzoek heeft een toename in aantal en methodologische kwaliteit 
van publicaties over gerandomiseerd onderzoek over de doeltreffendheid 
van de reproductieve chirurgie in de afgelopen jaren aangetoond. Dit 
beantwoordt althans voor een gedeelte de derde onderzoeksvraag van ons 
proefschrift. Onze bevindingen stemmen overeen met deze van een recent 
verschenen opinie artikel over ‘Twenty years of Cochrane reviews in 
Menstrual Disorders and Subfertility' (Farquhar et al, 2013). Het aantal 
RCTs over de behandeling van subfertiliteit is volgens de auteurs 
toegenomen van bijna 2000 in 1997 naar meer dan 5000 in 2013. Er is een 
duidelijke verschuiving naar het opzoeken en verzamelen van bewijs van 
effectiviteit van de hoogste kwaliteit; dit moet ongetwijfeld kunnen leiden 
naar een groter gebruik van deze bewijsvoering op de werkvloer met de 
mogelijkheid om de kloof tussen de theorie en klinische praktijkvoering te 
overbruggen.  
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1. KLINISCHE IMPLIKATIES 
 
• Laparoscopische chirurgie voor de behandeling van 
onvruchtbaarheid 
 
Men kan niet langer verdedigen om routinematig een laparoscopie te doen 
bij alle subfertiele vrouwen als laatste stap in de fertiliteit exploratie: om 
100% zekerheid te hebben over de staat van de eileiders zou men enkel de 
groep van onvruchtbare vrouwen met minimale of prognostisch dubieuze 
pathologie groter maken wat leidt tot een inflatie van de kosten voor het 
gezondheidszorgsysteem (Collins en Van Steirteghem, 2004). HSG en 
laparoscopie zijn even doeltreffend voor het voorspellen van de kansen op 
een spontane conceptie in een algemene subfertiele populatie (Verhoeve 
et al, 2011). Onvruchtbare vrouwen met een voorgeschiedenis van PID, 
verwikkelde appendicitis, kleinbekken chirurgie, ectopische graviditeit en 
endometriose hebben een hogere kans op tuboperitoneale pathologie 
(Luttjeboer et al, 2009) en moeten worden gecounseld om vroeg in de 
exploratie een diagnostische laparoscopie te ondergaan (NICE 2004; 
ASRM 2006). CAT via de microimmuno-fluorescentie test lijkt de eerste 
keuze voor de initiële screening op tuba pathologie (Broeze et al, 2011). 
Het combineren van de anamnese met CAT heeft een grotere 
voorspellende waarde voor de selectie van subfertiele vrouwen die in 
aanmerking komen voor een diagnostische laparoscopie vergeleken met 
ieder van beide apart en biedt als triage de mogelijkheid om het aantal 
'onnodige laparoscopies' te verminderen met 82% vergeleken met het 
routinematig uitvoeren van een laparoscopie bij alle gevallen (Coppus et 
al, 2007). Het HSG is een nuttige screeningstest voor het opsporen van 
tuba afwijkingen bij alle subfertiele vrouwen (Broeze et al, 2011; the 
Practice Committee of the American Society for Reproductive Medicine, 
2012). De combinatie van anamnese, CAT en HSG heeft de hoogste 
performantie voor de diagnostiek van bilaterale tuba pathologie (Broeze et 
al, 2012). Het routinematig uitvoeren van testen voor het opsporen van 
eileiderdoorgankelijkheid bij de vruchtbaarheidsexploratie is niet 
kosteneffectief bekeken vanuit het standpunt van de zorgverzekeraar of 
gezondheidsautoriteit: als het nodig is om informatie te verkrijgen over de 
status van de eileiders om klinische beslissingen te nemen voor de 
gezondheid van individuele vrouwen dan is het HSG gevolgd door 
geïndividualiseerde behandeling of een diagnostische laparoscopie in 
gevallen van niet doorgankelijke eileiders op het HSG meer rendabel dan 
de routinematig uitgevoerde diagnostische laparoscopie (Verhoeve et al, 
2013). 
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De ovariële kapseldrilling gevolgd door CC en gonadotrofines bij 
persisterende anovulatie is een aantrekkelijk alternatief voor de tweede 
lijn behandeling van vrouwen met CC-resistente PCOS vooral omwille 
van het lager risico op meerlingzwangerschap voor minstens dezelfde 
doeltreffendheid vergeleken met het onmiddellijk opstarten van 
gonadotrofine behandeling. Bovendien heeft een studie met langere 
termijn opvolging aangetoond dat ovariële kapseldrilling met 
elektrocauterisatie aanzienlijk de nood tot ovulatie-inductie of ART voor 
een eerste levendgeborene vermindert en de kans op een tweede kind 
verhoogt (Nahuis et al, 2011). Er bleken geen beduidende verschillen te 
bestaan in levenskwaliteit tussen ovariële kapseldrilling en gonadotrofine 
behandeling, behalve voor een subgroep van vrouwen zonder doorgaande 
zwangerschap waarbij meer depressieve symptomen in de studie arm van 
de gonadotrofine behandeling werden opgemerkt vergeleken met de groep 
van de kapseldrilling (van Wely et al, 2004). De totale kosten voor de 
behandeling voor een doorgaande zwangerschap zijn gelijk voor beide 
behandelstrategieën (van Wely et al, 2004) maar de gegevens van een 
langere termijn follow-up hebben aangetoond dat de gemiddelde 
behandelingskosten per levendgeboorte binnen 8 tot 12 jaar na de eerste 
behandeling aanzienlijk lager zijn voor de strategie waarbij eerst gestart 
wordt met ovariële kapseldrilling vergeleken met gonadotrofines (Nahuis 
et al, 2012). Daarom dient het starten met ovariële kapseldrilling gevolgd 
door clomiphene citraat en gonadotrofines in geval van persisterende 
anovulatie te worden aanbevolen als een rationele tweede lijn behandeling 
bij subfertiele vrouwen met CC-resistente PCOS. 
Reconstructieve chirurgie was de enige beschikbare behandelingsoptie 
voor tubaire onvruchtbaarheid in het tijdperk vóór de IVF. Tubaire 
chirurgie biedt vrouwen de mogelijkheid om meer dan één maal zwanger 
te kunnen worden door een eenmalig uitgevoerde minimaal invasieve 
ingreep waardoor ART en de hiermee verbonden risico’s kunnen worden 
vermeden. De nadelen van reconstructieve chirurgie zijn de risico’s 
gepaard met de chirurgische ingreep/narcose en de kans op recidief 
hydrosalpinx. In geval van bilaterale onherstelbare hydrosalpinges is er 
kwaliteitsvol bewijs dat salpingectomie of tubaire occlusie ondersteunt om 
de kansen op een zwangerschap via IVF te verhogen (Johnson et al, 2010; 
Johnson et al, 2011). Aan jonge vrouwen zonder verdere problemen kan 
een laparoscopische fimbrioplastie of neosalpingostomie worden 
aanbevolen om tuba pathologie met een goede prognose zoals phimosis of 
adhesies te herstellen (Mol et al, 1999); het uitvoeren van een bilaterale 
salpingectomie zou alle mogelijkheden voor een spontane zwangerschap 
in deze gevallen onherroepelijk wegnemen (Johnson et al, 2011). 
Microchirurgische of laparoscopische reanastomose door een deskundige 
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reproductieve chirurg verdient mogelijks de voorkeur na een 
voorafgaande eileidersterilisatie (the Practice Committee of the American 
Society for Reproductive Medicine, 2012). 
 
• Hysteroscopische chirurgie voor de behandeling van 
onvruchtbaarheid 
 
Het uitvoeren van een hysteroscopie voorafgaand aan een daaropvolgende 
IVF/ICSI behandeling kan de kans op een succesvolle reproductieve 
uitkomst vergroten bij vrouwen met primaire subfertiliteit en minstens 
twee mislukte IVF/ICSI pogingen. Een systematisch literatuuronderzoek 
met meta-analyse van vijf observationele studies en één gerandomiseerde 
studie heeft aangetoond dat een hysteroscopie vóór een eerste IVF-poging 
de kansen op een klinische zwangerschap en levendgeboorte kan 
vergroten; deze gegevens moeten omzichtig worden geïnterpreteerd 
wegens de aanzienlijke klinische verscheidenheid en de statistische 
heterogeniteit van de geïncludeerde studies (Pundir et al, 2013). Een 
hysteroscopie vóór een eerste IVF poging is mogelijk kosteneffectief 
zoals blijkt uit een studie van een kostenbeslissing model (Kasius et al, 
2013). Bijkomend onderzoek is nodig alvorens men met zekerheid kan 
aanbevelen om routinematig een hysteroscopie uit te voeren voorafgaand 
aan iedere eerste ART behandeling. 
 
• Anti-adhesieve behandeling na hysteroscopische chirurgie  
 
Gynaecologische chirurgen moeten vrouwen met zwangerschapswens 
informeren dat de vorming van intra-uteriene adhesies de belangrijkste 
lange termijn verwikkeling is na operatieve hysteroscopie bij vrouwen in 
de reproductieve leeftijd. Een recent Nederlands onderzoek heeft 
aangetoond dat het bedacht zijn op de problematiek van adhesies bij 
Nederlandse gynaecologen beperkt is en dat de counseling over dit 
probleem niet adequaat verloopt (Meuleman et al, 2013). Het gebruik van 
anti-adhesieve gels na operatieve hysteroscopie kan de incidentie van 
adhesies verminderen net als de mate/ernst van de intra-uteriene adhesies; 
de effecten op de reproductieve uitkomst zijn niet echter niet onderbouwd 
door bewijs van hoge kwaliteit vergelijkbaar met het gebruik van anti-
adhesieve gel na laparoscopische myomectomie (Pellicano et al, 2005). 
Dit gebrek aan voldoende bewijs mag men uiteraard niet over het hoofd 
zien tijdens de counseling. 
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2. TOEKOMSTIG ONDERZOEK 
 
• Laparoscopische chirurgie voor de behandeling van 
onvruchtbaarheid 
 
Bijkomend onderzoek is nodig om de doeltreffendheid van HyCoSy te 
onderzoeken voor het voorspellen van spontane zwangerschap; één 
gerandomiseerd onderzoek kon geen voordeel aantonen voor HyCoSy 
voor het vergroten van de kansen op een klinische zwangerschap bij 
subfertiele vrouwen (Lindborg et al, 2009). 
Verschillende vergelijkende studies suggereren een sterke overeenkomst 
tussen de bevindingen van transvaginale hydrolaparoscopie (THL) en 
conventionele laparoscopie (Campo et al, 1999; Casa et al, 2002; Darai et 
al, 2000; Nawroth et al, 2001). In een prospectieve cohort studie werden 
concordante FRRs gevonden voor unilaterale tuba pathologie, bilaterale 
tuba pathologie en adhesies/endometriose; dit suggereert dat de capaciteit 
van THL om de kans op een spontane doorgaande zwangerschap te 
voorspellen dezelfde is als deze van de gewone laparoscopie (van Tetering 
et al, 2007). Definitief bewijs kan slechts komen van bijkomend 
pragmatisch gerandomiseerd onderzoek dat THL vergelijkt met de 
standaard laparoscopie in een vergelijkbare doelgroep met een kort 
tijdsinterval tussen beide procedures. Bijkomend onderzoek is ook nodig 
om de waarde van klinische predictiemodellen voor tubaire pathologie en 
endometriose (alle stadia versus fase III of IV) te bestuderen voor het 
selecteren van vrouwen met onverklaarde onvruchtbaarheid die bij 
voorkeur vroeg in de onderzoeksfase THL als een poliklinische procedure 
onder lokale verdoving zouden moeten ondergaan. 
Verschillende auteurs melden dat het parallel debat over de 
gezondheidseconomische aspecten van ART om het meest geschikte 
financieringskader voor het verstrekken van veilige, billijke en 
kosteneffectieve behandeling te omschrijven uiterst ingewikkeld is (Mol 
et al, 2000; Connolly et al, 2010; Berg Brigham et al, 2012; Chambers et 
al, 2013). Kosteneffectiviteit studies die reconstructieve tuba chirurgie 
vergelijken met expectatief beleid als een alternatief of voorafgaande aan 
ART bij vrouwen met tubaire infertiliteit dienen hoog bovenaan op de 
onderzoeksagenda te worden geplaatst, zeker in landen met een hoog 
verbruik van ART, zoals België; de vergelijking tussen beide interventies 
moet ook de uitkomsten van ongewenste neveneffecten en 
gezondheidsgerelateerde levenskwaliteit in acht nemen. De 
terughoudendheid vanwege de artsen in de reproductieve geneeskunde om 
het als hoog gepercipieerde succes van ART openlijk in vraag te durven 
stellen lijkt een grote belemmering te zijn voor het uitvoeren van dergelijk 
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onderzoek (Kamphuis et al, 2014). We moeten anderzijds ook toegeven 
dat er belangrijke beperkingen zijn voor de uitvoerbaarheid van dergelijke 
studies bijvoorbeeld voor wat betreft de beschikbaarheid van voldoende 
chirurgische expertise voor reconstructieve tuba chirurgie (Pandian et al, 
2008) en een voldoende hoge prevalentie van tubaire pathologie (Sabatini 
en Davis, 2005). A priori gedefinieerde subgroep analyses zijn nodig om 
de kosteneffectiviteit van tubaire reconstructieve chirurgie te vergelijken 
met ART in specifieke subgroepen (bvb. oudere versus jongere vrouwen, 
poor responders, eerdere tubasterilisatie...). 
 
• Hysteroscopische chirurgie voor de behandeling van 
onvruchtbaarheid 
 
Wij zijn het eens met andere auteurs dat er op dit ogenblik onvoldoende 
hoog kwalitatief bewijs is gebaseerd op gerandomiseerd onderzoek met 
voldoende statistisch onderscheidingsvermogen dat enig voordeel kan 
aantonen voor de hysteroscopische myoomverwijdering voor het 
vergroten van de kans op zwangerschap of levendgeboorte bij vrouwen 
met onverklaarde onvruchtbaarheid of voorafgaand aan ART (Metwally et 
al, 2012). De bevindingen van een systematisch literatuuroverzicht van 
observationele studies (Pritts et al, 2009) suggereren een negatief impact 
van submuceuze myomen op de reproductieve uitkomst en een voordeel 
voor de hysteroscopische verwijdering van de fibromen. Wij staan als 
reproductieve chirurgen bijgevolg voor een moeilijke keuze: ofwel nemen 
wij dit niet op bewijs gebaseerd onderzoek voor (vertekende) waarheid 
ofwel kiezen wij het pad van de wetenschap om de effectiviteit en 
veiligheid van hysteroscopische myomectomie voor behandeling van 
vrouwen met onverklaarde onvruchtbaarheid of voorafgaande aan 
IUI/ART aan te tonen. Het niet verwijderen van de fibromen wordt 
wellicht door sommigen als onethisch aanzien, een aanvullende 
behandeling opstarten met ovariumstimulatie, IUI of ART lijkt dan voor 
anderen weer niet aangwezen; er is echter een derde en vaak over het 
hoofd geziene mogelijkheid om geïnformeerde toestemming te vragen aan 
de patiënte voor haar deelname aan een pragmatische multicentrische 
gerandomiseerde studie. Bijkomende gegevens uit gerandomiseerd 
onderzoek over verbanden tussen dosisrespons of lokalisatie van de 
fibromen en de overeenkomstige toename in voordeel of afname in nadeel 
zijn nodig om de causaliteit tussen submuceuze fibromen en 
onvruchtbaarheid te bestuderen. Er is verder onderzoek nodig naar het 
verband tussen de timing van de hysteroscopische interventie en de 
effecten op de kansen voor zwangerschap of levendgeboorte. Bijkomend 
onderzoek dient aan te tonen of hysteroscopie in de voorgaande cyclus 
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voordeel biedt aan alle vrouwen die behandeld moeten worden met 
IVF/ICSI of beperkt is tot de subgroep van vrouwen met primaire 
subfertiliteit en onverklaard herhaald implantatiefalen. Een recent 
gepubliceerd systematisch literatuuroverzicht met een meta-analyse van 
vier gerandomiseerde en drie observationele studies (Potdar et al, 2012) 
en één Cochrane review (Nastri et al, 2012) hebben een positief effect 
aangetoond van het aanbrengen van endometriaal trauma 
(endometriumbiopsie/endometrial scratch en diagnostische hysteroscopie) 
tijdens de cyclus die voorafgaat aan de ART behandeling op de kansen op 
levendgeboorte en klinische zwangerschap. Wanneer het endometriaal 
trauma werd aangebracht op de dag van de follikelaspiratie werd een 
beduidende daling van de kansen op een doorgaande en klinische 
zwangerschap aangetoond (Nastri et al, 2012). Het positief effect van het 
herhaald afnemen van een endometriumbiopsie werd voor het eerst 
geobserveerd in een onderzoek naar het patroon van expressie van een gap 
junction eiwit in het endometrium. Een gerandomiseerde studie kon 
vervolgens de hypothese bewijzen dat lokale schade van het endometrium 
de receptiviteit voor implantatie kan verhogen (Barash et al, 2003). Een 
gerandomiseerde vergelijking tussen hysteroscopie in de cyclus 
voorafgaand aan ART vergeleken met de dag van de follikelaspiratie biedt 
de mogelijkheid om eenzelfde verband tussen tijdstip en effect van de 
hysteroscopie vóór ART te bestuderen. Daarnaast moet ook worden 
onderzocht of het voordeel van het aanbrengen van endometriaal trauma 
via biopsie/scratching of hysteroscopie vóór ART verschilt volgens het 
tijdstip in de menstruele cyclus. De duur van dit positief effect is 
ongekend maar klinisch relevant; aanvullend onderzoek moet een 
antwoord kunnen geven op de vraag of het zinvol is om de interventie te 
herhalen bij persisterend implantatiefalen. Deze praktijk kan leiden tot een 
aanzienlijke meerkost naast toegenomen stress en ongemak bij de 
patiënten; daarom moeten aspecten van kosteneffectiviteit en 
gezondheidsgerelateerde levenskwaliteit eveneens in rekening worden 
gebracht. Het nuteffect van de endometrium-biopsie/scratch lijkt groter 
dan dat van de hysteroscopie voor de uitkomstmaat klinische 
zwangerschap (Potdar et al, 2012); dit resultaat moet met de nodige 
voorzichtigheid worden geïnterpreteerd, omdat alle gevallen van 
operatieve hysteroscopie uit de statistische pooling in deze review werden 
uitgesloten vanuit de voorafgaande assumptie dat operatieve 
hysteroscopie voor alle niet vermoede intracavitaire afwijkingen de 
kansen op een succesvolle uitkomst van ART vergroot (Potdar et al, 
2012). Verder onderzoek is nodig naar vergelijkende kosteneffectiviteit 
van endometriaal trauma via biopsie/scratch vergeleken met 
hysteroscopie. Bovendien is basis wetenschappelijk onderzoek nodig om 
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de onderliggende biologische werkingsmechanismen voor het verhogen 
van de receptiviteit van het endometrium gedurende het 
implantatievenster te verklaren. In 1907 werd een artikel gepubliceerd 
over de observatie van een toegenomen groei van endometriale stromale 
cellen uitgelokt door letsels aan het endometrium door schrapen van 
progestationele baarmoeders bij de cavia (Loeb, 1907). Een grotere influx 
van macrofagen en dendritische cellen belangrijk voor decidualizatie van 
humane endometriale stroma cellen (HESCs) en implantatie (Gnainsky et 
al, 2010), een verhoogde vrijzetting van pro-inflammatoire cytokines en 
groeifactoren, vooral leukemia-inhibiting factor (LIF), interleukin-1β (IL) 
en heparin-binding epidermal growth factor-like growth factor (HBEGF) 
(Paria et al, 2002), een gewijzigde genexpressie in het 
baarmoederslijmvlies met opregulatie van pro-implantatie eiwitten 
(Kalma et al, 2009) en synchronisatie van endometrium en embryonale 
ontwikkeling (Zhou et al, 2008) zijn plausiebele verklaringen. Dit 
basisonderzoek naar onderliggende hypothetische mechanismen voor het 
verhogen van de receptiviteit van het endometrium moet voor de klinische 
praktijk kunnen beantwoorden hoeveel endometriaal trauma nodig is om 
betere reproductieve uitkomsten met ART te kunnen behalen. 
 
• Anti-adhesieve behandeling na hysteroscopische chirurgie  
 
Het onderzoek naar de effectiviteit van anti-adhesieve barrière gel voor 
het voorkomen van intra-uteriene adhesies stemt overeen met de 
bevindingen van een Cochrane review (Metwally et al, 2006). Aanvullend 
onderzoek is nodig omdat de effecten van het gebruik van anti-adhesieve 
barrière gel na operatieve hysteroscopie bij de behandeling van subfertiele 
vrouwen op de reproductieve uitkomst onbekend zijn. 
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3. WILLEKEURIGE BESCHOUWINGEN(*) OVER DE 
TOEKOMST VAN OP BEWIJS GEFUNDEERDE PRAKTIJK-
VOERING IN DE REPRODUCTIEVE CHIRURGIE 
 
Er is weinig twijfel over de betrouwbaarheid van het toepassen van een 
streng wetenschappelijke benadering voor het meten van de 
doeltreffendheid van een interventie onder ideale experimentele 
omstandigheden via een gerandomiseerde studie; de RCT biedt de 
mogelijkheid om het echte behandelingseffect te meten met de kleinste 
kans op systematische vertekening. Een lege artis opgezette RCT heeft net 
daarom een grote interne validiteit. Dit betekent dat de schatting van het 
behandelingseffect voor de voorwaarden, de interventie en de populatie 
beschreven in het experiment uiterst betrouwbaar zijn. Maar geldt dit 
evenzeer voor alle onvruchtbare vrouwen? Of minstens voor die 
onvruchtbare vrouwen onder de behandeling van een reproductieve 
chirurg die de bevindingen van een "experimentele" gerandomiseerde 
studie raadpleegt om een behandeling gebaseerd op de beste beschikbare 
evidentie voor te stellen maar werkt in omstandigheden die mogelijk sterk 
verschillen van deze beschreven in het experiment? De toepasbaarheid 
van de bevindingen van een studie op een algemene of doelpopulatie 
noemt men de externe validiteit van een studie. Sinds kort lijkt er een 
toenemende interesse in zogenaamde 'real life' studies. In een review 
(Saturni et al, 2014) werd de afweging tussen de interne en externe 
validiteit van een studie onterecht herleid tot het onderscheid tussen 
'experimentele' RCTs die de werkzaamheid (efficacy) bestuderen versus 
'real life' studies die beogen om de doeltreffendheid (effectiveness) te 
meten; deze vereenvoudiging gaat voorbij aan het gegeven dat men 
studies die de werkzaamheid of doeltreffendheid onderzoeken eerder dient 
te plaatsen in een continuüm dan een dichotomie (Haynes et al, 2006). 
Kritiek op de streng wetenschappelijke benadering van de 'experimentele' 
RCT heeft binnen het vakgebied van de psychiatrie geleid tot wat 
omschreven wordt als door ‘praktijk effectief verondersteld bewijs’ of 
‘practice-based evidence’ om beter de uitkomsten op het niveau van de 
individuele patiënt te kunnen voorspellen (Margison et al, 2000). 
‘Practice-based evidence’ wordt gedefinieerd als de mogelijkheid om 
klinische vaardigheden en ervaring te gebruiken voor het snel herkennen 
van de gezondheidstoestand en diagnose van elke individuele patiënt, de 
afzonderlijke voor- en nadelen van de alternatieve behandelingen en de 
persoonlijke waarden en verwachtingen. Het 'gewetensvol, expliciet en 
verstandig gebruiken van de beste evidentie bij het nemen van 
beslissingen over de zorg van individuele patiënten' staat voor de 
integratie van individuele expertise van de zorgverstrekker met de beste 
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beschikbare gegevens van systematisch literatuuronderzoek rekening 
houdend met de unieke waarden en voorkeur van de individuele patiënt. 
‘Practice-based evidence’ is daarom een deel van ‘evidence-based 
practice’. 
De wetenschappelijke benadering van EBM lijkt minder aantrekkelijk 
voor de praktiserende arts die mogelijk opziet tegen de uitdaging om 
betrouwbaar bewijs te zoeken voor een bepaalde interventie in plaats van 
het verder aanbieden van behandelingen die niet op bewijs gebaseerd zijn 
(Kamphuis et al, 2014). Wij zijn het eens met andere auteurs dat de sterkte 
van een goed uitgevoerde RCT berust op de grote interne validiteit; dit 
laat de clinicus toe om effectieve interventies te onderscheiden van 
ineffectieve, onzekere of mogelijks schadelijke interventies (Johnson et al, 
2003; Johnson et al, 2008; Farquhar et al, 2013). Wij geven toe dat er veel 
belemmeringen kunnen zijn voor het opzetten van een degelijke 
chirurgische RCT. Een aantal barrières werd al door andere auteurs 
beschreven (McCulloch et al, 2002; McLeod, 1999) bijvoorbeeld de 
problematiek van de chirurgische leercurve en de verschillen in 
chirurgisch-technische vaardigheid (Devereaux et al, 2005), de 
moeilijkheid om chirurgische ingrepen te standaardiseren (Kapiteijn et al, 
1999), het probleem van blindering in chirurgische klinische trials 
(Moseley et al, 2002), het bestaan van tal van co-interventies (Haynes et 
al, 2006), problemen van rekrutering (Haynes et al, 2006) en problemen 
met het berekenen van het statistisch onderscheidingsvermogen en de 
grootte van de steekproef (Dimick et al, 2001). Er is de laatste tijd ook een 
toenemende erkenning van het probleem over het toepassen van EBM in 
de praktijk: de biomedische kennis blijft exponentieel toenemen terwijl de 
integratie van de bevindingen en de conclusies van het klinisch 
wetenschappelijk onderzoek in de dagelijkse praktijkvoering te traag 
verloopt (Oude Rengerik et al, 2011). Praktijkrichtlijnen gebaseerd op de 
beste beschikbare evidentie kunnen niet wenselijke variabiliteit in zorg 
tussen instellingen verminderen en bijgevolg de toepassing van op bewijs 
gebaseerde medische praktijkvoering faciliteren. Men heeft al geprobeerd 
om via een gerandomiseerde studie de doeltreffendheid te meten van 
veelzijdige strategieën die beogen om gedragsverandering en toepassing 
in de dagelijkse klinische praktijk te bevorderen (Mourad et al, 2011). Het 
is duidelijk dat op bewijs gefundeerde medische praktijkvoering een 
nodige maar op zich niet voldoende voorwaarde is voor de behoeften van 
zowel de zorgverstrekkers als de patiënten. De afgelopen jaren kwam ook 
de ‘patiënt centeredness’ in de kijker binnen de vruchtbaarheidskliniek 
(Dancet et al, 2010). Het kader voor ‘patiënt-centered care’ binnen de 
fertiliteitskliniek plaatst de vrouw centraal maar houdt wel rekening met 
bijkomende aspecten zoals doeltreffendheid, veiligheid, kosten en 
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belasting door IVF-behandeling (Dancet et al, 2014). Uit de definities van 
‘patient centered’ en ‘evidence-based practice’ wordt het in één oogopslag 
duidelijk dat beide behoren tot eenzelfde continuüm eerder dan 
competitief of wederzijds uitsluitend te zijn. 
Voor de clinici lijkt de verleiding soms groot om evidentie gebaseerd op 
observationeel onderzoek als een ethisch imperatief te gebruiken om geen 
bijkomend klinisch wetenschappelijk onderzoek van hogere 
methodologische kwaliteit te moeten opzetten, zoals in de gevallen van 
vrouwen met onverklaarde onvruchtbaarheid en submuceuze myomen of 
vrouwen met habitueel miskraam en uterien septum (Kowalik et al, 2010). 
Deze "zekerheid" gebaseerd op resultaten van onderzoek met een inherent 
risico op systematische vertekening moet niettemin opzij worden 
geschoven uit respect voor de beredeneerde onzekerheid binnen de grotere 
gemeenschap van deskundigen (Haynes et al, 2006). De echte 
onzekerheid van de deskundige professionele gemeenschap over de balans 
tussen winst en verlies voor twee of meer behandelingen voor een wel 
omschreven populatie wordt in de Angelsaksische literatuur omschreven 
als "clinical equipoise"(Freedman, 1987). Het tegen elkaar afwegen van 
de “clinical equipoise”en de 'zekerheid' op basis van studies van lagere 
methodologische kwaliteit zou de norm moeten zijn om te oordelen of 
bijkomend onderzoek voor het toetsen van de effectiviteit van een 
interventie al dan niet nodig is. Wij zijn daarom van oordeel dat het 
aanbieden van deelname aan een gerandomiseerde studie niet alleen een 
derde en vaak over het hoofd gezien alternatief is maar bovendien moet 
worden gezien als een echte behandelingsoptie in alle gevallen van 
“clinical equipoise”. 
Een laatste vraag betreft het bewijs voor de doeltreffendheid van EBM in 
de praktijkvoering. Is er enig bewijs dat op bewijs gebaseerde 
praktijkvoering doeltreffend is om positieve uitkomsten die belangrijk zijn 
voor patiënten te verbeteren (Dobbie et al, 2000)? Het lijkt een haast 
onoverkomelijke uitdaging om deze kapitale vraag wetenschappelijk te 
benaderen via een random vergelijking van ‘evidence-based’ met non-
‘evidence-based’ praktijkvoering. Gegevens van uitkomsten onderzoek 
kunnen naar onze mening een alternatief maar betrouwbaar antwoord 
geven op deze vraag. Uitkomsten onderzoek kan worden omschreven als 
de studie van de eindresultaten van gezondheidszorg die rekening houdt 
met patiënten ervaringen, voorkeuren en waarden; deze onderzoeksvorm 
heeft als doel om wetenschappelijk bewijs te leveren voor beslissingen 
genomen door allen die deelnemen aan gezondheidszorg (Clancy en 
Eisenberg, 1998). Tal van gegevens uit het uitkomsten onderzoek tonen 
aan dat patiënten die werden behandeld met ‘evidence-based practice’ 
vaak betere uitkomsten hadden dan hen die geen ‘evidence-based’ 
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behandelingen kregen in verschillende domeinen van de geneeskunde 
(Krumholz et al, 1996; Krumholz et al, 1998) waaronder ook de 
reproductieve geneeskunde (Twisk et al, 2006; Pandian et al, 2013; 
Mastenbroek et al, 2011) en de reproductieve chirurgie (Johnson et al, 
2008; Johnson et al, 2010). Wij zijn het eens met andere auteurs dat "de 
vraag naar streng bewijs voor de beoordeling van de doeltreffendheid van 
medische interventies een goede zaak is" (Imrie en Ramey, 2008). Dit 
geldt volgens ons evenzeer voor de reproductieve chirurgie: echte 
vooruitgang op het gebied van reproductieve chirurgie moet steunen op 
chirurgisch-technische vaardigheden, innovatie in technieken en 
instrumenten, basis wetenschappelijk onderzoek en het toetsen van het 
klinisch wetenschappelijk onderzoek aan de gouden standaard van de 
gerandomiseerde studie. Wanneer de balans van de doeltreffendheid in 
evenwicht, dus onbepaald is, zouden reproductieve chirurgen de leidraad 
moeten volgen van ‘clinical equipoise’ eerder dan zich te verschuilen 
achter valse zekerheid of pseudo-ethische bezwaren als excuus om hun 
klinische praktijkvoering niet te veranderen of terughoudend te zijn om 
aanvullend hoog kwalitatief klinisch onderzoek op te zetten. Er lijkt geen 
passender einde voor het verhaal van de houten lepel bij het begin van dit 
proefschrift dan de krachtige Oud-Engelse woorden uit de mond van één 
van Cochrane’s grootste landgenoten (*): "Now this is not the end. It is 
not even the beginning of the end. But it is, perhaps, the end of the 
beginning".  
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1. PhD Training
PhD portfolio 
 
 
246 
• SWOT analyse van de ambulante hysteroscopische chirurgie in 
België.        2013 
19de Doelencongres, Rotterdam    0.7 
• Verbetert stoppen met roken de kans op succesvolle 
zwangerschap?      2013 
19de Doelencongres, Rotterdam    0.7 
• Meta-analyse fertiliteitschirurgie   2012 
Dienst Gynaecologie/Verloskunde UZ Brussel  0.03 
• Is reproductieve chirurgie effectief in behandeling van 
infertiliteit?      2012 
Dienst reproductieve geneeskunde, UZ Gent  0.03 
• The impact of food supplements and antioxidants- impact on ART 
results       2012 
BSRM, Spa      0.2 
• The effectiveness of hysteroscopic surgery in treating female 
subfertility      2012 
         Indian Fertillity Society, Jodhpur, India   0.5 
• Diagnostic laparoscopy in the fertility exploration 2012 
Indian Fertillity Society, Jodhpur, India   0.5 
• Cochrane in gynaecologie en verloskunde  2011 
VVOG vergadering, Genk    0.1 
• Wat is de waarde van diagnostische en operatieve hysteroscopie/ 
laparoscopie in de reproductieve geneeskunde?  2011 
18de Doelencongres, Rotterdam    0.7 
• The role of hysteroscopy in the diagnosis and treatment of 
infertility      2011 
ESGE, London, United Kingdom   0.7 
• The effectiveness of reproductive surgery in the treatment of 
female infertility     2011 
ESGE, London, United Kingdom   0.7 
• The evidence-based use of hysteroscopy and laparoscopy in the 
fertility setting      2010 
Hôpital Universitaire Saint Pierre, Brussel  0.03 
Phd portfolio 
 
 
247 
• Nut van diagnostische en operatieve hysteroscopie en 
laparoscopie bij infertiliteit    2010 
 Pentalfa KU Leuven     0.1 
• The documentation and registration of complications in 
endoscopy      2009 
 ESGE, Florence, Italy     0.7 
• A European Consensus Practice Guideline on techniques of 
laparoscopic entry     2009 
 ESGE, Florence, Italy     0.7 
• The role of hysteroscopy in current reproductive medicine 
       2009 
 ESGE, Florence, Italy     0.7 
• The role of laparoscopy in the evaluation of the infertile couple 
  2008 
 1st World Congress on Office Hysteroscopy, Bari, Italy 0.5 
• An unusual case of infertility and its hysteroscopic treatment 
  2008 
 1st World Congress on Office Hysteroscopy, Bari, Italy 0.5 
• Registration of complications in minimally invasive procedures 
  2008 
 ESGE, Amsterdam     0.7 
• A European Consensus Guideline on Laparoscopic Entry 
         2008 
 ESGE, Amsterdam     0.7 
• The place of surgery in reproductive medicine  2007 
 Leuven University Fertility Centre, KU Leuven  0.1 
• Plaats van de diagnostische laparoscopie   2006 
 VVOG vergadering, Brussel    0.1 
• The position of diagnostic laparoscopy in current fertility practice
       2006 
 ESGE, Strasbourg, France    0.7 
   
PhD portfolio 
 
 
248 
 Posters 
 
• The effectiveness of anti-adhesion therapy following operative 
hysteroscopy for treating female subfertility: a systematic review 
and meta-analysis     2013 
 ESHRE, London, United Kingdom   1.0 
• Is reproductive surgery effective in the treatment of female 
subfertility: an evidence-based approach?  2011 
 ESHRE, Stockholm, Sweden    1.0 
• The position of hysteroscopy in fertility practice 2008 
 ESGE congress, Amsterdam    0.7 
(Inter) national conferences 
 
ESGE      2006-2013 3.5 
ESHRE      2011-2014 3.0 
VVOG      2006-2014 3.5 
BSRM      2008-2013 1.0 
ISGE      2008  0.5 
De Doelen     2007-2013 2.8 
Gynaecongres     2008  0.5 
Cochrane Colloquium     2011  0.75 
 
 
 
 
 
EBM terugkomdagen    2010-2014 1.7 
EBM driedaagse cursus    2010-2014 1.5 
Cursus Systematic review   2014  0.5 
Postgraduate Course ESGE   2012-2013 0.3 
EBM in 5 stappen    2010-2013 0.7 
Short Course Clinical Research/EBM  2014  0.14 
ETCA Training courses for ASO’s  2007-2013 2.3 
VVOG Endoscopy Training courses  2008-2013 2.8 
 
2. Teaching
Dankwoord 
 
 
249 
DANKWOORD 
Ik wil vele mensen van harte danken voor hun bijdrage aan mijn 
groeiproces. Dit proefschrift is geen einde of doel op zich, maar het begin 
van een volgend avontuur met nieuwe uitdagingen. Rust roest… 
Ik dank de Rector Magnificus Professor dr. D.C. Van den Boom, de 
decaan, Professor dr. M.M. Levi en Professor dr. W.M. Wiersinga om mij 
toe te laten tot de promotie aan de Faculteit der Geneeskunde van de 
Universiteit van Amsterdam. 
Welgemeende dank aan de leden van de promotiecommissie Professor dr. 
Fulco van der Veen, Professor dr. Patrick M.M. Bossuyt, Professor dr. 
Petra de Sutter, dr. W.M. Ankum en dr. Anne Timmermans. 
Oprechte dank aan Professor dr. Frans André Van Assche, al mijn 
Professoren-opleiders en collega’s assistenten tijdens mijn opleiding tot 
specialist aan de KU Leuven. Bijzondere dank aan Professor dr. Myriam 
Hanssens: je zette niet alleen onze zoon gezond en wel op de wereld maar 
je gaf mij een gouden raad mee op de voorpagina van een boek over 
prostaglandines. Sarwana  Nuradi, mijn eerste collega in ‘donkere’ tijden, 
jij wordt speciaal vernoemd. Professor Kamiel van den Berghe (†), mijn 
eerste mentor, een groot man met een warm hart en een grote integriteit: je 
afscheid was veel te vroeg. Jos Caudron (†) en Lieven Londers (†): jullie 
waren inspirerende voorbeelden. 
I thank Professor Emeritus dr. John A. Collins from the Mc Master 
University, Hamilton, Ontario, Canada and Professor Emeritus dr. Victor 
Gomel, the University of British Columbia, Vancouver, British Columbia, 
Canada for their advice on their areas of expertise and their wisdom: EBM 
and methodology (John) and reproductive surgery (Victor). I was blessed 
that our ways have crossed. Professor dr. Marc Keirse, presently School of 
Medicine at Flinders University, Adelaide, Southern Australia. Thank you 
for the inspiring Francqui Chair lectures on EBM and for being honest. I 
tore up the draft of my manuscript as suggested, rewrote it and it got 
accepted. Your advice has proven to be effective beyond chance. 
I thank Professor dr. Jan J. Brosens, Biomedical Research Unit in 
Reproductive Health, University of Warwick, Coventry, United Kingdom 
for assistance concerning the ‘black box’ of implantation of the human 
embryo. 
Dank aan Bert Aertgeerts, Filip Cools, Dirk Ramaekers, Trudy Bekkering, 
Stijn Van de Velde, Patrick Haentjens, Manu Simons, Hans van Brabandt, 
Patrick van Krunkelsven, Bart Geurden, Jef Adriaensens, Martine 
Goossens, Elizabeth Bosselaers en mijn overige collega’s en vrienden van 
CEBAM aan het Academisch Centrum voor Huisartsgeneeskunde te 
Leuven. Dank aan Professor dr. Walter Sermeus, Centrum voor 
Ziekenhuis- en Verplegingswetenschap te Leuven. 
Dankwoord 
 
 
250 
Many thanks to Professor dr. Cindy Farquhar, Auckland, New Zealand, 
coordinating editor of the Cochrane Menstrual Disorders and Subfertility 
Group: writing a Cochrane systematic review is indeed not for the faint 
hearted! Many thanks to Ms. Helen Nagels, managing editor and Ms. 
Marion Showell, trials search coordinator at Auckland, New Zealand. 
James Duffy, Khalid Khan, Jane Daniels, Harry Siristatidis, Artin 
Ternamian, Costas Panayotidis, Siladitya Bhattacharya, Stephan Gordts, 
Rudi Campo, Patrick Puttemans, Siegfried Heylen, Ivo Brosens, Tarek El-
Toukhy, Mark Possover, Arnaud Wattiez, Philippe Koninckx,.... Your 
impact upon my career as friends, researchers and colleagues is ever 
lasting. 
Paul Vermylen (†), Marcel De Bruyn, Jean Pierre Van Boxelaer, Philippe 
Delattin, Carine De Rop, Els Dufraimont, Els Lannoey, Jan Baekelandt, 
Sofie Pelckmans, Lore Lannoo en Nele Roggen, de collega’s van mijn 
maatschap. Dit was nooit mogelijk geweest zonder jullie begrip. Dank aan 
al onze assistenten in opleiding voor de jarenlange intellectuele 
kruisbestuiving. 
Dank aan Renilde Bastaens en alle Imelda vroedvrouwen, aan Monique 
Van Hiel en het OK team, aan Marleen van Dessel en de verpleging van 
Heelkunde 5. Dank aan de directie en de hele medische staf van 
Imeldaziekenhuis. Dank aan alle collega’s klinische biologie in het 
bijzonder voor ons bondgenootschap in het Zorgprogramma A 
Reproductieve Geneeskunde. 
Dank aan Sofie en Christel De Wit, Sarah Collin, Petra Praet, Marleen 
Parisis, Krista Grootaert, Katja Reyniers en Nicole Saenen voor 
secretariële ondersteuning in Vlaanderen. Cootje Kusters, Helene Boeren, 
Shirley Abels, Marjan du Prie, Ellis Hanko en Bettina Batista voor de 
Nederlandse ondersteuning.  
Dank aan alle bestuursleden en collega’s van de Vlaamse Vereniging voor 
Obstetrie en Gynaecologie: Prof. dr. Ignace Vergote, dr. Johan van 
Wiemeersch, dr. Geert Debruyne, Prof. dr. Willem Ombelet, dr. Piet 
Hinoul, Prof. dr. Jan Gerris, Prof. dr. Steven Weyers, Prof. dr. Jean 
Jacques Amy, Prof. dr. Marc Dhont, Prof. Dr. Marleen Temmerman, dr. 
Bart Bollen, dr. Koen Traen, dr. Guy Orye, dr. Dirk Smet, Prof. dr. Michel 
Degueldre, Prof. dr. Herman Tournaye, dr. Guy Verhulst, dr. Luc 
Debaene, dr Benoit Rombaut, dr. Geert Page, dr. Herwig Trappeniers, dr. 
Geert Vlaemynck, Prof. dr. Eric De Jonghe, Prof. dr. Yves Jacquemyn, 
Prof. dr. Paul Defoort, Prof. dr. Paul Devroey, Prof. dr. Patrick Neven, dr. 
Patrick Berteloot, Prof. dr. Jan Deprest, Prof. dr. Dirk Timmerman, Prof. 
dr. Herman Depypere, dr. Greet Mestdagh, dr. Geertrui Meganck, dr. 
Willem Verpoest… en zovele anderen. Ik heb enige schroom om de lange 
lijst verder af te gaan uit vrees om iemand te vergeten. Bijzondere dank 
Dankwoord 
 
 
251 
aan de sterke VVOG vrouwen: Mireille Merckx, Carine De Rop, Diane 
De Neubourg, Carla Tommassetti, Elke Sleurs, Anke Thaens en Anne 
Loccufier.  
Dank aan ‘the Dutch connection’: Hans Brölmann, Erika Bakkum, Frank 
Willem Jansen, Andreas Thurkow, Marlies Bongers, Matthé Burger, Ben 
Cohlen, Bas Veersema, Judith Huirne, Peggy Geomini, Petra Hajenius, 
Evert Slager, Hans Emmanuel, Minouche van Rumste… Niets is toeval, 
het is ook door en voor jullie dat ik in Nederland kom promoveren.  
Dank aan Professor dr. Jan Deprest, Professor dr. Stephan Gordts, 
Professor dr. Steven Weyers, Professor dr. Frederic Amant en dr. Thierry 
Van den Bosch: het is fijn met en onder jullie te mogen werken als 
associate editor van Gynaecological Surgery.  
Professor dr. Bruno Van Herendael en Professor dr. Thomas D’Hooghe: 
jullie plaats in dit project is heel bijzonder. Bruno, zonder jouw aanbod 
om mee cursus te komen geven bij het ETCA had ik wellicht nooit de 
reviews over hysteroscopie geschreven. Je cruciale rol in dit proefschrift 
kan dan ook nooit genoeg worden benadrukt. Beste Tom, dank om mijn 
hand vast te willen houden bij mijn eerste stapjes in een ondertussen uit de 
hand gelopen hobby, het schrijven van wetenschappelijke publicaties. Jij 
staat steeds op de laatste plaats, althans van de auteurslijst van mijn 
belangrijkste publicaties: ingewijden weten echter heel goed wat dit 
inhoudt… 
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waar ik alle kansen kreeg om mij te ontplooien. Bijzondere dank aan mijn 
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Dank aan de CEO van de familie, Trinette Pots, mijn schoonmoeder, een 
heel bijzondere vrouw die het werk thuis heel wat lichter maakt. Resten 
nog mijn twee oogappels. Chantal, je bent een ‘bangelijk’ echte 
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hij in 1980 zijn diploma middelbaar onderwijs aan het Heilige 
Maagdcollege behaalde in de afdeling Latijn-Wiskunde. Op 30 juni 1987 
behaalde hij zijn artsendiploma met de grootste onderscheiding aan de 
Faculteit Geneeskunde van de KU Leuven. Van 1987 tot 1992 genoot hij 
opleiding tot specialist in de verloskunde-gynecologie aan de 
Universitaire Ziekenhuizen van de KU Leuven onder supervisie van Prof. 
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Stellingen behorende bij het proefschrift van Jan Bosteels 
1. Het routinematig uitvoeren van een laparoscopie bij alle gevallen 
van onvruchtbaarheid is niet zinvol (dit proefschrift). 
2. Op grond van de huidige kennis is er onvoldoende grond om een 
hysteroscopie uit te voeren bij alle vrouwen met subfertiliteit (dit 
proefschrift). 
3. Omdat bij niet-effectieve behandelingen de veiligheid er niet toe 
doet, dient bij evaluatie van medische interventies eerst de 
effectiviteit en pas dan de veiligheid geëvalueerd te worden. 
4. Trauma aan het endometrium zou misschien de kans kunnen 
verhogen op succesvolle implantatie van het embryo bij vrouwen 
die behandeld worden met Medisch Begeleide Voortplanting 
(Nastri et al, Cochrane Database Syst Rev 2012, Issue 7. Art. No.: 
CD009517). 
5. Het hoge verbruik van IVF in België ( bijna 3000 cycli per 
miljoen inwoners) en de daarmee gepaard gaande hoge kosten 
(bijna 100 miljoen Euro geraamd in 2008) vereisen een 
maatschappelijke doorlichting (Berg Brigham et al, Hum Reprod 
2013, 28 (3): 666-675). 
6. Om de wetenschappelijke onderbouwing van de reproductieve 
chirurgie te versterken moet men ofwel chirurgen klinische 
epidemiologie aanleren ofwel klinische epidemiologen 
inschakelen op diensten waar klinisch-wetenschappelijk 
onderzoek wordt uitgevoerd (Madhok R and Handoll HHG; 
Bridgman S and Maffulli N. Randomized trials in surgery. Letters 
to the Editor of the BMJ. BMJ 2002; 325: 658-9). 
7. Een ‘fee for service’ systeem kan leiden tot zowel een slechte 
coördinatie als een overconsumptie van zorg. 
8. Een optimale zorgfinanciering hoort een effectiviteitgestuurde 
betalingscomponent (P4P) te bevatten. 
9. “Efficiency is doing things right; effectiveness is doing the right 
things” (Peter F.Drucker). 
10. “Absence of evidence is not evidence of absence” (Carl Sagan). 
 
